

主 | 编

Laura Valle Stephen B. Gruber Gabriel Capellá

主 | 译

张 卫 高显华 袁 瑛

遗传性结直肠癌

Hereditary Colorectal Cancer

遗传学基础和临床意义

Genetic Basis and Clinical Implications



上海科学技术出版社

参考文献

第1章

1. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. *N Engl J Med*. 1994; 331(25): 1669–74. <https://doi.org/10.1056/NEJM199412223312501>.
2. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology*. 1999; 116(6): 1453–6.
3. Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. *Genet Med*. 2009; 11(1): 35–41. <https://doi.org/10.1097/GIM.0b013e31818fa2ff>.
4. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. *Gastroenterology*. 2014; 147(2): 502–26. <https://doi.org/10.1053/j.gastro.2014.04.001>.
5. Boland CR, Lynch HT. The history of Lynch syndrome. *Familial Cancer*. 2013; 12(2): 145–57. <https://doi.org/10.1007/s10689-013-9637-8>.
6. Warthin AS. The further study of a cancer family. *J Cancer Research*. 1925; 9: 279–86.
7. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICG-HNPCC). *Dis Colon Rectum*. 1991; 34(5): 424–5.
8. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science*. 1993; 260(5109): 816–9.
9. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature*. 1993; 363(6429): 558–561.
10. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell*. 1994; 77(1): 1. p following 166.
11. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. *Cell*. 1993; 75(6): 1215–25.
12. Peltomaki P, Aaltonen LA, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, et al. Genetic mapping of a locus predisposing to human colorectal cancer. *Science*. 1993; 260(5109): 810–2.
13. Lindblom A, Tannergard P, Werelius B, Nordenskjold M. Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer. *Nat Genet*. 1993; 5(3): 279–82. <https://doi.org/10.1038/ng1193-279>.
14. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA Mismatch Repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature*. 1994; 368(6468): 258–261.
15. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. *Science*. 1994; 263(5153): 1625–29.
16. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutations of two PMS homologues

- in hereditary nonpolyposis colon cancer. *Nature*. 1994; 371(6492): 75–80. <https://doi.org/10.1038/371075a0>.
17. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. *Nat Genet*. 1997; 17(3): 271–2. <https://doi.org/10.1038/ng1197-271>.
 18. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. *Nat Genet*. 2009; 41(1): 112–7. <https://doi.org/10.1038/ng.283>.
 19. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of micro-satellite instability in colorectal cancer. *Cancer Res*. 1998; 58(22): 5248–57.
 20. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med*. 2005; 352(18): 1851–60.
 21. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. *J Clin Oncol*. 2017; 35(10): 1086–95. <https://doi.org/10.1200/JCO.2016.71.0012>.
 22. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, et al. PMS2 monoallelic mutation carriers: the known unknown. *Genet Med*. 2016; 18(1): 13–9. <https://doi.org/10.1038/gim.2015.27>.
 23. Haraldsdottir S, Rafnar T, Frankel WL, Einarsson S, Sigurdsson A, Hampel H, et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. *Nat Commun*. 2017; 8: 14755. <https://doi.org/10.1038/ncomms14755>.
 24. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomark Prev*. 2017; 26(3): 404–12. <https://doi.org/10.1158/1055-9965.EPI-16-0693>.
 25. Pinheiro M, Pinto C, Peixoto A, Veiga I, Lopes P, Henrique R, et al. Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. *Br J Cancer*. 2015; 113(4): 686–92. <https://doi.org/10.1038/bjc.2015.281>.
 26. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet*. 2005; 42(6): 491–6. 42/6/491 [pii] . <https://doi.org/10.1136/jmg.2004.024299>.
 27. Jenkins MA, Baglietto L, Dowty JG, Van Vliet CM, Smith L, Mead LJ, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. *Clin Gastroenterol Hepatol*. 2006; 4(4): 489–98. <https://doi.org/10.1016/j.cgh.2006.01.002>. S1542-3565(06)00049-8 [pii] .
 28. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology*. 2009; 137(5): 1621–7. <https://doi.org/10.1053/j.gastro.2009.07.039>. S0016-5085(09)01158-5 [pii] .
 29. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer*. 1999; 81(2): 214–8.
 30. Moller P, Seppala TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. 2017. <https://doi.org/10.1136/gutjnl-2017-314057>.
 31. Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. *J Natl Cancer Inst*. 2013; 105(4): 274–9. <https://doi.org/10.1093/jnci/djs525>.
 32. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut*. 2013; 62(6): 812–23. <https://doi.org/10.1136/gutjnl-2012-304356>.
 33. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology*. 2008; 135(2): 419–28. <https://doi.org/10.1053/j.gastro.2008.04.026>. S0016-5085(08)00737-3 [pii] .
 34. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst*. 2010; 102(3): 193–201. <https://doi.org/10.1093/jnci/djp473>. djp473 [pii] .
 35. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. *J Clin Oncol*. 2001; 19(20): 4074–80.

36. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. *J Clin Oncol.* 2012; 30(35): 4409–15. <https://doi.org/10.1200/JCO.2012.43.2278>.
37. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. *Gastroenterology.* 2010; 138(2): 487–92. <https://doi.org/10.1053/j.gas-tro.2009.10.051>. S0016–5085(09)01948–9 [pii] .
38. van der Post RS, Kiemeny LA, Ligtenberg MJ, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. *J Med Genet.* 2010; 47(7): 464–70. <https://doi.org/10.1136/jmg.2010.076992>.
39. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA.* 2009; 302(16): 1790–5. <https://doi.org/10.1001/jama.2009.1529>. 302/16/1790 [pii] .
40. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol.* 2012; 30(9): 958–64. <https://doi.org/10.1200/JCO.2011.39.5590>.
41. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. *J Clin Oncol.* 2013; 31(14): 1713–8. <https://doi.org/10.1200/JCO.2012.44.1238>.
42. Kempers MJ, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol.* 2011; 12(1): 49–55. [https://doi.org/10.1016/S1470-2045\(10\)70265-5](https://doi.org/10.1016/S1470-2045(10)70265-5). S1470–2045(10)70265–5 [pii] .
43. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, et al. PMS2 monoallelic mutation carriers: the known unknown. *Genet Med.* 2015. <https://doi.org/10.1038/gim.2015.27>.
44. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2017; 66(3): 464–72. <https://doi.org/10.1136/gutjnl-2015-309675>.
45. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015; 110(2): 223–62; quiz 63. <https://doi.org/10.1038/ajg.2014.435>.
46. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med.* 2000; 342(2): 69–77. <https://doi.org/10.1056/NEJM200001133420201>.
47. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. *Gastroenterology.* 2004; 126(2): 394–401.
48. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med.* 2003; 349(3): 247–57. <https://doi.org/10.1056/NEJMoa022289>.
49. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015; 372(26): 2509–20. <https://doi.org/10.1056/NEJMoa1500596>.
50. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science.* 2017; 357(6349): 409–13. <https://doi.org/10.1126/science.aan6733>.
51. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut.* 2011; 60(7): 950–7. <https://doi.org/10.1136/gut.2010.228056>.
52. Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. *Ann Surg Oncol.* 2013; 20(6): 1829–36. <https://doi.org/10.1245/s10434-012-2858-5>.
53. Vasen HF, Abdirahman M, Brohet R, Langers AM, Kleibeuker JH, van Kouwen M, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology.* 2010; 138(7): 2300–6. <https://doi.org/10.1053/j.gastro.2010.02.053>. S0016–5085(10)00326–4 [pii] .
54. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol.* 2009; 27(28): 4793–7. <https://doi.org/10.1200/JCO.2009.23.7784>.
55. Engel C, Rahner N, Schulmann K, Holinski-Feder E, Goecke TO, Schackert HK, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol.*

- 2010; 8(2): 174–82. <https://doi.org/10.1016/j.cgh.2009.10.003>.
56. Edelstein DL, Axilbund J, Baxter M, Hyland LM, Romans K, Griffin CA, et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. *Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc.* 2011; 9(4): 340–3. <https://doi.org/10.1016/j.cgh.2010.10.033>.
57. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Engl J Med.* 2003; 348(10): 919–32. <https://doi.org/10.1056/NEJMra012242>. 348/10/919 [pii] .
58. Ahadova A, von Knebel Doeberitz M, Blaker H, Kloor M. CTNNB1–mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. *Familial Cancer.* 2016; 15(4): 579–86. <https://doi.org/10.1007/s10689-016-9899-z>.
59. Kaminski MF, Hassan C, Bisschops R, Pohl J, Pellise M, Dekker E, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy.* 2014; 46(5): 435–49. <https://doi.org/10.1055/s-0034-1365348>.
60. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet.* 2011; 378(9809): 2081–7. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0).
61. Goverde A, Spaander MC, van Doorn HC, Dubbink HJ, van den Ouweland AM, Tops CM, et al. Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70 years of age. *Gynecol Oncol.* 2016; 143(3): 453–9. <https://doi.org/10.1016/j.ygyno.2016.10.008>.
62. Committee on Practice B-G, Society of Gynecologic O. ACOG Practice Bulletin No. 147: Lynch syndrome. *Obstet Gynecol.* 2014; 124(5): 1042–54. <https://doi.org/10.1097/01.AOG.0000456325.50739.72>.
63. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA.* 2011; 305(22): 2304–10. <https://doi.org/10.1001/jama.2011.743>.
64. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med.* 2006; 354(3): 261–9. <https://doi.org/10.1056/NEJMoa052627>.
65. Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. *J Natl Cancer Inst.* 2012; 104(18): 1363–72. <https://doi.org/10.1093/jnci/djs351>.
66. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, et al. The risk of extracolonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer.* 2008; 123(2): 444–9. <https://doi.org/10.1002/ijc.23508>.
67. Kastrinos F, Stoffel EM, Balmana J, Steyerberg EW, Mercado R, Syngal S. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. *Cancer Epidemiol Biomark Prev.* 2008; 17(8): 2044–51. <https://doi.org/10.1158/1055-9965.EPI-08-0301>. 17/8/2044 [pii] .
68. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut.* 2013; 62(3): 339–47. <https://doi.org/10.1136/gutjnl-2012-303108>.
69. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst.* 1997; 89(23): 1758–62.
70. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst.* 2004; 96(4): 261–8.
71. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA.* 2012; 308(15): 1555–65. <https://doi.org/10.1001/jama.2012.13088.1383232> [pii] .
72. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med.* 2009; 11(1): 42–65. <https://doi.org/10.1097/GIM.0b013e31818fa2db>.
73. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol.* 2008; 26(35): 5783–8. <https://doi.org/10.1200/JCO.2008.17.5950>. JCO.2008.17.5950 [pii] .
74. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al.

- Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. *Gastroenterology*. 2014; 146(3): 643–6 e8. <https://doi.org/10.1053/j.gastro.2013.12.002>.
75. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. *Gastroenterology*. 2014; 147(6): 1308–16 e1. <https://doi.org/10.1053/j.gastro.2014.08.041>.
 76. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Ann Intern Med*. 2011; 155(2): 69–79. <https://doi.org/10.1059/0003-4819-155-2-201107190-00002>. 155/2/69 [pii] .
 77. Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA*. 2006; 296(12): 1479–87. <https://doi.org/10.1001/jama.296.12.1479>.
 78. Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, et al. The PREMM(1, 2, 6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. *Gastroenterology*. 2011; 140(1): 73–81. <https://doi.org/10.1053/j.gastro.2010.08.021>. S0016-5085(10)01239-4 [pii] .
 79. Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, et al. Development and validation of the PREMM5 model for comprehensive risk assessment of Lynch syndrome. *J Clin Oncol*. 2017; 35(19): 2165–72. <https://doi.org/10.1200/JCO.2016.69.6120>.
 80. Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. *Cancer Prev Res (Phila)*. 2011; 4(1): 9–22. <https://doi.org/10.1158/1940-6207.CAPR-10-0262>. 1940-6207.CAPR-10-0262 [pii] .
 81. Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. *N Engl J Med*. 2007; 356(7): 697–705. <https://doi.org/10.1056/NEJMoa064522>.
 82. Hitchins MP, Rapkins RW, Kwok CT, Srivastava S, Wong JJ, Khachigian LM, et al. Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. *Cancer Cell*. 2011; 20(2): 200–13. <https://doi.org/10.1016/j.ccr.2011.07.003>.
 83. Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K. American Society of Clinical O. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol : Off J Am Soc Clin Oncol*. 2010; 28(5): 893–901. <https://doi.org/10.1200/JCO.2009.27.0660>.
 84. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group ACoMG, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med*. 2015; 17(1): 70–87. <https://doi.org/10.1038/gim.2014.147>.
 85. Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, et al. American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers. *J Clin Oncol: Off J Am Soc Clin Oncol*. 2014; 32(8): 833–40. <https://doi.org/10.1200/JCO.2013.50.9257>.
 86. Balmana J, Balaguer F, Cervantes A, Arnold D, Group EGW. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2013; 24(Suppl 6): vi73–80. <https://doi.org/10.1093/annonc/mdt209>.
 87. Douglas JA, et al. History and molecular genetics of Lynch syndrome in Family G. A century later. *JAMA*. 2005; 294(17): 2195–202.

第2章

1. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med*. 2005; 352: 1851–60.
2. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA*. 2012; 308: 1555–65. <https://doi.org/10.1001/jama.2012.13088>.
3. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res*. 2006; 66: 7810–7.
4. Overbeek LIH, Kets CM, Hebeda KM, Bodmer D, van der Looij E, Willems R, et al. Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer. *Br J Cancer*. 2007; 96: 1605–12. <https://doi.org/10.1038/sj.bjc.6603754>.
5. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, Zapater P, Castillejo A, Barbera VM, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. *Gastroenterology*. 2013; 144: 924–6. <https://doi.org/10.1053/j.gastro.2013.01.044>.
6. Win AK, Buchanan DD, Rosty C, MacInnis RJ, Dowty JG, Dite GS, et al. Role of tumour molecular and pathology

- features to estimate colorectal cancer risk for first-degree relatives. *Gut*. 2015; 64(1): 101–10. <https://doi.org/10.1136/gutjnl-2013-306567>.
7. Vargas-Parra GM, Gonzalez-Acosta M, Thompson BA, Gomez C, Fernandez A, Damaso E, et al. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis. *Int J Cancer*. 2017. <https://doi.org/10.1002/ijc.30820>.
 8. Kang SY, Park CK, Chang DK, Kim JW, Son HJ, Cho YB, et al. Lynch-like syndrome : characterization and comparison with EPCAM deletion carriers. *Int J Cancer*. 2015; 136: 1568–78. <https://doi.org/10.1002/ijc.29133>.
 9. Chika N, Eguchi H, Kumamoto K, Suzuki O, Ishibashi K, Tachikawa T, et al. Prevalence of Lynch syndrome and lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. *Jpn J Clin Oncol*. 2017; 47(2): 108–17. <https://doi.org/10.1093/jjco/hyw178>.
 10. Mas-Moya J, Dudley B, Brand RE, Thull D, Bahary N, Nikiforova MN, et al. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with lynch-like syndrome versus patients with Lynch syndrome. *Hum Pathol*. 2015; 46(11): 1616–25. <https://doi.org/10.1016/j.humpath.2015.06.022>.
 11. O’Kane GM, Ryan E, McVeigh TP, Creavin B, Hyland JM, O’Donoghue DP, et al. Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers. *Cancer Med*. 2017; 6(6): 1465–72. <https://doi.org/10.1002/cam4.1025>.
 12. Buchanan DD, Rosty C, Clendenning M, Win AK. Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome). *Appl Clin Genet*. 2014; 7: 183–93.
 13. Geurts-Giele WR, Leenen CH, Dubbink HJ, Meijssen IC, Post E, Sleddens HF, et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. *J Pathol*. 2014; 234: 548–59. <https://doi.org/10.1002/path.4419>.
 14. Thompson BA, Spurdle AB, Plazzer J-P, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet*. 2014; 46: 107–15. <https://doi.org/10.1038/ng.2854>.
 15. Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. *J Clin Oncol Off J Am Soc Clin Oncol*. 2015; 33(5): 426–32. <https://doi.org/10.1200/JCO.2014.56.5689>.
 16. Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. *Clin Genet*. 2014; 86(6): 510–20. <https://doi.org/10.1111/cge.12359>.
 17. Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. *Familial Cancer*. 2017; 16(1): 159–66. <https://doi.org/10.1007/s10689-016-9913-5>.
 18. Howarth DR, Lum SS, Esquivel P, Garberoglio CA, Senthil M, Solomon NL. Initial results of multigene panel testing for hereditary breast and ovarian cancer and Lynch syndrome. *Am Surg*. 2015; 81(10): 941–4.
 19. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and Spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol*. 2017; 3(4): 464–71. <https://doi.org/10.1001/jamaoncol.2016.5194>.
 20. Ricker C, Culver JO, Lowstuter K, Sturgeon D, Sturgeon JD, Chanock CR, et al. Increased yield of actionable mutations using multigene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. *Cancer Genet*. 2016; 209(4): 130–7. <https://doi.org/10.1016/j.cancergen.2015.12.013>.
 21. Rohlin A, Rambech E, Kvist A, Torngren T, Eiengard F, Lundstam U, et al. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. *Familial Cancer*. 2017; 16(2): 195–203. <https://doi.org/10.1007/s10689-016-9934-0>.
 22. Slavin TP, Neuhausen SL, Nehoray B, Niell-Swiler M, Solomon I, Rybak C, et al. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. *Familial Cancer*. 2017. <https://doi.org/10.1007/s10689-017-0019-5>.
 23. Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. *Gastroenterology*. 2015; 149(3): 604–13 e20. <https://doi.org/10.1053/j.gastro.2015.05.006>.
 24. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 2017; 35(10): 1086–95. <https://doi.org/10.1200/JCO.2016.35.1086>.

- org/10.1200/JCO.2016.71.0012.
25. LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2, 000 patients. *Genet Med Off J Am Coll Med Genet.* 2014; 16(11): 830–7. <https://doi.org/10.1038/gim.2014.40>.
 26. Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. *Genet Med Off J Am Coll Med Genet.* 2016; 18(8): 823–32. <https://doi.org/10.1038/gim.2015.166>.
 27. Clendenning M, Buchanan DD, Walsh MD, Nagler B, Rosty C, Thompson B, et al. Mutation deep within an intron of MSH2 causes Lynch syndrome. *Familial Cancer.* 2011; 10: 297–301. <https://doi.org/10.1007/s10689-011-9427-0>.
 28. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. *Nat Genet.* 2009; 41: 112–7. <https://doi.org/10.1038/ng.283>.
 29. Morak M, Koehler U, Schackert HK, Steinke V, Royer-Pokora B, Schulmann K, et al. Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome. *J Med Genet.* 2011; 48: 513–9. <https://doi.org/10.1136/jmedgenet-2011-100050>.
 30. Wagner A, van der Klift H, Franken P, Wijnen J, Breukel C, Bezrookove V, et al. A 10-Mb para-centric inversion of chromosome arm 2p inactivates MSH2 and is responsible for hereditary nonpolyposis colorectal cancer in a North-American kindred. *Genes Chromosomes Cancer.* 2002; 35(1): 49–57. <https://doi.org/10.1002/gcc.10094>.
 31. Mork ME, Rodriguez A, Taggart MW, Rodriguez-Bigas MA, Lynch PM, Bannon SA, et al. Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome. *Familial Cancer.* 2016. <https://doi.org/10.1007/s10689-016-9960-y>.
 32. Rhees J, Arnold M, Boland CR. Inversion of exons 1–7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. *Familial Cancer.* 2014; 13: 219–25. <https://doi.org/10.1007/s10689-013-9688-x>.
 33. Liu Q, Hesson LB, Nunez AC, Packham D, Williams R, Ward RL, et al. A cryptic paracentric inversion of MSH2 exons 2–6 causes Lynch syndrome. *Carcinogenesis.* 2016; 37(1): 10–7. <https://doi.org/10.1093/carcin/bgv154>.
 34. Liu Q, Thompson BA, Ward RL, Hesson LB, Sloane MA. Understanding the pathogenicity of noncoding mismatch repair gene promoter variants in Lynch syndrome. *Hum Mutat.* 2016; 37(5): 417–26. <https://doi.org/10.1002/humu.22971>.
 35. Wilding JL, McGowan S, Liu Y, Bodmer WF. Replication error deficient and proficient colorectal cancer gene expression differences caused by 3' UTR polyT sequence deletions. *Proc Natl Acad Sci U S A.* 2010; 107(49): 21058–63. <https://doi.org/10.1073/pnas.1015604107>.
 36. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). *Proc Natl Acad Sci.* 2010; 107: 21098–103. <https://doi.org/10.1073/pnas.1015541107>.
 37. Sourrouille I, Coulet F, Lefevre JH, Colas C, Eyries M, Svrcek M, et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. *Familial Cancer.* 2013; 12: 27–33.
 38. Pastrello C, Fornasarig M, Pin E, Berto E, Pivetta B, Viel A. Somatic mosaicism in a patient with Lynch syndrome. *Am J Med Genet A.* 2009; 149: 212–5. <https://doi.org/10.1002/ajmg.a.32620>.
 39. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. *Gastroenterology.* 2014; 147: 1308–16.e1. <https://doi.org/10.1053/j.gastro.2014.08.041>.
 40. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WAG, Goossens M, Ouchene H, Hendriks-Cornelissen SJB, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. *Gastroenterology.* 2014; 146: 643–6.e8. <https://doi.org/10.1053/j.gastro.2013.12.002>.
 41. Jansen AM, Geilenkirchen MA, van Wezel T, Jagmohan-Changur SC, Ruano D, van der Klift HM, et al. Whole gene capture analysis of 15 CRC susceptibility genes in suspected Lynch syndrome patients. *PLoS One.* 2016; 11(6): e0157381. <https://doi.org/10.1371/journal.pone.0157381>.
 42. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci U S A.* 1998; 95(12): 6870–5.
 43. Yamamoto H, Imai K. Microsatellite instability: an update. *Arch Toxicol.* 2015; 89: 899–921. <https://doi.org/10.1007/s00204-015-1474-0>.
 44. Nagasaka T, Rhees J, Kloor M, Gebert J, Naomoto Y, Boland CR, et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. *Cancer Res.* 2010; 70: 3098–108. <https://doi.org/10.1158/0008-5472.CCR-09-4000>.

- org/10.1158/0008-5472.CAN-09-3290.
45. Rumilla K, Schowalter KV, Lindor NM, Thomas BC, Mensink KA, Gallinger S, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. *J Mol Diagn.* 2011; 13: 93-9.
 46. Lima EM. DNA mismatch repair gene methylation in gastric cancer in individuals from northern Brazil. *Biocell.* 2008; 32: 237-43.
 47. Vymetalkova VP, Slyskova J, Korenkova V, Bielik L, Langerova L, Prochazka P, et al. Molecular characteristics of mismatch repair genes in sporadic colorectal tumors in Czech patients. *BMC Med Genet.* 2014; 15: 17. <https://doi.org/10.1186/1471-2350-15-17>.
 48. Truninger K, Menigatti M, Luz J, Russell A, Haider R, Gebbers J-O, et al. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. *Gastroenterology.* 2005; 128: 1160-71. <https://doi.org/10.1053/j.gastro.2005.01.056>.
 49. Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A, et al. Biallelic MUTYH mutations can mimic Lynch syndrome. *Eur J Hum Genet.* 2014; 22: 1334-7. <https://doi.org/10.1038/ejhg.2014.15>.
 50. Castillejo A, Vargas G, Castillejo I, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among lynch-like syndrome patients. *European. J Cancer.* 2014; 50: 2241-50. <https://doi.org/10.1016/j.ejca.2014.05.022>.
 51. Gomez-Fernandez N, Castellvi-Bel S, Fernandez-Rozadilla C, Balaguer F, Munoz J, Madrigal I, et al. Molecular analysis of the APC and MUTYH genes in Galician and Catalanian FAP families: a different spectrum of mutations? *BMC Med Genet.* 2009; 10: 57.
 52. Guarinos C, Juárez M, Egoavil C, Rodríguez-Soler M, Pérez-Carbonell L, Salas R, et al. Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps. *Clin Cancer Res Off J Am Assoc Cancer Res.* 2014; 20: 1158-68. <https://doi.org/10.1158/1078-0432.CCR-13-1490>.
 53. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). *Crit Rev Oncol Hematol.* 2011; 79: 1-16. <https://doi.org/10.1016/j.critrevonc.2010.05.011>.
 54. Balaguer F, Castellvi-Bel S, Castells A, Andreu M, Munoz J, Gisbert JP, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2007; 5: 379-87. <https://doi.org/10.1016/j.cgh.2006.12.025>.
 55. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. *Gastroenterology.* 2009; 136(4): 1251-60.
 56. Colebatch A, Hitchins M, Williams R, Meagher a, Hawkins NJ, Ward RL. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. *Br J Cancer.* 2006; 95: 1239-43. <https://doi.org/10.1038/sj.bjc.6603421>.
 57. Lefevre JH, Colas C, Coulet F, Bonilla C, Mourra N, Flejou JF, et al. MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions. *Familial Cancer.* 2010; 9(4): 589-94.
 58. Seguí N, Navarro M, Pineda M, Köger N, Bellido F, González S, et al. Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype. *Gut.* 2015; 64: 355-6. <https://doi.org/10.1136/gutjnl-2014-307084>.
 59. Giráldez MD, Balaguer F, Bujanda L, Cuatrecasas M, Muñoz J, Alonso-Espinaco V, et al. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. *Clin Cancer Res Off J Am Assoc Cancer Res.* 2010; 16: 5402-13. <https://doi.org/10.1158/1078-0432.CCR-10-1491>.
 60. Knopperts AP, Nielsen M, Niessen RC, Tops CMJ, Jorritsma B, Varkevisser J, et al. Contribution of biallelic germline MUTYH mutations to early-onset and familial colorectal cancer and to low number of adenomatous polyps: case-series and literature review. *Familial Cancer.* 2013; 12: 43-50. <https://doi.org/10.1007/s10689-012-9570-2>.
 61. Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GM, Halling KC, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. *Gastroenterology.* 2004; 127: 9-16.
 62. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015; 110: 223-62.
 63. Croitoru ME, Cleary SP, Berk T, Nicola NDI, Kopolovic I, Bapat B, et al. Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients. *J Surg Oncol.* 2007: 499-506. <https://doi.org/10.1002/jso>.
 64. Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. *Gastroenterology.* 2009; 137: 489-94, 94.e1; quiz 725-6. <https://doi.org/10.1053/j.gastro.2009.05.011>.

- doi.org/10.1053/j.gastro.2009.04.047.
65. Khalaf R, Jones C, Strutt W, Williamson P. Colorectal cancer in a monoallelic MYH mutation carrier. *J Gastrointest Surg Off J Soc Surg Aliment Tract.* 2013; 17: 1500–2. <https://doi.org/10.1007/s11605-013-2206-5>.
 66. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. *Gastroenterology.* 2014; 146(5): 1208–11e1–5. <https://doi.org/10.1053/j.gastro.2014.01.022>.
 67. Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. *J Clin Oncol Off J Am Soc Clin Oncol.* 2009; 27: 3975–80. <https://doi.org/10.1200/JCO.2008.21.6853>.
 68. Ma X, Zhang B, Zheng W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. *Gut.* 2014; 63: 326–36. <https://doi.org/10.1136/gutjnl-2012-304121>.
 69. Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. *Br J Cancer.* 2010; 103: 1875–84. <https://doi.org/10.1038/sj.bjc.6605966>.
 70. Palles C, Cazier J-B, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet.* 2012; 45: 136–44. <https://doi.org/10.1038/ng.2503>.
 71. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo M-I, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. *Hum Mol Genet.* 2014; 23: 3506–12. <https://doi.org/10.1093/hmg/ddu058>.
 72. Elsayed FA, Kets CM, Ruano D, van den Akker B, Mensenkamp AR, Schrupf M, et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. *Eur J Hum Genet EJHG.* 2014; 1–5. <https://doi.org/10.1038/ejhg.2014.242>.
 73. Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, et al. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. *Eur J Hum Genet.* 2016; 24(7): 1089–92. <https://doi.org/10.1038/ejhg.2015.252>.
 74. Yoshida R, Miyashita K, Inoue M, Shimamoto A, Yan Z, Egashira A, et al. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. *Eur J Hum Genet.* 2011; 19(3): 320–5. <https://doi.org/10.1038/ejhg.2010.216>.
 75. Seguí N, Mina LB, Lázaro C, Sanz-Pamplona R, Pons T, Navarro M, et al. Germline mutations in FAN1 cause hereditary colorectal cancer by impairing DNA repair. *Gastroenterology.* 2015; 1–4. <https://doi.org/10.1053/j.gastro.2015.05.056>.
 76. Smith AL, Alirezaie N, Connor A, Chan-Seng-Yue M, Grant R, Selander I, et al. Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. *Cancer Lett.* 2016; 370(2): 302–12. <https://doi.org/10.1016/j.canlet.2015.10.030>.
 77. Broderick P, Dobbins SE, Chubb D, Kinnersley B, Dunlop MG, Tomlinson I, et al. Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients: a systematic review. *Gastroenterology.* 2017; 152(1): 75–7 e4. <https://doi.org/10.1053/j.gastro.2016.09.041>.
 78. Cannavo E, Gerrits B, Marra G, Schlapbach R, Jiricny J. Characterization of the interactome of the human MutL homologues MLH1, PMS1, and PMS2. *J Biol Chem.* 2007; 282: 2976–86. <https://doi.org/10.1074/jbc.M609989200>.
 79. Kinch LN, Ginalski K, Rychlewski L, Grishin NV. Identification of novel restriction endonuclease-like fold families among hypothetical proteins. *Nucleic Acids Res.* 2005; 33: 3598–605. <https://doi.org/10.1093/nar/gki676>.
 80. MacKay C, Déclais A-C, Lundin C, Agostinho A, Deans AJ, MacArtney TJ, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. *Cell.* 2010; 142: 65–76. <https://doi.org/10.1016/j.cell.2010.06.021>.
 81. O'Donnell L, Durocher D. DNA repair has a new FAN1 club. *Mol Cell.* 2010; 39: 167–9. <https://doi.org/10.1016/j.molcel.2010.07.010>.
 82. Traver S, Coulombe P, Peiffer I, Hutchins JR, Kitzmann M, Latreille D, et al. MCM9 is required for mammalian DNA mismatch repair. *Mol Cell.* 2015; 59(5): 831–9. <https://doi.org/10.1016/j.molcel.2015.07.010>.
 83. Nishimura K, Ishiai M, Horikawa K, Fukagawa T, Takata M, Takisawa H, et al. Mcm8 and Mcm9 form a complex that functions in homologous recombination repair induced by DNA interstrand crosslinks. *Mol Cell.* 2012; 47(4): 511–22. <https://doi.org/10.1016/j.molcel.2012.05.047>.
 84. Goldberg Y, Halpern N, Hubert A, Adler SN, Cohen S, Plesser-Duvdevani M, et al. Mutated MCM9 is associated with predisposition to hereditary mixed polyposis and colorectal cancer in addition to primary ovarian failure.

- Cancer Genet. 2015; 208(12): 621–4. <https://doi.org/10.1016/j.cancergen.2015.10.001>.
85. Liu Q, Hesson LB, Nunez AC, Packham D, Hawkins NJ, Ward RL, et al. Pathogenic germline MCM9 variants are rare in Australian lynch-like syndrome patients. *Cancer Genet.* 2016; 209(11): 497–500. <https://doi.org/10.1016/j.cancergen.2016.10.001>.
 86. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. *Br J Cancer.* 2014; 110(2): 530–4. <https://doi.org/10.1038/bjc.2013.741>.
 87. Leland S, Nagarajan P, Polyzos A, Thomas S, Samaan G, Donnell R, et al. Heterozygosity for a Bub1 mutation causes female-specific germ cell aneuploidy in mice. *Proc Natl Acad Sci U S A.* 2009; 106: 12776–81. <https://doi.org/10.1073/pnas.0903075106>.
 88. de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJL, Smeets D, Fu L, et al. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. *Gastroenterology.* 2013; 145: 544–7. <https://doi.org/10.1053/j.gastro.2013.06.001>.
 89. Hanks S, Coleman K, Reid S, Plaja A, Firth H, FitzPatrick D, et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. *Nat Genet.* 2004; 36: 1159–61. <https://doi.org/10.1038/ng1449>.
 90. Li F, Mao G, Tong D, Huang J, Gu L, Yang W, et al. The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSa. *Cell.* 2013; 153: 590–600. <https://doi.org/10.1016/j.cell.2013.03.025>.
 91. Choi YJ, Oh HR, Choi MR, Gwak M, An CH, Chung YJ, et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. *Hum Pathol.* 2014; 45: 1674–81. <https://doi.org/10.1016/j.humpath.2014.04.013>.
 92. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase ϵ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. *Cancer.* 2015; 121: 386–94. <https://doi.org/10.1002/cncr.29046>.
 93. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. *Nat Genet.* 2015; 47: 257–62. <https://doi.org/10.1038/ng.3202>.

第3章

1. Wang Q, Lasset C, Desseigne F, Frappaz D, Bergeron C, Navarro C, et al. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. *Cancer Res.* 1999; 59(2): 294–7.
2. Ricciardone MD, Ozçelik T, Cevher B, Ozdag H, Tuncer M, Gürgey A, et al. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. *Cancer Res.* 1999; 59(2): 290–3.
3. Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. *J Med Genet.* 2015; 52(11): 770–8.
4. Wimmer K, Kratz CP, Vasen HFA, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). *J Med Genet.* 2014; 51(6): 355–65.
5. Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. *Eur J Cancer Oxf Engl* 1990. 2014; 50(5): 987–96.
6. Turcot J, Despres JP, St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. *Dis Colon Rectum.* 1959; 2: 465–8.
7. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al. The molecular basis of Turcot’s syndrome. *N Engl J Med.* 1995; 332(13): 839–47.
8. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. *Nat Genet.* 2015; 47(3): 257–62.
9. Ripperger T, Schlegelberger B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. *Eur J Med Genet.* 2016; 59(3): 133–42.
10. Aronson M, Gallinger S, Cohen Z, Cohen S, Dvir R, Elhasid R, et al. Gastrointestinal findings in the largest series of patients with hereditary biallelic mismatch repair deficiency syndrome: report from the International Consortium. *Am J Gastroenterol.* 2016; 111(2): 275–84.

11. Wimmer K, Beilken A, Nustede R, Ripperger T, Lamottke B, Ure B, et al. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. *Familial Cancer*. 2017; 16(1): 67–71.
12. Chmara M, Wernstedt A, Wasag B, Peeters H, Renard M, Beert E, et al. Multiple pilomatricomas with somatic CTNNB1 mutations in children with constitutive mismatch repair deficiency. *Genes Chromosomes Cancer*. 2013; 52(7): 656–64.
13. Wimmer K, Rosenbaum T, Messiaen L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. *Clin Genet*. 2017; 91(4): 507–19.
14. Gardès P, Forveille M, Alyanakian M-A, Aucouturier P, Ilencikova D, Leroux D, et al. Human MSH6 deficiency is associated with impaired antibody maturation. *J Immunol Baltim Md 1950*. 2012; 188(4): 2023–9.
15. Crouse GF. Non-canonical actions of mismatch repair. *DNA Repair*. 2016; 38: 102–9.
16. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2017; 26(3): 404–12.
17. Colas C. Clinical and biological consequences of constitutional mismatch repair deficiency in human [Thèse de doctorat en Génétique des tumeurs] . Paris 6. 2011.
18. Felton KEA, Gilchrist DM, Andrew SE. Constitutive deficiency in DNA mismatch repair. *Clin Genet*. 2007; 71(6): 483–98.
19. Li L, Hamel N, Baker K, McGuffin MJ, Couillard M, Gologan A, et al. A homozygous PMS2 founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. *J Med Genet*. 2015; 52(5): 348–52.
20. Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. *Gastroenterology*. 2015; 149(4): 1017–1029.e3.
21. Wimmer K, Wernstedt A. PMS2 gene mutational analysis: direct cDNA sequencing to circumvent pseudogene interference. *Methods Mol Biol Clifton NJ*. 2014; 1167: 289–302.
22. Vaughn CP, Hart KJ, Samowitz WS, Swensen JJ. Avoidance of pseudogene interference in the detection of 3' deletions in PMS2. *Hum Mutat*. 2011; 32(9): 1063–71.
23. van der Klift HM, Mensenkamp AR, Drost M, Bik EC, Vos YJ, Gille HJJ, et al. Comprehensive mutation analysis of PMS2 in a large cohort of probands suspected of lynch syndrome or constitutional mismatch repair deficiency syndrome. *Hum Mutat*. 2016; 37(11): 1162–79.
24. Ingham D, Diggie CP, Berry I, Bristow CA, Hayward BE, Rahman N, et al. Simple detection of germline microsatellite instability for diagnosis of constitutional mismatch repair cancer syndrome. *Hum Mutat*. 2013; 34(6): 847–52.
25. Vogt J, Wernstedt A, Ripperger T, Pabst B, Zschocke J, Kratz C, et al. PMS2 inactivation by a complex rearrangement involving an HERV retroelement and the inverted 100-kb duplison on 7p22.1. *Eur J Hum Genet EJHG*. 2016; 24(11): 1598–604.
26. Vasen HFA, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium 'Care for CMMR-D' (C4CMMR-D). *J Med Genet*. 2014; 51(5): 283–93.
27. Durno CA, Aronson M, Tabori U, Malkin D, Gallinger S, Chan HSL. Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. *Pediatr Blood Cancer*. 2012; 59(4): 652–6.
28. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. *Nat Rev Cancer*. 2008; 8(1): 24–36.
29. Ilencikova D, Sejnova D, Jindrova J, Babal P. High-grade brain tumors in siblings with biallelic MSH6 mutations. *Pediatr Blood Cancer*. 2011; 57(6): 1067–70.
30. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. *Cancer Res*. 2006; 66(8): 3987–91.
31. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. *J Clin Oncol Off J Am Soc Clin Oncol*. 2016; 34(19): 2206–11.
32. Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet Lond Engl*. 2011; 378(9809): 2081–7.

33. Gottschling S, Reinhard H, Pagenstecher C, Krüger S, Raedle J, Plotz G, et al. Hypothesis: possible role of retinoic acid therapy in patients with biallelic mismatch repair gene defects. *Eur J Pediatr*. 2008; 167(2): 225–9.

第4章

1. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam- I criteria families without mismatch repair deficiency: familial colorectal cancer type X. *JAMA*. 2005; 293(16): 1979–85.
2. Dominguez-Valentin M, Therkildsen C, Da Silva S, Nilbert M. Familial colorectal cancer type X: genetic profiles and phenotypic features. *Mod Pathol*. 2014; 28(1): 30–6.
3. Llor X, Pons E, Xicola RM, Castells A, Alenda C, Pinol V, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. *Clin Cancer Res*. 2005; 11(20): 7304–10.
4. Mueller-Koch Y, Vogelsang H, Kopp R, Lohse P, Keller G, Aust D, et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. *Gut*. 2005; 54(12): 1733–40.
5. Valle L, Perea J, Carbonell P, Fernandez V, Dotor AM, Benitez J, et al. Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. *J Clin Oncol*. 2007; 25(7): 781–6.
6. Francisco I, Albuquerque C, Lage P, Belo H, Vitoriano I, Filipe B, et al. Familial colorectal cancer type X syndrome: two distinct molecular entities? *Familial Cancer*. 2011; 10(4): 623–31.
7. Shiovitz S, Copeland WK, Passarelli MN, Burnett-Hartman AN, Grady WM, Potter JD, et al. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. *Br J Cancer*. 2014; 111(3): 598–602.
8. Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. *World J Gastroenterol*. 2006; 12(31): 4943–50.
9. Lindor NM. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. *Surg Oncol Clin N Am*. 2009; 18(4): 637–45.
10. Klarskov L, Holck S, Bernstein I, Nilbert M. Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. *J Clin Pathol*. 2012; 65(4): 352–6.
11. Abdel-Rahman WM, Ollikainen M, Kariola R, Jarvinen HJ, Mecklin JP, Nystrom-Lahti M, et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. *Oncogene*. 2005; 24(9): 1542–51.
12. Goel A, Xicola RM, Nguyen TP, Doyle BJ, Sohn VR, Bandipalliam P, et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. *Gastroenterology*. 2010; 138(5): 1854–62.
13. Therkildsen C, Jonsson G, Dominguez-Valentin M, Nissen A, Rambech E, Halvarsson B, et al. Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. *Eur J Cancer*. 2013; 49(6): 1226–35.
14. Ogino S, Kawasaki T, Noshō K, Ohnishi M, Suemoto Y, Kirkner GJ, et al. LINE-1 hypo-methylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. *Int J Cancer*. 2008; 122(12): 2767–73.
15. Igarashi S, Suzuki H, Niinuma T, Shimizu H, Nojima M, Iwaki H, et al. A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. *Clin Cancer Res*. 2010; 16(21): 5114–23.
16. Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, et al. A high degree of LINE-1 hypo-methylation is a unique feature of early-onset colorectal cancer. *PLoS One*. 2012; 7(9): e45357.
17. Ogino S, Noshō K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. *J Natl Cancer Inst*. 2008; 100(23): 1734–8.
18. Boland CR. Recent discoveries in the molecular genetics of Lynch syndrome. *Familial Cancer*. 2016; 15(3): 395–403.
19. Ikeda K, Shiraishi K, Eguchi A, Shibata H, Yoshimoto K, Mori T, et al. Long interspersed nucleotide element 1 hypomethylation is associated with poor prognosis of lung adenocarcinoma. *Ann Thorac Surg*. 2013; 96(5): 1790–4.
20. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K, Ishimoto T, et al. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. *Ann Surg*. 2013; 257(3): 449–55.
21. Shigaki H, Baba Y, Watanabe M, Murata A, Iwagami S, Miyake K, et al. LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. *Gastric Cancer*. 2013; 16(4): 480–7.

22. Sanchez-de-Abajo A, de la Hoya M, van Puijnenbroek M, Tosar A, Lopez-Asenjo JA, Diaz-Rubio E, et al. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. *Clin Cancer Res.* 2007; 13(19): 5729–35.
23. Middeldorp A, van Eijk R, Oosting J, Forte GI, van Puijnenbroek M, van Nieuwenhuizen M, et al. Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. *Int J Cancer.* 2012; 130(4): 837–46.
24. Bellido F, Pineda M, Sanz-Pamplona R, Navarro M, Nadal M, Lazaro C, et al. Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency. *Eur J Cancer.* 2014; 50(11): 1964–72.
25. Leppert M, Dobbs M, Scambler P, O’Connell P, Nakamura Y, Stauffer D, et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. *Science (New York, NY).* 1987; 238(4832): 1411–3.
26. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science (New York, NY).* 1991; 253(5020): 665–9.
27. Wiesner GL, Daley D, Lewis S, Ticknor C, Platzer P, Lutterbaugh J, et al. A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2–31.2. *Proc Natl Acad Sci U S A.* 2003; 100(22): 12961–5.
28. Kemp ZE, Carvajal-Carmona LG, Barclay E, Gorman M, Martin L, Wood W, et al. Evidence of linkage to chromosome 9q22.33 in colorectal cancer kindreds from the United Kingdom. *Cancer Res.* 2006; 66(10): 5003–6.
29. Skoglund J, Djureinovic T, Zhou XL, Vandrovicova J, Renkonen E, Iselius L, et al. Linkage analysis in a large Swedish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 9q22.32–31.1. *J Med Genet.* 2006; 43(2): e7.
30. Neklason DW, Kerber RA, Nilson DB, Anton-Culver H, Schwartz AG, Griffin CA, et al. Common familial colorectal cancer linked to chromosome 7q31: a genome-wide analysis. *Cancer Res.* 2008; 68(21): 8993–7.
31. Papaemmanuil E, Carvajal-Carmona L, Sellick GS, Kemp Z, Webb E, Spain S, et al. Deciphering the genetics of hereditary non-syndromic colorectal cancer. *Eur J Hum Genet.* 2008; 16(12): 1477–86.
32. Picelli S, Vandrovicova J, Jones S, Djureinovic T, Skoglund J, Zhou XL, et al. Genome-wide linkage scan for colorectal cancer susceptibility genes supports linkage to chromosome 3q. *BMC Cancer.* 2008; 8: 87.
33. Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, et al. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. *Cancer Res.* 2010; 70(13): 5409–18.
34. Neklason DW, Tuohy TM, Stevens J, Otterud B, Baird L, Kerber RA, et al. Colorectal adenomas and cancer link to chromosome 13q22.1–13q31.3 in a large family with excess colorectal cancer. *J Med Genet.* 2010; 47(10): 692–9.
35. Saunders IW, Ross J, Macrae F, Young GP, Blanco I, Brohede J, et al. Evidence of linkage to chromosomes 10p15.3–p15.1, 14q24.3–q31.1 and 9q33.3–q34.3 in non-syndromic colorectal cancer families. *Eur J Hum Genet.* 2012; 20(1): 91–6.
36. Kontham V, von Holst S, Lindblom A. Linkage analysis in familial non-Lynch syndrome colorectal cancer families from Sweden. *PLoS One.* 2013; 8(12): e83936.
37. Teerlink C, Nelson Q, Burt R, Cannon-Albright L. Significant evidence of linkage for a gene predisposing to colorectal cancer and multiple primary cancers on 22q11. *Clin Transl Gastroenterol.* 2014; 5: e50.
38. Rudkjobing LA, Eiberg H, Mikkelsen HB, Binderup ML, Bisgaard ML. The analysis of a large Danish family supports the presence of a susceptibility locus for adenoma and colorectal cancer on chromosome 11q24. *Familial Cancer.* 2015; 14(3): 393–400.
39. Sanchez-Tome E, Rivera B, Perea J, Pita G, Rueda D, Mercadillo F, et al. Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X. *J Gastroenterol.* 2015; 50(6): 657–66.
40. Valle L. Recent discoveries in the genetics of familial colorectal cancer and polyposis. *Clin Gastroenterol Hepatol.* 2017; 15(3): 461–462.
41. Nieminen TT, O’Donohue MF, Wu Y, Lohi H, Scherer SW, Paterson AD, et al. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary non-polyposis colorectal carcinoma without DNA mismatch repair deficiency. *Gastroenterology.* 2014; 147(3): 595–8 e5.
42. Broderick P, Dobbins SE, Chubb D, Kinnersley B, Dunlop MG, Tomlinson I, et al. Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients: a systematic review. *Gastroenterology.* 2016; 152(1): 75–7 e4.
43. Segui N, Mina LB, Lazaro C, Sanz-Pamplona R, Pons T, Navarro M, et al. Germline mutations in FAN1 cause hereditary colorectal cancer by impairing DNA repair. *Gastroenterology.* 2015; 149(3): 563–6.
44. Smith AL, Alirezaie N, Connor A, Chan-Seng-Yue M, Grant R, Selander I, et al. Candidate DNA repair

- susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. *Cancer Lett.* 2016; 370(2): 302–12.
45. de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, et al. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. *Gastroenterology.* 2013; 145(3): 544–7.
 46. Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, et al. Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. *Nat Commun.* 2004; 5: 5191.
 47. Kinnersley B, Chubb D, Dobbins SE, Frampton M, Buch S, Timofeeva MN, et al. Correspondence: SEMA4A variation and risk of colorectal cancer. *Nat Commun.* 2016; 7: 10611.
 48. Bellido F, Sowada N, Mur P, Lázaro C, Pons T, Valdés-Mas R, et al. Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. *Gastroenterology.* 2018; 154(1): 181–194. doi: 10.1053/j.gastro.2017.09.005
 49. Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, Schackert HK, Gorgens H, Hahn MM, et al. Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early-onset familial colorectal cancer. *Gastroenterology.* 2010; 139(6): 2221–4.
 50. de Voer RM, Hahn MM, Weren RD, Mensenkamp AR, Gilissen C, van Zelst-Stams WA, et al. Identification of novel candidate genes for early-onset colorectal cancer susceptibility. *PLoS Genet.* 2016; 12(2): e1005880.
 51. Spier I, Holzapfel S, Altmüller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer.* 2015; 137(2): 320–31.
 52. Villacis RA, Abreu FB, Miranda PM, Domingues MA, Carraro DM, Santos EM, et al. ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients. *Tumour Biol.* 2016; 37(3): 3145–53.
 53. Wei C, Peng B, Han Y, Chen WV, Rother J, Tomlinson GE, et al. Mutations of HNRNPA0 and WIF1 predispose members of a large family to multiple cancers. *Familial Cancer.* 2015; 14(2): 297–306.
 54. Gylfe AE, Katainen R, Kondelin J, Tanskanen T, Cajuso T, Hanninen U, et al. Eleven candidate susceptibility genes for common familial colorectal cancer. *PLoS Genet.* 2013; 9(10): e1003876.
 55. Esteban-Jurado C, Vila-Casadesus M, Garre P, Lozano JJ, Pristoupilova A, Beltran S, et al. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer. *Genet Med.* 2014; 17(2): 131–42.
 56. Tanskanen T, Gylfe AE, Katainen R, Taipale M, Renkonen-Sinisalo L, Jarvinen H, et al. Systematic search for rare variants in Finnish early-onset colorectal cancer patients. *Cancer Genet.* 2015; 208(1–2): 35–40.
 57. Esteban-Jurado C, Franch-Exposito S, Munoz J, Ocana T, Carballal S, Lopez-Ceron M, et al. The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer. *Eur J Hum Genet.* 2016; 24(10): 1501–5.
 58. Garre P, Martin L, Sanz J, Romero A, Tosar A, Bando I, et al. BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X. *Clin Genet.* 2015; 87(6): 582–7.
 59. Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. *Gastroenterology.* 2015; 149(3): 604–13 e20.
 60. DeRycke MS, Gunawardena SR, Middha S, Asmann YW, Schaid DJ, McDonnell SK, et al. Identification of novel variants in colorectal cancer families by high-throughput exome sequencing. *Cancer Epidemiol Biomark Prev.* 2013; 22(7): 1239–51.
 61. Smith CG, Naven M, Harris R, Colley J, West H, Li N, et al. Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. *Hum Mutat.* 2013; 34(7): 1026–34.
 62. Chubb D, Broderick P, Dobbins SE, Frampton M, Kinnersley B, Penegar S, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. *Nat Commun.* 2016; 7: 11883.
 63. Sill H, Schulz E, Steinke-Lange V, Boland CR. Correspondence: reply to ‘SEMA4A variation and risk of colorectal cancer’. *Nat Commun.* 2016; 7: 10695.
 64. Spier I, Kerick M, Drichel D, Horpaopan S, Altmüller J, Laner A, et al. Exome sequencing identifies potential novel candidate genes in patients with unexplained colorectal adenomatous polyposis. *Familial Cancer.* 2016; 15(2): 281–8.
 65. Garre P, Briceno V, Xicola RM, Doyle BJ, de la Hoya M, Sanz J, et al. Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC). *Clin Cancer Res.* 2011; 17(7): 1701–12.
 66. Dallosso AR, Dolwani S, Jones N, Jones S, Colley J, Maynard J, et al. Inherited predisposition to colorectal

- adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. *Gut*. 2008; 57(9): 1252–5.
67. Kinnersley B, Buch S, Castellvi-Bel S, Farrington SM, Forsti A, Hampe J, et al. Re: role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. *J Natl Cancer Inst*. 2014; 106(5): dju086.
 68. Lubbe SJ, Pittman AM, Matijssen C, Twiss P, Olver B, Lloyd A, et al. Evaluation of germline BMP4 mutation as a cause of colorectal cancer. *Hum Mutat*. 2011; 32(1): E1928–38.
 69. Zogopoulos G, Jorgensen C, Bacani J, Montpetit A, Lepage P, Ferretti V, et al. Germline EPHB2 receptor variants in familial colorectal cancer. *PLoS One*. 2008; 3(8): e2885.
 70. Coissieux MM, Tomsic J, Castets M, Hampel H, Tuupanen S, Andrieu N, et al. Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. *Gastroenterology*. 2011; 141(6): 2039–46.
 71. Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, et al. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. *Proc Natl Acad Sci U S A*. 2009; 106(31): 12921–5.
 72. Clarke E, Green RC, Green JS, Mahoney K, Parfrey PS, Younghusband HB, et al. Inherited deleterious variants in GALNT12 are associated with CRC susceptibility. *Hum Mutat*. 2012; 33(7): 1056–8.
 73. Mur P, Elena SC, Ausso S, Aiza G, Rafael VM, Pineda M, et al. Scarce evidence of the causal role of germline mutations in UNC5C in hereditary colorectal cancer and polyposis. *Sci Rep*. 2016; 6: 20697.
 74. Segui N, Pineda M, Navarro M, Lazaro C, Brunet J, Infante M, et al. GALNT12 is not a major contributor of familial colorectal cancer type X. *Hum Mutat*. 2014; 35(1): 50–2.
 75. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and Spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol*. 2017; 3(4): 464–71.
 76. Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, et al. Germline TP53 mutations in patients with early-onset colorectal cancer in the colon cancer family registry. *JAMA Oncol*. 2015; 1(2): 214–21.
 77. Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GM, Halling KC, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. *Gastroenterology*. 2004; 127(1): 9–16.
 78. Knopperts AP, Nielsen M, Niessen RC, Tops CM, Jorritsma B, Varkevisser J, et al. Contribution of bi-allelic germline MUTYH mutations to early-onset and familial colorectal cancer and to low number of adenomatous polyps: case-series and literature review. *Familial Cancer*. 2013; 12(1): 43–50.
 79. Castillejo A, Vargas G, Castillejo MI, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. *Eur J Cancer*. 2014; 50(13): 2241–50.
 80. Segui N, Navarro M, Pineda M, Koger N, Bellido F, Gonzalez S, et al. Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype. *Gut*. 2015; 64(2): 355–6.
 81. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. *Hum Mol Genet*. 2014; 23(13): 3506–12.
 82. Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. *Genet Med*. 2016; 18(4): 325–32.
 83. Dobbins SE, Broderick P, Chubb D, Kinnersley B, Sherborne AL, Houlston RS. Undefined familial colorectal cancer and the role of pleiotropism in cancer susceptibility genes. *Familial Cancer*. 2016; 15(4): 593–9.
 84. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. *J Clin Oncol*. 2017; 35(10): 1086–95.

第5章

1. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895–2015. *Nat Rev Cancer*. 2015; 15(3): 181–94. <https://doi.org/10.1038/nrc3878>.
2. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. *Am J Hum Genet*. 2001; 68(1): 118–27. <https://doi.org/10.1086/316942>.
3. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. *Hum Mutat*. 2013; 34(3): 490–7. <https://doi.org/10.1002/humu.22262>.
4. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major

- genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomark Prev.* 2017; 26(3): 404–12. <https://doi.org/10.1158/1055-9965.epi-16-0693>.
5. Quehenberger F, Vasen HFA, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet.* 2005; 42(6): 491–6. <https://doi.org/10.1136/jmg.2004.024299>.
 6. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in *MLH1*, *MSH2*, and *MSH6* genes in Lynch syndrome. *JAMA.* 2011; 305(22): 2304–10. <https://doi.org/10.1001/jama.2011.743>.
 7. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line *PMS2* mutations. *Gastroenterology.* 2008; 135(2): 419–28. <https://doi.org/10.1053/j.gastro.2008.04.026>.
 8. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology.* 2009; 137(5): 1621–7. <https://doi.org/10.1053/j.gastro.2009.07.039>.
 9. Choi YH, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, et al. Penetrance of colorectal cancer among *MLH1/MSH2* carriers participating in the colorectal cancer familial registry in Ontario. *Hered Cancer Clin Pract.* 2009; 7(1): 14. <https://doi.org/10.1186/1897-4287-7-14>.
 10. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. *Hum Mol Genet.* 1997; 6(1): 105–10. <https://doi.org/10.1093/hmg/6.1.105>.
 11. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. *Gastroenterology.* 2005; 129(2): 415–21. <https://doi.org/10.1016/j.gastro.2005.05.011>.
 12. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol.* 2012; 30(9): 958–64. <https://doi.org/10.1200/JCO.2011.39.5590>.
 13. ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuisen ME, Bernstein I, et al. Lynch syndrome caused by germline *PMS2* mutations: delineating the cancer risk. *J Clin Oncol.* 2015; 33(4): 319–25. <https://doi.org/10.1200/jco.2014.57.8088>.
 14. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2017; 66(3): 464–72. <https://doi.org/10.1136/gutjnl-2015-309675>.
 15. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. *Gut.* 2017; 66(9): 1657–64. <https://doi.org/10.1136/gutjnl-2016-311403>.
 16. Moller P, Seppala TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database. *Gut.* 2017. <https://doi.org/10.1136/gutjnl-2017-314057>.
 17. Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, et al. The phenotypic expression of three *MSH2* mutations in large Newfoundland families with Lynch syndrome. *Fam Cancer.* 2007; 6(1): 1–12. <https://doi.org/10.1007/s10689-006-0014-8>.
 18. Kamiza AB, Hsieh LL, Tang R, Chien HT, Lai CH, Chiu LL, et al. Risk factors associated with colorectal cancer in a subset of patients with mutations in *MLH1* and *MSH2* in Taiwan fulfilling the Amsterdam II criteria for Lynch syndrome. *PLoS One.* 2015; 10(6): e0130018. <https://doi.org/10.1371/journal.pone.0130018>.
 19. Park J-G, Park YJ, Wijnen JT, Vasen HFA. Gene-environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. *Int J Cancer.* 1999; 82(4): 516–9. [https://doi.org/10.1002/\(SICI\)1097-0215\(19990812\)82:4<516::AID-IJC8>3.0.CO;2-U](https://doi.org/10.1002/(SICI)1097-0215(19990812)82:4<516::AID-IJC8>3.0.CO;2-U).
 20. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. *Nat Rev Cancer.* 2009; 9(10): 749–58. <https://doi.org/10.1038/nrc2723>.
 21. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell.* 1997; 88(3): 323–31. [https://doi.org/10.1016/S0092-8674\(00\)81871-1](https://doi.org/10.1016/S0092-8674(00)81871-1).
 22. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. *Clin Cancer Res.* 2004; 10(17): 5845–9. <https://doi.org/10.1158/1078-0432.ccr-03-0590>.
 23. Kruger S, Engel C, Bier A, Silber AS, Gorgens H, Mangold E, et al. The additive effect of p53 Arg72Pro and

- RNASL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. *Cancer Lett.* 2007; 252(1): 55–64. <https://doi.org/10.1016/j.canlet.2006.12.006>.
24. Kruger S, Silber AS, Engel C, Gorgens H, Mangold E, Pagenstecher C, et al. Arg462Gln sequence variation in the prostate-cancer-susceptibility gene RNASL and age of onset of hereditary non-polyposis colorectal cancer: a case-control study. *Lancet Oncol.* 2005; 6(8): 566–72. [https://doi.org/10.1016/s1470-2045\(05\)70253-9](https://doi.org/10.1016/s1470-2045(05)70253-9).
 25. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. *Clin Cancer Res.* 2005; 11(19 Pt 1): 6840–4. <https://doi.org/10.1158/1078-0432.ccr-05-1139>.
 26. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. *Int J Cancer.* 2006; 118(10): 2479–84. <https://doi.org/10.1002/ijc.21661>.
 27. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. *Cancer Res.* 2000; 60(2): 249–52.
 28. Bala S, Peltomaki P. CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. *Cancer Res.* 2001; 61(16): 6042–5.
 29. Kruger S, Engel C, Bier A, Mangold E, Pagenstecher C, Doberitz M, et al. Absence of association between cyclin D1 (CCND1) G870A polymorphism and age of onset in hereditary nonpolyposis colorectal cancer. *Cancer Lett.* 2006; 236(2): 191–7. <https://doi.org/10.1016/j.canlet.2005.05.013>.
 30. Talseth BA, Ashton KA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, et al. Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. *Int J Cancer.* 2008; 122(6): 1273–7. <https://doi.org/10.1002/ijc.23177>.
 31. Chen J, Sen S, Amos CI, Wei C, Jones JS, Lynch P, et al. Association between Aurora-A kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. *Mol Carcinog.* 2007; 46(4): 249–56. <https://doi.org/10.1002/mc.20283>.
 32. Chen J, Pande M, Huang YJ, Wei C, Amos CI, Talseth-Palmer BA, et al. Cell cycle-related genes as modifiers of age of onset of colorectal cancer in Lynch syndrome: a large-scale study in non-Hispanic white patients. *Carcinogenesis.* 2013; 34(2): 299–306. <https://doi.org/10.1093/carcin/bgs344>.
 33. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. *Int J Cancer.* 2007; 120(3): 563–5. <https://doi.org/10.1002/ijc.22339>.
 34. Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, Lynch PM, et al. IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. *J Natl Cancer Inst.* 2006; 98(2): 139–43. <https://doi.org/10.1093/jnci/djj016>.
 35. Reeves SG, Rich D, Meldrum CJ, Colyvas K, Kurzawski G, Suchy J, et al. IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer. *Int J Cancer.* 2008; 123(6): 1339–43. <https://doi.org/10.1002/ijc.23668>.
 36. Houille S, Charbonnier F, Houivet E, Tinat J, Buisine MP, Caron O, et al. Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. *Eur J Hum Genet.* 2011; 19(8): 887–92. <https://doi.org/10.1038/ejhg.2011.44>.
 37. Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, et al. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. *Cancer Causes Control.* 2009; 20(9): 1769–77. <https://doi.org/10.1007/s10552-009-9416-x>.
 38. Wood NJ, Quinton NA, Burdall S, Sheridan E, Duffy SR. Exploring the potential chemopre-ventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. *Int J Gynecol Cancer.* 2007; 17(2): 447–54. <https://doi.org/10.1111/j.1525-1438.2007.00867.x>.
 39. Kunkel TA, Erie DA. DNA mismatch repair. *Annu Rev Biochem.* 2005; 74: 681–710. <https://doi.org/10.1146/annurev.biochem.74.082803.133243>.
 40. David SS, O’Shea VL, Kundu S. Base-excision repair of oxidative DNA damage. *Nature.* 2007; 447(7147): 941–50. <https://doi.org/10.1038/nature05978>.
 41. Maillet P, Chappuis PO, Vaudan G, Dobbie Z, Muller H, Hutter P, et al. A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. *Int J Cancer.* 2000; 88(6): 928–31. [https://doi.org/10.1002/1097-0215\(20001215\)88:6<928::AID-IJC14>3.0.CO;2-P](https://doi.org/10.1002/1097-0215(20001215)88:6<928::AID-IJC14>3.0.CO;2-P).
 42. Jones JS, Gu X, Lynch PM, Rodriguez-Bigas M, Amos CI, Frazier ML. ATM polymorphism and hereditary nonpolyposis colorectal cancer (HNPCC) age of onset (United States). *Cancer Causes Control.* 2005; 16(6): 749–53. <https://doi.org/10.1007/s10552-005-1540-7>.

43. Kim IJ, Ku JL, Kang HC, Park JH, Yoon KA, Shin Y, et al. Mutational analysis of *OGGI*, *MYH*, *MTH1* in FAP, HNPCC and sporadic colorectal cancer patients: R154H *OGGI* polymorphism is associated with sporadic colorectal cancer patients. *Hum Genet.* 2004; 115(6): 498–503. <https://doi.org/10.1007/s00439-004-1186-7>.
44. Reeves SG, Meldrum C, Groombridge C, Spigelman A, Suchy J, Kurzawski G, et al. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome. *Cancer Epidemiol.* 2012; 36(2): 183–9. <https://doi.org/10.1016/j.canep.2011.09.003>.
45. Meeker AK, Argani P. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? *J Mammary Gland Biol Neoplasia.* 2004; 9(3): 285–96. <https://doi.org/10.1023/B:JOMG.0000048775.04140.92>.
46. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. *Cancer Res.* 2004; 64(7): 2324–7. <https://doi.org/10.1158/0008-5472.CAN-03-4035>.
47. Bellido F, Guino E, Jagmohan-Changur S, Segui N, Pineda M, Navarro M, et al. Genetic variant in the telomerase gene modifies cancer risk in Lynch syndrome. *Eur J Hum Genet.* 2013; 21(5): 511–6. <https://doi.org/10.1038/ejhg.2012.204>.
48. Djojoseburoto MW, Choi YS, Lee HW, Rudolph KL. Telomeres and telomerase in aging, regeneration and cancer. *Mol Cells.* 2003; 15(2): 164–75.
49. Win AK, Clendenning M, Crawford W, Rosty C, Preston SG, Southey MC, et al. Genetic variants within the *hTERT* gene and the risk of colorectal cancer in Lynch syndrome. *Genes Cancer.* 2015; 6(11–12): 445–51. <https://doi.org/10.18632/genesandcancer.85>.
50. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. *Cancer Surv.* 1995; 25: 27–65.
51. Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B, Leppert M. NAT2, GSTM1, cigarette smoking, and risk of colon cancer. *Cancer Epidemiol Biomark Prev.* 1998; 7(12): 1079–84.
52. Brockton N, Little J, Sharp L, Cotton SC. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. *Am J Epidemiol.* 2000; 151(9): 846–61.
53. Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT, Bingham SA. Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. *Carcinogenesis.* 2001; 22(7): 1053–60. <https://doi.org/10.1093/carcin/22.7.1053>.
54. Ye Z, Parry JM. Genetic polymorphisms in the cytochrome P450 1A1, glutathione S-transferase M1 and T1, and susceptibility to colon cancer. *Teratog Carcinog Mutagen.* 2002; 22(5): 385–92. <https://doi.org/10.1002/tcm.10035>.
55. He LJ, YuYM, Qiao F, Liu JS, Sun XF, Jiang LL. Genetic polymorphisms of N-acetyltransferase 2 and colorectal cancer risk. *World J Gastroenterol.* 2005; 11(27): 4268–71. <https://doi.org/10.3748/wjg.v11.i27.4268>.
56. Heinimann K, Scott RJ, Chappuis P, Weber W, Muller H, Dobbie Z, et al. N-acetyltransferase 2 influences cancer prevalence in hMLH1/hMSH2 mutation carriers. *Cancer Res.* 1999; 59(13): 3038–40.
57. Frazier ML, O'Donnell FT, Kong S, Gu X, Campos I, Luthra R, et al. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. *Cancer Res.* 2001; 61(4): 1269–71.
58. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Genetic polymorphisms in xenobiotic clearance genes and their influence on disease expression in hereditary nonpolyposis colorectal cancer patients. *Cancer Epidemiol Biomark Prev.* 2006; 15(11): 2307–10. <https://doi.org/10.1158/1055-9965.EPI-06-0040>.
59. Pistorius S, Gorgens H, Kruger S, Engel C, Mangold E, Pagenstecher C, et al. N-acetyltransferase (NAT) 2 acetylator status and age of onset in patients with hereditary nonpolyposis colorectal cancer (HNPCC). *Cancer Lett.* 2006; 241(1): 150–7. <https://doi.org/10.1016/j.canlet.2005.10.018>.
60. Felix R, Bodmer W, Fearnhead NS, van der Merwe L, Goldberg P, Ramesar RS. GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. *Mutat Res.* 2006; 602(1–2): 175–81. <https://doi.org/10.1016/j.mrfmmm.2006.09.004>.
61. Pande M, Amos CI, Osterwisch DR, Chen J, Lynch PM, Broaddus R, et al. Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in Lynch syndrome. *Cancer Epidemiol Biomark Prev.* 2008; 17(9): 2393–401. <https://doi.org/10.1158/1055-9965.EPI-08-0326>.
62. Moisio AL, Sistonen P, Mecklin JP, Jarvinen H, Peltomaki P. Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. *Gastroenterology.* 1998; 115(6): 1387–94.

63. Jones JS, Gu X, Campos IM, Lynch PM, Amos CI, Frazier ML. GSTM1 polymorphism does not affect hereditary nonpolyposis colorectal cancer age of onset. *Cancer Epidemiol Biomark Prev.* 2004; 13(4): 676–8.
64. Campbell PT, Edwards L, McLaughlin JR, Green J, Younghusband HB, Woods MO. Cytochrome P450 17A1 and catechol O-methyltransferase polymorphisms and age at Lynch syndrome colon cancer onset in Newfoundland. *Clin Cancer Res.* 2007; 13(13): 3783–8. <https://doi.org/10.1158/1078-0432.CCR-06-2987>.
65. Pande M, Chen J, Amos CI, Lynch PM, Broaddus R, Frazier ML. Influence of methylene-tetrahydrofolate reductase gene polymorphisms C677T and A1298C on age-associated risk for colorectal cancer in a caucasian Lynch syndrome population. *Cancer Epidemiol Biomark Prev.* 2007; 16(9): 1753–9. <https://doi.org/10.1158/1055-9965.epi-07-0384>.
66. Shin JH, JL K, Shin KH, Shin YK, Kang SB, Park JG. Glutathione S-transferase M1 associated with cancer occurrence in Korean HNPCC families carrying the hMLH1/hMSH2 mutation. *Oncol Rep.* 2003; 10(2): 483–6. <https://doi.org/10.3892/or.10.2.483>.
67. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. *Nat Genet.* 2007; 39(8): 984–8. <https://doi.org/10.1038/ng2085>.
68. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, et al. A genome-wide association study shows that common alleles of *SMAD7* influence colorectal cancer risk. *Nat Genet.* 2007; 39(11): 1315–7. <https://doi.org/10.1038/ng.2007.18>.
69. Zanke BW, Greenwood CMT, Rangrej J, Kustra R, Tenesa A, Farrington SM, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. *Nat Genet.* 2007; 39(8): 989–94. <https://doi.org/10.1038/ng2089>.
70. Tomlinson IPM, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. *Nat Genet.* 2008; 40(5): 623–30. <https://doi.org/10.1038/ng.111>.
71. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. *Nat Genet.* 2008; 40(12): 1426–35. <https://doi.org/10.1038/ng.262>.
72. Tenesa A, Farrington SM, Prendergast JGD, Porteous ME, Walker M, Haq N, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat Genet.* 2008; 40(5): 631–7. <https://doi.org/10.1038/ng.133>.
73. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. *Nat Genet.* 2010; 42(11): 973–7. <https://doi.org/10.1038/ng.670>.
74. Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, et al. Common variation near *CDKN1A*, *POLD3* and *SHROOM2* influences colorectal cancer risk. *Nat Genet.* 2012; 44(7): 770–6. <https://doi.org/10.1038/ng.2293>.
75. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis. *Gastroenterology.* 2013; 144(4): 799–807.e24. <https://doi.org/10.1053/j.gastro.2012.12.020>.
76. Jia WH, Zhang B, Matsuo K, Shin A, Xiang YB, Jee SH, et al. Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. *Nat Genet.* 2013; 45(2): 191–6. <https://doi.org/10.1038/ng.2505>.
77. Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, et al. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. *Hum Mol Genet.* 2014; 23(17): 4729–37. <https://doi.org/10.1093/hmg/ddu177>.
78. Real LM, Ruiz A, Gayan J, Gonzalez-Perez A, Saez ME, Ramirez-Lorca R, et al. A colorectal cancer susceptibility new variant at 4q26 in the Spanish population identified by genome-wide association analysis. *PLoS One.* 2014; 9(6): e101178. <https://doi.org/10.1371/journal.pone.0101178>.
79. Schmit SL, Schumacher FR, Edlund CK, Conti DV, Raskin L, Lejbkovicz F, et al. A novel colorectal cancer risk locus at 4q32.2 identified from an international genome-wide association study. *Carcinogenesis.* 2014; 35(11): 2512–9. <https://doi.org/10.1093/carcin/bgu148>.
80. Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, et al. Genome-wide association study of colorectal cancer identifies six new susceptibility loci. *Nat Commun.* 2015; 6: 7138. <https://doi.org/10.1038/ncomms8138>.
81. Peters U, Hutter CM, Hsu L, Schumacher FR, Conti DV, Carlson CS, et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk. *Hum Genet.* 2012; 131(2): 217–34. <https://doi.org/10.1007/s00439->

- 011-1055-0.
82. Wijnen JT, Brohet RM, van Eijk R, Jagmohan-Changur S, Middeldorp A, Tops CM, et al. Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. *Gastroenterology*. 2009; 136(1): 131-7. <https://doi.org/10.1053/j.gastro.2008.09.033>.
 83. Talseth-Palmer BA, Brenne IS, Ashton KA, Evans TJ, McPhillips M, Groombridge C, et al. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome. *J Med Genet*. 2011; 48(4): 279-84. <https://doi.org/10.1136/jmg.2010.079962>.
 84. Talseth-Palmer BA, Wijnen JT, Brenne IS, Jagmohan-Changur S, Barker D, Ashton KA, et al. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in *MLH1* mutation carriers. *Int J Cancer*. 2013; 132(7): 1556-64. <https://doi.org/10.1002/ijc.27843>.
 85. Carvajal-Carmona LG, Cazier JB, Jones AM, Howarth K, Broderick P, Pittman A, et al. Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes. *Hum Mol Genet*. 2011; 20(14): 2879-88. <https://doi.org/10.1093/hmg/ddr190>.
 86. Win AK, Hopper JL, Buchanan DD, Young JP, Tenesa A, Dowty JG, et al. Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? *Eur J Cancer*. 2013; 49(7): 1578-87. <https://doi.org/10.1016/j.ejca.2013.01.029>.
 87. ten Broeke SW, Elsayed FA, Pagan L, Olderde-Berends MJW, Garcia EG, Gille HJP et al. SNP association study in *PMS2*-associated Lynch syndrome. *Fam Cancer*. 2017. <https://doi.org/10.1007/s10689-017-0061-3>.
 88. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, et al. Genome-wide association study in *BRCA1* mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet*. 2013; 9(3): e1003212. <https://doi.org/10.1371/journal.pgen.1003212>.
 89. Win AK, Dowty JG, English DR, Campbell PT, Young JP, Winship I, et al. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. *Br J Cancer*. 2011; 105(1): 162-9. <https://doi.org/10.1038/bjc.2011.172>.
 90. Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, et al. Smoking and colorectal cancer in Lynch syndrome: results from the colon cancer family registry and The University of Texas M.D. Anderson Cancer Center. *Clin Cancer Res*. 2010; 16(4): 1331-9. <https://doi.org/10.1158/1078-0432.ccr-09-1877>.
 91. Dashti SG, Buchanan DD, Jayasekara H, Ait Ouakrim D, Clendenning M, Rosty C, et al. Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers. *Cancer Epidemiol Biomark Prev*. 2017; 26(3): 366-75. <https://doi.org/10.1158/1055-9965.epi-16-0496>.
 92. Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. *J Natl Cancer Inst*. 2015; 107(9): djv170. <https://doi.org/10.1093/jnci/djv170>.
 93. Chau R, Dashti SG, Ait Ouakrim D, Buchanan DD, Clendenning M, Rosty C, et al. Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. *Int J Epidemiol*. 2016; 45(3): 940-53. <https://doi.org/10.1093/ije/dyw036>.
 94. Win AK, Dowty JG, Antill YC, English DR, Baron JA, Young JP, et al. Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers. *Obstet Gynecol*. 2011; 117(4): 899-905. <https://doi.org/10.1097/AOG.0b013e3182110ea3>.
 95. Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. *JAMA*. 2015; 314(1): 61-71. <https://doi.org/10.1001/jama.2015.6789>.
 96. Botma A, Nagengast FM, Braem MGM, Hendriks JCM, Kleibeuker JH, Vasen HFA, et al. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. *J Clin Oncol*. 2010; 28(28): 4346-53. <https://doi.org/10.1200/jco.2010.28.0453>.
 97. Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM, Kleibeuker JH, Vasen HF, et al. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. *Gastroenterology*. 2012; 142(2): 241-7. <https://doi.org/10.1053/j.gastro.2011.10.033>.
 98. Heine-Broring RC, Winkels RM, Botma A, van Duijnhoven FJ, Jung AY, Kleibeuker JH, et al. Dietary supplement use and colorectal adenoma risk in individuals with Lynch syndrome: the GEOLynch cohort study. *PLoS One*. 2013; 8(6): e66819. <https://doi.org/10.1371/journal.pone.0066819>.
 99. Botma A, Vasen HF, van Duijnhoven FJ, Kleibeuker JH, Nagengast FM, Kampman E. Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study. *Cancer*. 2013; 119(3): 512-21. <https://doi.org/10.1002/cncr.27726>.

100. Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 study. *J Clin Oncol*. 2015; 33(31): 3591–7. <https://doi.org/10.1200/jco.2014.58.9952>.
101. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011; 378(9809): 2081–7. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0).
102. Campbell PT, Cotterchio M, Dicks E, Parfrey P, Gallinger S, McLaughlin JR. Excess body weight and colorectal cancer risk in Canada: associations in subgroups of clinically defined familial risk of cancer. *Cancer Epidemiol Biomark Prev*. 2007; 16(9): 1735–44. <https://doi.org/10.1158/1055-9965.epi-06-1059>.
103. Diergaarde B, Braam H, Vasen HF, Nagengast FM, GNPv M, Kok FJ, et al. Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol*. 2007; 5(6): 736–42. <https://doi.org/10.1016/j.cgh.2007.02.019>.
104. Watson P, Ashwathnarayan R, Lynch HT, Roy HK. Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). *Arch Intern Med*. 2004; 164(22): 2429–31. <https://doi.org/10.1001/archinte.164.22.2429>.
105. Brand RM, Jones DD, Lynch HT, Brand RE, Watson P, Ashwathnayan R, et al. Risk of colon cancer in hereditary non-polyposis colorectal cancer patients as predicted by fuzzy modeling: influence of smoking. *World J Gastroenterol*. 2006; 12(28): 4485–91. <https://doi.org/10.3748/wjg.v12.i28.4485>.
106. Staff S, Aaltonen M, Huhtala H, Pylvanainen K, Mecklin JP, Maenpaa J. Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study. *Br J Cancer*. 2016; 115(3): 375–81. <https://doi.org/10.1038/bjc.2016.193>.
107. Tanakaya K, Furukawa Y, Nakamura Y, Hirata K, Tomita N, Tamura K, et al. Relationship between smoking and multiple colorectal cancers in patients with Japanese Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. *Jpn J Clin Oncol*. 2015; 45(3): 307–10. <https://doi.org/10.1093/jjco/hyu218>.
108. Milne RL, Antoniou AC. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. *Endocr Relat Cancer*. 2016; 23(10): T69–84. <https://doi.org/10.1530/erc-16-0277>.
109. Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genet Epidemiol*. 2005; 29(1): 1–11. <https://doi.org/10.1002/gepi.20074>.
110. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum*. 1991; 34(5): 424–5. <http://dx.doi.org/10.1007/BF02053699>.
111. Vasen HFA, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. *Gastroenterology*. 1999; 116(6): 1453–6. [https://doi.org/10.1016/S0016-5085\(99\)70510-X](https://doi.org/10.1016/S0016-5085(99)70510-X).
112. Umar A, Boland CR, Terdiman JP, Syngal S, Adl C, Ruschhoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst*. 2004; 96(4): 261–8. <https://doi.org/10.1093/jnci/djh034>.
113. Burn J, Bishop DT, Mecklin J-P, Macrae F, Moeslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. *N Engl J Med*. 2008; 359(24): 2567–78. <https://doi.org/10.1056/NEJMoa0801297>.
114. Lu KH, Loose DS, Yates MS, Noguerras-Gonzalez GM, Munsell MF, Chen LM, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. *Cancer Prev Res (Phila)*. 2013; 6(8): 774–81. <https://doi.org/10.1158/1940-6207.capr-13-0020>.

第6章

1. Clark JC, Collan Y, Eide TJ, Esteve J, Ewen S, Gibbs NM, Jensen OM, Koskela E, MacLennan R, Simpson JG, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. *Int J Cancer*. 1985; 36: 179–86.
2. Rex DK, Lehman GA, Ulbright TM, Smith JJ, Pound DC, Hawes RH, Helper DJ, Wiersema MJ, Langefeld CD, Li W. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. *Am J Gastroenterol*. 1993; 88: 825–31.

- Tomlinson I, Jaeger E, Leedham S, Thomas H. The classification of intestinal polyposis. *Nat Genet.* 2013; 45(1): 2.

第7章

- Burn J, Chapman P, Delhanty J, Wood C, Lalloo F, Cachon-Gonzalez MB, et al. The UK Northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations. *J Med Genet.* 1991; 28(5): 289–96.
- Bulow S, Faurschou NT, Bulow C, Bisgaard ML, Karlsen L, Moesgaard F. The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register. *Int J Color Dis.* 1996; 11(2): 88–91.
- Bjork J, Akerbrant H, Iselius L, Alm T, Hultcrantz R. Epidemiology of familial adenomatous polyposis in Sweden: changes over time and differences in phenotype between males and females. *Scand J Gastroenterol.* 1999; 34(12): 1230–5.
- Bussey HJ. Familial polyposis coli. *Pathol Annu.* 1979; 14(Pt 1): 61–81.
- Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. *Gut.* 1992; 33(3): 357–60.
- Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. *Hum Mutat.* 1994; 3(2): 121–5.
- Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. *JAMA.* 2012; 308(5): 485–92. <https://doi.org/10.1001/jama.2012.8780>.
- Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol.* 2016. <https://doi.org/10.1001/jamaoncol.2016.5194>.
- Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. *Familial Cancer.* 2006; 5(3): 221–6.
- Zhang L, Shay JW. Multiple roles of APC and its therapeutic implications in colorectal cancer. *J Natl Cancer Inst.* 2017; 109(8). <https://doi.org/10.1093/jnci/djw332>.
- Nielsen M, Bik E, Hes FJ, Breuning MH, Vasen HF, Bakker E, et al. Genotype-phenotype correlations in 19 Dutch cases with APC gene deletions and a literature review. *Eur J Hum Genet: EJHG.* 2007; 15(10): 1034–42. <https://doi.org/10.1038/sj.ejhg.5201871>.
- Sieber OM, Lamlum H, Crabtree MD, Rowan AJ, Barclay E, Lipton L, et al. Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or ‘multiple’ colorectal adenomas. *Proc Natl Acad Sci U S A.* 2002; 99(5): 2954–8.
- Aretz S, Stienen D, Uhlhaas S, Pagenstecher C, Mangold E, Caspari R, et al. Large submicroscopic genomic APC deletions are a common cause of typical familial adenomatous polyposis. *J Med Genet.* 2005; 42(2): 185–92. <https://doi.org/10.1136/jmg.2004.022822>.
- Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, et al. Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. *Eur J Hum Genet: EJHG.* 2004; 12(1): 52–8. <https://doi.org/10.1038/sj.ejhg.5201088>.
- Hes FJ, Nielsen M, Bik EC, Konvalinka D, Wijnen JT, Bakker E, et al. Somatic APC mosaicism: an underestimated cause of polyposis coli. *Gut.* 2008; 57(1): 71–6. <https://doi.org/10.1136/gut.2006.117796>.
- Aretz S, Stienen D, Friedrichs N, Stemmler S, Uhlhaas S, Rahner N, et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). *Hum Mutat.* 2007; 28(10): 985–92. <https://doi.org/10.1002/humu.20549>.
- Jansen AM, Crobach S, Geurts-Giele WR, van den Akker BE, Garcia MV, Ruano D, et al. Distinct patterns of somatic mosaicism in the APC gene in neoplasms from patients with unexplained adenomatous polyposis. *Gastroenterology.* 2017; 152(3): 546–9 e3. <https://doi.org/10.1053/j.gastro.2016.10.040>.
- Spier I, Drichel D, Kerick M, Kirfel J, Horpaopan S, Laner A, et al. Low-level APC mutational mosaicism is the underlying cause in a substantial fraction of unexplained colorectal adenomatous polyposis cases. *J Med Genet.* 2016; 53(3): 172–9. <https://doi.org/10.1136/jmedgenet-2015-103468>.
- Spier I, Horpaopan S, Vogt S, Uhlhaas S, Morak M, Stienen D, et al. Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. *Hum Mutat.* 2012; 33(7): 1045–50. <https://doi.org/10.1002/humu.22082>.
- Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, Rawstorne E, et al. Multiple rare nonsynonymous

- variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. *Cancer Res.* 2008; 68(2): 358–63.
21. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. *Crit Rev Oncol Hematol.* 2007; 61(2): 153–61.
 22. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. *Hum Mol Genet.* 1992; 1(4): 229–33.
 23. Bussey HJR. *Familial polyposis coli: family studies, histopathology, differential diagnosis, and results of treatment.* Baltimore: Johns Hopkins University Press; 1975.
 24. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. *N Engl J Med.* 1992; 326(10): 658–62.
 25. Ponder BA. Cancer genetics. *Nature.* 2001; 411(6835): 336–41.
 26. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med.* 2000; 343(2): 78–85.
 27. Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, et al. Duodenal adenomatosis in familial adenomatous polyposis. *Gut.* 2004; 53(3): 381–6.
 28. Campos FG, Sulbaran M, Safatle-Ribeiro AV, Martinez CAR. Duodenal adenoma surveillance in patients with familial adenomatous polyposis. *World J Gastrointest Endosc.* 2015; 7(10): 950–9. <https://doi.org/10.4253/wjge.v7.i10.950>.
 29. Hashimoto T, Ogawa R, Matsubara A, Taniguchi H, Sugano K, Ushiyama M, et al. Familial adenomatous polyposis-associated and sporadic pyloric gland adenomas of the upper gastroin-testinal tract share common genetic features. *Histopathology.* 2015; 67(5): 689–98. <https://doi.org/10.1111/his.12705>.
 30. Bjork J, Akerbrant H, Iselius L, Bergman A, Engwall Y, Wahlstrom J, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. *Gastroenterology.* 2001; 121(5): 1127–35.
 31. Ghorbanoghli Z, Bastiaansen BA, Langers AM, Nagengast FM, Poley JW, Hardwick JC, et al. Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. *J Med Genet.* 2017. <https://doi.org/10.1136/jmedgenet-2017-104545>.
 32. Latchford AR, Neale KF, Spigelman AD, Phillips RK, Clark SK. Features of duodenal cancer in patients with familial adenomatous polyposis. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2009; 7(6): 659–63. <https://doi.org/10.1016/j.cgh.2009.02.028>.
 33. Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. *Gut.* 2002; 50(5): 636–41.
 34. Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. *Gastroenterology.* 1992; 102(6): 1980–2.
 35. Giardiello FM, Krush AJ, Petersen GM, Booker SV, Kerr M, Tong LL, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. *Gastroenterology.* 1994; 106(6): 1542–7.
 36. Nugent KP, Phillips RK, Hodgson SV, Cottrell S, Smith-Ravin J, Pack K, et al. Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis. *Gut.* 1994; 35(11): 1622–3.
 37. Rozen P, Samuel Z, Shomrat R, Legum C. Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. *Gut.* 1999; 45(6): 829–33.
 38. Ghorbanoghli Z, Nieuwenhuis MH, Houwing-Duistermaat JJ, Jagmohan-Changur S, Hes FJ, Tops CM, et al. Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers. *Familial Cancer.* 2016; 15(4): 563–70. <https://doi.org/10.1007/s10689-016-9877-5>.
 39. Talseth-Palmer BA, Wijnen JT, Andreassen EK, Barker D, Jagmohan-Changur S, Tops CM, et al. The importance of a large sample cohort for studies on modifier genes influencing disease severity in FAP patients. *Hered Cancer Clin Pract.* 2013; 11(1): 20. <https://doi.org/10.1186/1897-4287-11-20>.
 40. Worthley DL, Phillips KD, Wayte N, Schrader KA, Healey S, Kaurah P, et al. Gastric adeno-carcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. *Gut.* 2012; 61(5): 774–9. <https://doi.org/10.1136/gutjnl-2011-300348>.
 41. Jasperson KW, Patel SG, Ahnen DJ. APC-associated polyposis conditions. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, LJM B, et al., editors. *GeneReviews(R).* Seattle: University of Washington; 1993.
 42. Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, et al. Point mutations in exon 1B of APC reveal gastric

- adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. *Am J Hum Genet.* 2016; 98(5): 830–42. <https://doi.org/10.1016/j.ajhg.2016.03.001>.
43. McDuffie LA, Sabesan A, Allgaeuer M, Xin L, Koh C, Heller T, et al. Beta-Catenin activation in fundic gland polyps, gastric cancer and colonic polyps in families afflicted by ‘gastric adenocarcinoma and proximal polyposis of the stomach’ (GAPPS). *J Clin Pathol.* 2016; 69(9): 826–33. <https://doi.org/10.1136/jclinpath-2016-203746>.
 44. Uchino S, Ishikawa H, Miyauchi A, Hirokawa M, Noguchi S, Ushiyama M, et al. Age- and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis. *J Clin Endocrinol Metab.* 2016; 101(12): 4611–7. <https://doi.org/10.1210/jc.2016-2043>.
 45. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. *Br J Surg.* 1996; 83(11): 1494–504.
 46. Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). *Eur J Surg Oncol.* 2009; 35(1): 3–10. <https://doi.org/10.1016/j.ejso.2008.07.003>.
 47. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors—a characterization of patients seen at Mayo Clinic 1976–1999. *Familial Cancer.* 2006; 5(2): 191–4. <https://doi.org/10.1007/s10689-005-5959-5>.
 48. Kattentidt Mouravieva AA, Geurts-Giele IR, de Krijger RR, van Noesel MM, van de Ven CP, van den Ouweland AM, et al. Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours. *Eur J Cancer (Oxford, England: 1990).* 2012; 48(12): 1867–74. <https://doi.org/10.1016/j.ejca.2012.01.004>.
 49. Nieuwenhuis MH, Lefevre JH, Bulow S, Jarvinen H, Bertario L, Kerneis S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. *Dis Colon Rectum.* 2011; 54(10): 1229–34. <https://doi.org/10.1097/DCR.0b013e318227e4e8>.
 50. Smith TG, Clark SK, Katz DE, Reznick RH, Phillips RK. Adrenal masses are associated with familial adenomatous polyposis. *Dis Colon Rectum.* 2000; 43(12): 1739–42.
 51. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. *Am J Gastroenterol.* 2006; 101(2): 385–98.
 52. Friedl W, Aretz S. Familial adenomatous polyposis: experience from a study of 1164 unrelated German polyposis patients. *Hered Cancer Clin Pract.* 2005; 3(3): 95–114. <https://doi.org/10.1186/1897-4287-3-3-95>.
 53. Coffin CM, Hornick JL, Zhou H, Fletcher CD. Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. *Am J Surg Pathol.* 2007; 31(3): 410–6. <https://doi.org/10.1097/01.pas.0000213348.65014.0a>.
 54. Dahl NA, Sheil A, Knapke S, Geller JI. Gardner fibroma: clinical and histopathologic implications of germline APC mutation association. *J Pediatr Hematol Oncol.* 2016; 38(5): e154–7. <https://doi.org/10.1097/MPH.0000000000000493>.
 55. Levesque S, Ahmed N, Nguyen VH, Nahal A, Blumenkrantz M, Puligandla P, et al. Neonatal Gardner fibroma: a sentinel presentation of severe familial adenomatous polyposis. *Pediatrics.* 2010; 126(6): e1599–602. <https://doi.org/10.1542/peds.2010-1045>.
 56. Vieira J, Pinto C, Afonso M, do Bom Sucesso M, Lopes P, Pinheiro M, et al. Identification of previously unrecognized FAP in children with Gardner fibroma. *Eur J Hum Genet EJHG.* 2015; 23(5): 715–8. <https://doi.org/10.1038/ejhg.2014.144>.
 57. Schafer M, Kadmon M, Schmidt W, Treiber I, Moog U, Sutter C, et al. Neonatal Gardner fibroma leads to detection of familial adenomatous polyposis: two case reports. *Eur J Pediatr Surg Rep.* 2016; 4(1): 17–21. <https://doi.org/10.1055/s-0036-1582443>.
 58. Coleman P, Barnard NA. Congenital hypertrophy of the retinal pigment epithelium: prevalence and ocular features in the optometric population. *Ophthalmic Physiol Opt.* 2007; 27(6): 547–55. <https://doi.org/10.1111/j.1475-1313.2007.00513.x>.
 59. Nusliha A, Dalpatadu U, Amarasinghe B, Chandrasinghe PC, Deen KI. Congenital hypertrophy of retinal pigment epithelium (CHRPE) in patients with familial adenomatous polyposis (FAP); a polyposis registry experience. *BMC Res Notes.* 2014; 7: 734. <https://doi.org/10.1186/1756-0500-7-734>.
 60. Aretz S, Koch A, Uhlhaas S, Friedl W, Propping P, von Schweinitz D, et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? *Pediatr Blood Cancer.* 2006; 47(6): 811–8. <https://doi.org/10.1002/pbc.20698>.
 61. Harvey J, Clark S, Hyer W, Hadzic N, Tomlinson I, Hinds R. Germline APC mutations are not commonly seen in children with sporadic hepatoblastoma. *J Pediatr Gastroenterol Nutr.* 2008; 47(5): 675–7. <https://doi.org/10.1097/MPG.0b013e318174e808>.
 62. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. *Hum Mol Genet.* 2001; 10(7): 721–33.
 63. Segditsas S, Rowan AJ, Howarth K, Jones A, Leedham S, Wright NA, Gorman P, Chambers W, Domingo E,

- Roylance RR, Sawyer EJ, Sieber OM, Tomlinson IP. APC and the three-hit hypothesis. *Oncogene*. 2009 Jan 8; 28(1): 146–55. <https://doi.org/10.1038/onc.2008.361>. Epub 2008 Oct 6.
64. Sieber O, Segditsas S, Knudsen A, Zhang J, Luz J, Rowan A, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly, but depend on the site of the germline mutation. *Gut*. 2006; 55: 1440.
65. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. *Science*. 2014; 346(6205): 1248012. <https://doi.org/10.1126/science.1248012>.
66. Albuquerque C, Breukel C, van der Luijt R, Fidalgo P, Lage P, Slors FJ, et al. The ‘just-right’ signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. *Hum Mol Genet*. 2002; 11(13): 1549–60.
67. Cheadle JP, Krawczak M, Thomas MW, Hodges AK, Al-Tassan N, Fleming N, et al. Different combinations of biallelic APC mutation confer different growth advantages in colorectal tumours. *Cancer Res*. 2002; 62(2): 363–6.
68. Kumamoto K, Ishida H, Ohsawa T, Ishibashi K, Ushiyama M, Yoshida T, et al. Germline and somatic mutations of the APC gene in papillary thyroid carcinoma associated with familial adenomatous polyposis: analysis of three cases and a review of the literature. *Oncol Lett*. 2015; 10(4): 2239–43. <https://doi.org/10.3892/ol.2015.3578>.
69. Latchford A, Volikos E, Johnson V, Rogers P, Suraweera N, Tomlinson I, et al. APC mutations in FAP-associated desmoid tumours are non-random but not ‘just right’. *Hum Mol Genet*. 2007; 16(1): 78–82. <https://doi.org/10.1093/hmg/ddl442>.
70. Rashid M, Fischer A, Wilson CH, Tiffen J, Rust AG, Stevens P, et al. Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes. *J Pathol*. 2016; 238(1): 98–108. <https://doi.org/10.1002/path.4643>.
71. Cardoso J, Molenaar L, de Menezes RX, van Leerdam M, Rosenberg C, Moslein G, et al. Chromosomal instability in MYH- and APC-mutant adenomatous polyps. *Cancer Res*. 2006; 66(5): 2514–9.
72. Major MB, Camp ND, Berndt JD, Yi XH, Goldenberg SJ, Hubbert C, et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. *Science*. 2007; 316(5827): 1043–6. <https://doi.org/10.1126/science/1141515>.
73. Wang WL, Nero C, Pappo A, Lev D, Lazar AJ, Lopez-Terrada D. CTNNB1 genotyping and APC screening in pediatric desmoid tumors: a proposed algorithm. *Pediatr Dev Pathol Off J Soc Pediatr Pathol Paediatr Pathol Soc*. 2012; 15(5): 361–7. <https://doi.org/10.2350/11-07-1064-OA.1>.

第8章

1. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet*. 2013; 45(2): 136–44. <https://doi.org/10.1038/ng.2503>.
2. Aoude LG, Heitzer E, Johansson P, Gartside M, Wadt K, Pritchard AL, et al. POLE mutations in families predisposed to cutaneous melanoma. *Familial Cancer*. 2015; 14(4): 621–8. <https://doi.org/10.1007/s10689-015-9826-8>.
3. Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. *Genet Med*. 2016; 18(4): 325–32. <https://doi.org/10.1038/gim.2015.75>.
4. Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. *J Clin Oncol*. 2015; 33(5): 426–32. <https://doi.org/10.1200/JCO.2014.56.5689>.
5. Elsayed FA, Kets CM, Ruano D, van den Akker B, Mensenkamp AR, Schrumpf M, et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. *Eur J Hum Genet*. 2015; 23(8): 1080–4.
6. Hansen MF, Johansen J, Bjornevoll I, Sylvander AE, Steinsbekk KS, Saetrom P, et al. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. *Familial Cancer*. 2015; 14(3): 437–48. <https://doi.org/10.1007/s10689-015-9803-2>.
7. Rohlin A, Eiengard F, Lundstam U, Zagoras T, Nilsson S, Edsjo A, et al. GREM1 and POLE variants in hereditary colorectal cancer syndromes. *Genes Chromosom Cancer*. 2016; 55(1): 95–106. <https://doi.org/10.1002/gcc.22314>.
8. Rohlin A, Zagoras T, Nilsson S, Lundstam U, Wahlstrom J, Hulten L, et al. A mutation in POLE predisposing to a multi-tumour phenotype. *Int J Oncol*. 2014; 45(1): 77–81. <https://doi.org/10.3892/ijo.2014.2410>.

9. Spier I, Holzapfel S, Altmüller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer*. 2015; 137(2): 320–31. <https://doi.org/10.1002/ijc.29396>.
10. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. *Hum Mol Genet*. 2014; 23(13): 3506–12. <https://doi.org/10.1093/hmg/ddu058>.
11. Wimmer K, Beilken A, Nustede R, Ripperger T, Lamottke B, Ure B, et al. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. *Familial Cancer*. 2017; 16(1): 67–71.
12. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature*. 2013; 500(7463): 415–21. <https://doi.org/10.1038/nature12477>.
13. Shevelev IV, Hubscher U. The 3' 5' exonucleases. *Nat Rev Mol Cell Biol*. 2002; 3(5): 364–76. <https://doi.org/10.1038/nrm804>.
14. McCulloch SD, Kunkel TA. The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. *Cell Res*. 2008; 18(1): 148–61. <https://doi.org/10.1038/cr.2008.4>.
15. Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. Division of labor at the eukaryotic replication fork. *Mol Cell*. 2008; 30(2): 137–44. <https://doi.org/10.1016/j.molcel.2008.02.022>.
16. Derbyshire V, Grindley ND, Joyce CM. The 3'-5' exonuclease of DNA polymerase I of *Escherichia coli*: contribution of each amino acid at the active site to the reaction. *EMBO J*. 1991; 10(1): 17–24.
17. Murphy K, Darmawan H, Schultz A, Fidalgo da Silva E, Reha-Krantz LJ. A method to select for mutator DNA polymerase deltas in *Saccharomyces cerevisiae*. *Genome*. 2006; 49(4): 403–10. <https://doi.org/10.1139/g05-106>.
18. Shinbrot E, Henninger EE, Weinhold N, Covington KR, Goksenin AY, Schultz N, et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. *Genome Res*. 2014; 24(11): 1740–50.
19. Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. *Nature Rev*. 2016; 16(2): 71–81.
20. Esteban-Jurado C, Gimenez-Zaragoza D, Muñoz J, Franch-Exposito S, Alvarez-Barona M, Ocana T, et al. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. *Oncotarget*. 2017; 8(16): 26732–43. <https://doi.org/10.18632/oncotarget.15810>.
21. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermuted cancers. *Nat Genet*. 2015; 47(3): 257–62. <https://doi.org/10.1038/ng.3202>.
22. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. *Hum Mol Genet*. 2013; 22(14): 2820–8.
23. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013; 497(7447): 67–73.
24. Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. *J Natl Cancer Inst*. 2015; 107(1): 402.
25. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. *Br J Cancer*. 2015; 113(2): 299–310.
26. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012; 487(7407): 330–7.
27. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. *Nature*. 2012; 488(7413): 660–4.
28. Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. *Lancet*. 2016; 1(3): 207–16.
29. Zou Y, Liu FY, Liu H, Wang F, Li W, Huang MZ, et al. Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. *Mutat Res*. 2014; 761: 49–52.
30. Erson-Omay EZ, Caglayan AO, Schultz N, Weinhold N, Omay SB, Ozduman K, et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. *Neuro-Oncology*. 2015; 17(10): 1356–64.
31. Briggs S, Tomlinson I. Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. *J Pathol*. 2013; 230(2): 148–53.

32. Kane DP, Shcherbakova PV. A common cancer-associated DNA polymerase epsilon mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. *Cancer Res.* 2014; 74(7): 1895–901.
33. Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. *Curr Opin Genet Dev.* 2014; 24: 107–13.
34. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for lynch syndrome testing. *Cancer.* 2014; 121(3): 386–94.
35. Sole RV, Deisboeck TS. An error catastrophe in cancer? *J Theor Biol.* 2004; 228(1): 47–54.
36. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. *Nature Rev.* 2011; 11(6): 450–7.
37. Herr AJ, Ogawa M, Lawrence NA, Williams LN, Eggington JM, Singh M, et al. Mutator suppression and escape from replication error-induced extinction in yeast. *PLoS Genet.* 2011; 7(10): e1002282.
38. Williams LN, Herr AJ, Preston BD. Emergence of DNA polymerase epsilon antimutators that escape error-induced extinction in yeast. *Genetics.* 2013; 193(3): 751–70.
39. Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. *Gynecol Oncol.* 2014; 134(1): 15–9.
40. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. *Mod Pathol.* 2015; 28(6): 836–44.
41. Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. *Mod Pathol.* 2015; 28(4): 505–14.
42. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. *Nature.* 2012; 482(7385): 400–4.
43. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. *Nature.* 2012; 482(7385): 405–9.
44. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J Clin Oncol.* 2013; 31(32): e439–42.
45. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. *Clin Cancer Res.* 2015; 21(14): 3347–55.
46. van Gool IC, Bosse T, Church DN. POLE proofreading mutation, immune response and prognosis in endometrial cancer. *Oncoimmunology.* 2016; 5(3): e1072675.
47. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015; 372(26): 2509–20.
48. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of Hypermutated Glioblastoma: a patient with Germline POLE deficiency treated with check-point blockade immunotherapy. *Cancer Discov.* 2016; 6(11): 1230–6.
49. Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. *Clin Cancer Res.* 2016; 22(23): 5682–7.
50. Piulats JM, Matias-Guiu X. Immunotherapy in endometrial cancer: in the Nick of time. *Clin Cancer Res.* 2016; 22(23): 5623–5.
51. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. *N Engl J Med.* 2016; 375(9): 819–29.
52. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature.* 2015; 520(7547): 373–7.
53. Dovedi SJ, Cheadle EJ, Popple A, Poon E, Morrow M, Stewart R, et al. Fractionated radiation therapy stimulates anti-tumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD1 blockade. *Clin Cancer Res.* 2017; 23(18): 5514–26.
54. Spier I, Holzapfel S, Altmuller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. *Int J Cancer.* 2014; 137(2): 320–31.
55. Sinha A, Tekkis PP, Rashid S, Phillips RK, Clark SK. Risk factors for secondary proctectomy in patients with familial adenomatous polyposis. *Br J Surg.* 2010; 97(11): 1710–5.
56. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical

- management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut*. 2013; 62(6): 812–23.
57. Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, et al. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. *Eur J Hum Genet*. 2016; 24(7): 1089–92. <https://doi.org/10.1038/ejhg.2015.252>.
58. Abdus Sattar AK, Lin TC, Jones C, Konigsberg WH. Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. *Biochemistry*. 1996; 35(51): 16621–9. <https://doi.org/10.1021/bi961552q>.

第9章

1. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G: C->T: A mutations in colorectal tumors. *Nat Genet*. 2002; 30(2): 227–32. <https://doi.org/10.1038/ng828>.
2. Out AA, Tops CM, Nielsen M, Weiss MM, van Minderhout IJ, Fokkema IF, et al. Leiden open variation database of the MUTYH gene. *Hum Mutat*. 2010; 31(11): 1205–15. <https://doi.org/10.1002/humu.21343>.
3. Ohtsubo T, Nishioka K, Imaiso Y, Iwai S, Shimokawa H, Oda H, et al. Identification of human MutY homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. *Nucleic Acids Res*. 2015; 43(7): 3870–1. <https://doi.org/10.1093/nar/gkv264>.
4. Michaels ML, Cruz C, Grollman AP, Miller JH. Evidence that MutY and MutM combine to prevent mutations by an oxidatively damaged form of guanine in DNA. *Proc Natl Acad Sci U S A*. 1992; 89(15): 7022–5.
5. Boiteux S, Coste F, Castaing B. Repair of 8-oxo-7, 8-dihydroguanine in prokaryotic and eukaryotic cells: properties and biological roles of the Fpg and OGG1 DNA N-glycosylases. *Free Radic Biol Med*. 2016. <https://doi.org/10.1016/j.freeradbiomed.2016.11.042>.
6. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). *Crit Rev Oncol Hematol*. 2011; 79(1): 1–16. <https://doi.org/10.1016/j.critrevonc.2010.05.011>; S1040–8428(10)00147–2 [pii] .
7. Aretz S, Tricarico R, Papi L, Spier I, Pin E, Horpaopan S, et al. MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. *Eur J Hum Genet*. 2014; 22(7): 923–9.
8. Miyaki M, Iijima T, Yamaguchi T, Hishima T, Tamura K, Utsunomiya J, et al. Germline mutations of the MYH gene in Japanese patients with multiple colorectal adenomas. *Mutat Res*. 2005; 578(1–2): 430–3. <https://doi.org/10.1016/j.mrfmmm.2005.01.017>.
9. Peterlongo P, Mitra N, Sanchez de Abajo A, de la Hoya M, Bassi C, Bertario L, et al. Increased frequency of disease-causing MYH mutations in colon cancer families. *Carcinogenesis*. 2006; 27(11): 2243–9. <https://doi.org/10.1093/carcin/bgl093>.
10. Kim DW, Kim IJ, Kang HC, Jang SG, Kim K, Yoon HJ, et al. Germline mutations of the MYH gene in Korean patients with multiple colorectal adenomas. *Int J Color Dis*. 2007; 22(10): 1173–8. <https://doi.org/10.1007/s00384-007-0289-8>.
11. Yanaru-Fujisawa R, Matsumoto T, Ushijima Y, Esaki M, Hirahashi M, Gushima M, et al. Genomic and functional analyses of MUTYH in Japanese patients with adenomatous polyposis. *Clin Genet*. 2008; 73(6): 545–53. <https://doi.org/10.1111/j.1399-0004.2008.00998.x>.
12. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2016. <https://doi.org/10.1158/1055-9965.EPI-16-0693>.
13. Dolwani S, Williams GT, West KP, Newman J, Stock D, Griffiths AP, et al. Analysis of inherited MYH/(MutYH) mutations in British Asian patients with colorectal cancer. *Gut*. 2007; 56(4): 593. <https://doi.org/10.1136/gut.2006.094532>.
14. Prior TW, Bridgeman SJ. Identifying mutations for MYH-associated polyposis. *Curr Protoc Hum Genet*. 2010; Chapter 10: Unit 10.3. <https://doi.org/10.1002/0471142905.hg1013s64>.
15. Nielsen M, J-vdB MC, Jones N, Vogt S, Tops CM, Vasen HF, et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. *Gastroenterology*. 2009; 136(2): 471–6. <https://doi.org/10.1053/j.gastro.2008.10.056>; S0016–5085(08)01894–5 [pii] .
16. Gismondi V, Meta M, Bonelli L, Radice P, Sala P, Bertario L, et al. Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adeno-matous polyposis coli and

- colorectal adenomas. *Int J Cancer (Journal International du Cancer)*. 2004; 109(5): 680–4. <https://doi.org/10.1002/ijc.20054>.
17. Ricci MT, Miccoli S, Turchetti D, Bondavalli D, Viel A, Quaia M, et al. Type and frequency of MUTYH variants in Italian patients with suspected MAP: a retrospective multicenter study. *J Hum Genet*. 2017; 62(2): 309–15. <https://doi.org/10.1038/jhg.2016.132>.
 18. Rouleau E, Zattara H, Lefol C, Noguchi T, Briaux A, Buecher B, et al. First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome. *Clin Genet*. 2011; 80(3): 301–3. <https://doi.org/10.1111/j.1399-0004.2011.01699.x>.
 19. Torrezan GT, da Silva FC, Krepischi AC, Santos EM, Ferreira Fde O, Rossi BM, et al. Breakpoint characterization of a novel large intragenic deletion of MUTYH detected in a MAP patient: case report. *BMC Med Genet*. 2011; 12: 128. <https://doi.org/10.1186/1471-2350-12-128>.
 20. Castillejo A, Vargas G, Castillejo MI, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. *Eur J Cancer*. 2014; 50(13): 2241–50.
 21. Gomez-Fernandez N, Castellvi-Bel S, Fernandez-Rozadilla C, Balaguer F, Munoz J, Madrigal I, et al. Molecular analysis of the APC and MUTYH genes in Galician and Catalanian FAP families: a different spectrum of mutations? *BMC Med Genet*. 2009; 10: 57. <https://doi.org/10.1186/1471-2350-10-57>.
 22. Abdelmaksoud-Dammak R, Miladi-Abdennadher I, Amouri A, Tahri N, Ayadi L, Khabir A, et al. High prevalence of the c.1227_1228dup (p.Glu410GlyfsX43) mutation in Tunisian families affected with MUTYH-associated-polyposis. *Familial Cancer*. 2012; 11(3): 503–8. <https://doi.org/10.1007/s10689-012-9543-5>.
 23. Shinmura K, Kato H, Goto M, Yamada H, Tao H, Nakamura S, et al. Functional evaluation of nine missense-type variants of the human DNA glycosylase enzyme MUTYH in the Japanese population. *Hum Mutat*. 2016; 37(4): 350–3. <https://doi.org/10.1002/humu.22949>.
 24. Shinmura K, Goto M, Tao H, Matsuura S, Matsuda T, Sugimura H. Impaired suppressive activities of human MUTYH variant proteins against oxidative mutagenesis. *World J Gastroenterol*. 2012; 18(47): 6935–42. <https://doi.org/10.3748/wjg.v18.i47.6935>.
 25. Shinmura K, Goto M, Tao H, Kato H, Suzuki R, Nakamura S, et al. Impaired 8-Hydroxyguanine repair activity of MUTYH variant p.Arg109Trp found in a Japanese patient with early-onset colorectal cancer. *Oxidative Med Cell Longev*. 2014. <https://doi.org/10.1155/2014/617351>. ArtN 617351.
 26. Goto M, Shinmura K, Nakabeppu Y, Tao H, Yamada H, Tsuneyoshi T, et al. Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant proteins found in patients with colorectal polyposis and cancer. *Hum Mutat*. 2010; 31(11): E1861–74. <https://doi.org/10.1002/humu.21363>.
 27. Bai H, Grist S, Gardner J, Suthers G, Wilson TM, Lu AL. Functional characterization of human MutY homolog (hMYH) missense mutation (R231L) that is linked with hMYH-associated polyposis. *Cancer Lett*. 2007; 250(1): 74–81. <https://doi.org/10.1016/j.canlet.2006.09.016>.
 28. Ali M, Kim H, Cleary S, Cupples C, Gallinger S, Bristow R. Characterization of mutant MUTYH proteins associated with familial colorectal cancer. *Gastroenterology*. 2008; 135(2): 499–507. <https://doi.org/10.1053/j.gastro.2008.04.035>.
 29. Aretz S, Uhlhaas S, Goergens H, Siberg K, Vogel M, Pagenstecher C, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. *Int J Cancer (Journal International du Cancer)*. 2006; 119(4): 807–14. <https://doi.org/10.1002/ijc.21905>.
 30. Isidro G, Laranjeira F, Pires A, Leite J, Regateiro F, Castro e Sousa F, et al. Germline MUTYH (MYH) mutations in Portuguese individuals with multiple colorectal adenomas. *Hum Mutat*. 2004; 24(4): 353–4. <https://doi.org/10.1002/humu.9282>.
 31. Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. *J Clin Oncol: Off J Am Soc Clin Oncol*. 2009; 27(24): 3975–80. <https://doi.org/10.1200/JCO.2008.21.6853>.
 32. Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen GM, Halling KC, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. *Gastroenterology*. 2004; 127(1): 9–16.
 33. Croitoru ME, Cleary SP, Di Nicola N, Manno M, Selander T, Aronson M, et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. *J Natl Cancer Inst*. 2004; 96(21): 1631–4. <https://doi.org/10.1093/jnci/djh288>.
 34. Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. *Br J Cancer*. 2010; 103(12): 1875–84. <https://doi.org/10.1038/sj.bjc.6605444>.

- org/10.1038/sj.bjc.6605966.
35. Sieber OM, Lipton L, Crabtree M, Heinemann K, Fidalgo P, Phillips RK, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med*. 2003; 348(9): 791–9. <https://doi.org/10.1056/NEJMoa025283>.
 36. Nielsen M, Franken PF, Reinards TH, Weiss MM, Wagner A, van der Klift H, et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). *J Med Genet*. 2005; 42(9): e54. <https://doi.org/10.1136/jmg.2005.033217>.
 37. Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. *Lancet*. 2003; 362(9377): 39–41.
 38. Farrington SM, Tenesa A, Barnetson R, Wiltshire A, Prendergast J, Porteous M, et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. *Am J Hum Genet*. 2005; 77(1): 112–9.
 39. Nieuwenhuis MH, Vogt S, Jones N, Nielsen M, Hes FJ, Sampson JR, et al. Evidence for accelerated colorectal adenoma—carcinoma progression in MUTYH-associated polyposis? *Gut*. 2012; 61(5): 734–8. <https://doi.org/10.1136/gut.2010.229104>.
 40. Balaguer F, Castellvi-Bel S, Castells A, Andreu M, Munoz J, Gisbert JP, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol*. 2007; 5(3): 379–87.
 41. Fleischmann C, Peto J, Cheadle J, Shah B, Sampson J, Houlston RS. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. *Int J Cancer*. 2004; 109(4): 554–8.
 42. Avezzu A, Agostini M, Pucciarelli S, Lise M, Urso ED, Mammi I, et al. The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. *Cancer Lett*. 2008; 268(2): 308–13.
 43. van Puijenbroek M, Nielsen M, Tops CM, Halfwerk H, Vasen HF, Weiss MM, et al. Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G>T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. *Clin Cancer Res: Off J Am Assoc Cancer Res*. 2008; 14(1): 139–42. <https://doi.org/10.1158/1078-0432.ccr-07-1705>.
 44. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. *Gastroenterology*. 2009; 136(4): 1251–60.
 45. Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology*. 2009; 137(6): 1976–85 e1–10. <https://doi.org/10.1053/j.gastro.2009.08.052>.
 46. Walton SJ, Kallenberg FG, Clark SK, Dekker E, Latchford A. Frequency and features of duodenal adenomas in patients with MUTYH-associated polyposis. *Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc*. 2016; 14(7): 986–92. <https://doi.org/10.1016/j.cgh.2016.02.020>.
 47. Win AK, Reece JC, Dowty JG, Buchanan DD, Clendenning M, Rosty C, et al. Risk of extra-colonic cancers for people with biallelic and monoallelic mutations in MUTYH. *Int J Cancer (Journal International du Cancer)*. 2016; 139(7): 1557–63. <https://doi.org/10.1002/ijc.30197>.
 48. Roberts ME, Riegert-Johnson DL, Thomas BC, Rumilla KM, Thomas CS, Heckman MG, et al. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome. *Genet Med: Off J Am Coll Med Genet*. 2014; 16(9): 711–6. <https://doi.org/10.1038/gim.2014.19>.
 49. Nielsen M, Lynch H, Infante E, Brand R. MUTYH-associated polyposis. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. *GeneReviews(R)*. Seattle: University of Washington; 1993, All rights reserved.
 50. Ponti G, Ponz DL, Maffei S, Pedroni M, Losi L, Di Gregorio C, et al. Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. *Clin Genet*. 2005; 68(5): 442–7.
 51. Coleman P, Barnard NA. Congenital hypertrophy of the retinal pigment epithelium: prevalence and ocular features in the optometric population. *Ophthalmic Physiol Opt*. 2007; 27(6): 547–55. <https://doi.org/10.1111/j.1475-1313.2007.00513.x>.
 52. Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. *Gastroenterology*. 2009; 137(2): 489–94, 94 e1; quiz 725–6. <https://doi.org/10.1053/j.gastro.2009.04.047>.
 53. Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. *Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2006; 15(2): 312–4. <https://doi.org/10.1158/1055-9965.EPI-05-0793>.

54. Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD, et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. *Int J Cancer (Journal International du Cancer)*. 2011; 129(9): 2256–62. <https://doi.org/10.1002/ijc.25870>.
55. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. *Gastroenterology*. 2014; 146(5): 1208–11.e1–5. <https://doi.org/10.1053/j.gastro.2014.01.022>.
56. Rennert G, Lejbkowitz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O. MutYH mutation carriers have increased breast cancer risk. *Cancer*. 2012; 118(8): 1989–93. <https://doi.org/10.1002/cncr.26506>.
57. Zhu M, Chen X, Zhang H, Xiao N, Zhu C, He Q, et al. AluYb8 insertion in the MUTYH gene and risk of early-onset breast and gastric cancers in the Chinese population. *Asian Pac J Cancer Prev*. 2011; 12(6): 1451–5.
58. Wasielewski M, Out AA, Vermeulen J, Nielsen M, van den Ouweland A, Tops CM, et al. Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer. *Breast Cancer Res Treat*. 2010; 124(3): 635–41. <https://doi.org/10.1007/s10549-010-0801-7>.
59. Beiner ME, Zhang WW, Zhang S, Gallinger S, Sun P, Narod SA. Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. *Breast Cancer Res Treat*. 2009; 114(3): 575–8.
60. Out AA, Wasielewski M, Huijts PE, van Minderhout IJ, Houwing-Duistermaat JJ, Tops CM, et al. MUTYH gene variants and breast cancer in a Dutch case-control study. *Breast Cancer Res Treat*. 2012; 134: 219–27.
61. Baudhuin LM, Roberts LR, Enders FT, Swanson RL, Mettler TA, Aderca I, et al. MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients. *J Cancer Res Clin Oncol*. 2006; 132(3): 159–62.
62. Pilati C, Shinde J, Alexandrov LB, Assie G, Andre T, Helias-Rodzewicz Z, et al. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. *J Pathol*. 2017; 242(1): 10–5. <https://doi.org/10.1002/path.4880>.
63. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. *Nature*. 2017; 543(7643): 65–71. <https://doi.org/10.1038/nature21063>.
64. Grasso F, Giacomini E, Sanchez M, Degan P, Gismondi V, Mazzei F, et al. Genetic instability in lymphoblastoid cell lines expressing biallelic and monoallelic variants in the human MUTYH gene. *Hum Mol Genet*. 2014; 23(14): 3843–52. <https://doi.org/10.1093/hmg/ddu097>.
65. Boparai KS, Dekker E, Van Eeden S, Polak MM, Bartelsman JF, Mathus-Vliegen EM, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of Myh-Associated Polyposis (Map). *Gastroenterology*. 2008; 135: 2014–8.
66. Church J, Kravochuck S. The ‘studded’ rectum: phenotypic evidence of MYH-associated polyposis. *Dis Colon Rectum*. 2016; 59(6): 565–9. <https://doi.org/10.1097/DCR.0000000000000575>.
67. Nielsen M, de Miranda NF, van Puijenbroek M, Jordanova ES, Middeldorp A, van Wezel T, et al. Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas. *BMC Cancer*. 2009; 9: 184. <https://doi.org/10.1186/1471-2407-9-184>.
68. de Miranda NF, Nielsen M, Pereira D, van Puijenbroek M, Vasen HF, Hes FJ, et al. MUTYH-associated polyposis carcinomas frequently lose HLA class I expression—a common event amongst DNA-repair-deficient colorectal cancers. *J Pathol*. 2009; 219(1): 69–76. <https://doi.org/10.1002/path.2569>.
69. Lipton L, Halford SE, Johnson V, Novelli MR, Jones A, Cummings C, et al. Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. *Cancer Res*. 2003; 63(22): 7595–9.
70. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. *Br J Cancer*. 2001; 85(5): 692–6.
71. Middeldorp A, van Puijenbroek M, Nielsen M, Corver WE, Jordanova ES, ter HN, et al. High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomas. *J Pathol*. 2008; 216(1): 25–31.
72. Lefevre JH, Rodrigue CM, Mourra N, Bennis M, Flejou JF, Parc R, et al. Implication of MYH in colorectal polyposis. *Ann Surg*. 2006; 244(6): 874–9.
73. Colebatch A, Hitchins M, Williams R, Meagher A, Hawkins NJ, Ward RL. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. *Br J Cancer*. 2006; 95(9): 1239–43.
74. Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A, Holinski-Feder E. Biallelic MUTYH mutations can mimic Lynch syndrome. *Eur J Hum Genet*. 2014 Nov; 22(11): 1334–7. doi: 10.1038/ejhg.2014.15. Epub 2014 Feb 12.
75. Segui N, Navarro M, Pineda M, Koger N, Bellido F, Gonzalez S, et al. Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype. *Gut*. 2015; 64(2): 355–6. <https://doi.org/10.1136/gutjnl-2014-307084>.

76. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. *Nat Genet.* 2015; 47(6): 668–71. <https://doi.org/10.1038/ng.3287>.
77. Rashid M, Fischer A, Wilson CH, Tiffen J, Rust AG, Stevens P, et al. Adenoma development in familial adenomatous polyposis and MUTYH-associated polyposis: somatic landscape and driver genes. *J Pathol.* 2016; 238(1): 98–108. <https://doi.org/10.1002/path.4643>.
78. Cardoso J, Molenaar L, de Menezes RX, van Leerdam M, Rosenberg C, Moslein G, et al. Chromosomal instability in MYH- and APC-mutant adenomatous polyps. *Cancer Res.* 2006; 66(5): 2514–9.

第 10 章

1. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. *Nat Genet.* 2015; 47(6): 668–71. <https://doi.org/10.1038/ng.3287>; ng.3287 [pii] .
2. Belhadj S, Mur P, Navarro M, Gonzalez S, Moreno V, Capella G, et al. Delineating the phenotypic spectrum of the NTHL1-associated polyposis. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2017; 15(3): 461–2. <https://doi.org/10.1016/j.cgh.2016.09.153>.
3. Kenwrick S, Spasic-Boskovic O, Taylor A, Brugger K, Rai H, Abbs S, Wyke J, Tischkowitz M, Maher E, Whitworth J. Compound heterozygosity for two novel mutations in NTHL1 in an individual with adenomatous polyposis and multiple tumours. Abstract joint meeting UK/Dutch clinical genetics societies. 2016.
4. Rivera B, Castellsague E, Bah I, van Kempen LC, Foulkes WD. Biallelic NTHL1 mutations in a woman with multiple primary tumors. *N Engl J Med.* 2015; 373(20): 1985–6. <https://doi.org/10.1056/NEJMc1506878>.
5. Broderick P, Dobbins SE, Chubb D, Kinnersley B, Dunlop MG, Tomlinson I, et al. Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients—a systematic review. *Gastroenterology.* 2017; 152(1): 75–7e4. <https://doi.org/10.1053/j.gastro.2016.09.041>.
6. Chan MK, Ocampo-Hafalla MT, Vartanian V, Jaruga P, Kirkali G, Koenig KL, et al. Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA. *DNA Repair.* 2009; 8(7): 786–94. <https://doi.org/10.1016/j.dnarep.2009.03.001>.
7. Kino K, Takao M, Miyazawa H, Hanaoka F. A DNA oligomer containing 2, 2, 4-triamino-5(2H)-oxazolone is incised by human NEIL1 and NTH1. *Mutat Res.* 2012; 734(1–2): 73–7. <https://doi.org/10.1016/j.mrfmmm.2012.03.007>.
8. Hazra TK, Das A, Das S, Choudhury S, Kow YW, Roy R. Oxidative DNA damage repair in mammalian cells: a new perspective. *DNA Repair.* 2007; 6(4): 470–80. <https://doi.org/10.1016/j.dnarep.2006.10.011>.
9. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. *Cancer Prev Res.* 2012; 5(2): 164–78. <https://doi.org/10.1158/1940-6207.CAPR-11-0391>.
10. Broderick P, Bagratuni T, Vijayakrishnan J, Lubbe S, Chandler I, Houlston RS. Evaluation of NTHL1, NEIL1, NEIL2, MPG, TDG, UNG and SMUG1 genes in familial colorectal cancer predisposition. *BMC Cancer.* 2006; 6: 243. <https://doi.org/10.1186/1471-2407-6-243>.
11. Dallosso AR, Dolwani S, Jones N, Jones S, Colley J, Maynard J, et al. Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. *Gut.* 2008; 57(9): 1252–5. <https://doi.org/10.1136/gut.2007.145748>.
12. Drost J, van Boxtel R, Blokzijl F, Mizutani T, Sasaki N, Sasselli V, de Ligt J, Behjati S, Grolleman JE, van Wezel T, Nik-Zainal S, Kuiper RP, Cuppen E, Clevers H (2017) Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. *Science* 358 (6360): 234–8.

第 11 章

1. Durno CA, Sherman PM, Aronson M, Malkin D, Hawkins C, Bakry D, Bouff et E, Gallinger S, Pollett A, Campbell B, Tabori U, International BMMRD Consortium. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. *Eur J Cancer.* 2015; 51: 977–83.
2. Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, Coulet F, Cabaret O, Andreiuolo F, Charpy C, et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. *J Med Genet.* 2015; 52: 770–8.
3. Herkert JC, Niessen RC, Olderode-Berends MJ, Veenstra-Knol HE, Vos YJ, van der Klift HM, Scheenstra R, Tops

- CM, Karrenbeld A, Peters FT, et al. Paediatric intestinal cancer and polyposis due to biallelic PMS2 mutations: case series, review and follow-up guidelines. *Eur J Cancer*. 2011; 47: 965–82.
- van der Klift HM, Mensenkamp AR, Drost M, Bik EC, Vos YJ, Gille HJ, Redeker BE, Tiersma Y, Zonneveld JB, Garcia EG, Letteboer TG, Olderode-Berends MJ, van Hest LP, van Os TA, Verhoef S, Wagner A, van Asperen CJ, Ten Broeke SW, Hes FJ, de Wind N, Nielsen M, Devilee P, Ligtenberg MJ, Wijnen JT, Tops CM. Comprehensive mutation analysis of PMS2 in a large cohort of probands suspected of Lynch syndrome or constitutional mismatch repair deficiency syndrome. *Hum Mutat*. 2016; 37: 1162–79.
 - Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, Kirfel J, Tafazzoli A, Horpaopan S, Uhlhaas S, Stienen D, Friedrichs N, Altmüller J, Laner A, Holzapfel S, Peters S, Kayser K, Thiele H, Holinski-Feder E, Marra G, Kristiansen G, Nöthen MM, Büttner R, Möslein G, Betz RC, Brieger A, Lifton RP, Aretz S. Exome sequencing identifies biallelic MSH3 germ-line mutations as a recessive subtype of colorectal adenomatous polyposis. *Am J Hum Genet*. 2016; 99: 337–51.
 - Levi Z, Kariv R, Barnes-Kedar I, Goldberg Y, Half E, Morgentern S, Eli B, Baris HN, Vilkin A, Belfer RG, Niv Y, Elhasid R, Dvir R, Abu-Freha N, Cohen S. The gastrointestinal manifestation of constitutional mismatch repair deficiency syndrome: from a single adenoma to polyposis-like phenotype and early onset cancer. *Clin Genet*. 2015; 88: 474–8.
 - Vasen HF, Ghorbanoghli Z, Bourdeaut F, Cabaret O, Caron O, Duval A, Entz-Werle N, Goldberg Y, Ilencikova D, Kratz CP, Lavoine N, Loeffen J, Menko FH, Muleris M, Sebille G, Colas C, Burkhardt B, Brugieres L, Wimmer K, EU-Consortium Care for CMMR-D (C4CMMR-D). Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European consortium ‘care for CMMR-D’ (C4CMMR-D). *J Med Genet*. 2014; 51: 283–93.
 - Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, Gerdes AM, Goldberg Y, Ilencikova D, Muleris M, Duval A, Lavoine N, Ruiz-Ponte C, Slavc I, Burkhardt B, Brugieres L, EU-Consortium Care for CMMRD (C4CMMRD). Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). *J Med Genet*. 2014; 51: 355–65.

第 12 章

- Hes FJ, Ruano D, Nieuwenhuis M, et al. Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. *J Med Genet*. 2014; 51: 55–60.
- Thirlwell C, Howarth KM, Segditsas S, et al. Investigation of pathogenic mechanisms in multiple colorectal adenoma patients without germline APC or MYH/MUTYH mutations. *Br J Cancer*. 2007; 96: 1729–34.
- Mongin C, Coulet F, Lefevre JH, et al. Unexplained polyposis: a challenge for geneticists, pathologists and gastroenterologists. *Clin Genet*. 2012; 81: 38–46.
- Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, Kirfel J, Tafazzoli A, Horpaopan S, Uhlhaas S, Stienen D, Friedrichs N, Altmüller J, Laner A, Holzapfel S, Peters S, Kayser K, Thiele H, Holinski-Feder E, Marra G, Kristiansen G, Nöthen MM, Büttner R, Möslein G, Betz RC, Brieger A, Lifton RP, Aretz S. Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. *Am J Hum Genet*. 2016; 99: 337–51.
- Ngeow J, Heald B, Rybicki LA, Orloff MS, Chen JL, Liu X, Yerian L, Willis J, Lehtonen HJ, Lehtonen R, Mester JL, Moline J, Burke CA, Church J, Aaltonen LA, Eng C. Prevalence of germline PTEN, BMPR1A, SMAD4, STK11, and ENG mutations in patients with moderate-load colorectal polyps. *Gastroenterology*. 2013; 144: 1402–9.
- Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, Rawstorne E, Colley J, Moskvina V, Frye C, Sampson JR, Wenstrup R, Scholl T, Cheadle JP. Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. *Cancer Res*. 2008; 68: 358–63.
- Spier I, Horpaopan S, Vogt S, Uhlhaas S, Morak M, Stienen D, Draaken M, Ludwig M, Holinski-Feder E, Nöthen MM, Hoffmann P, Aretz S. Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. *Hum Mutat*. 2012; 33: 1045–50.
- Nieminen TT, Pavicic W, Porkka N, Kankainen M, Järvinen HJ, Lepistö A, Peltomäki P. Pseudoexons provide a mechanism for allele-specific expression of APC in familial adenomatous polyposis. *Oncotarget*. 2016; 7(43): 70685–98.
- Spier I, Drichel D, Kerick M, Kirfel J, Horpaopan S, Laner A, Holzapfel S, Peters S, Adam R, Zhao B, Becker T, Lifton RP, Perner S, Hoffmann P, Kristiansen G, Timmermann B, Nöthen MM, Holinski-Feder E, Schweiger MR, Aretz S. Low-level APC mutational mosaicism is the underlying cause in a substantial fraction of unexplained

- colorectal adenomatous polyposis cases. *J Med Genet.* 2016; 53: 172–9.
10. Jansen AM, Crobach S, Geurts-Giele WR, van den Akker BE, Garcia MV, Ruano D, Nielsen M, Tops CM, Wijnen JT, Hes FJ, van Wezel T, Dinjens WN, Morreau H. Distinct patterns of somatic mosaicism in the APC gene in neoplasms from patients with unexplained adenomatous polyposis. *Gastroenterology.* 2017; 152: 546–9.
 11. Aceto GM, Fantini F, De Iure S, Di Nicola M, Palka G, Valanzano R, Di Gregorio P, Stigliano V, Genuardi M, Battista P, Cama A, Curia MC. Correlation between mutations and mRNA expression of APC and MUTYH genes: new insight into hereditary colorectal polyposis pre-disposition. *J Exp Clin Cancer Res.* 2015; 34: 131.
 12. Rigter LS, Kallenberg FG, Bastiaansen B, van Os TA, van Leeuwen FE, van Leerdam ME, Dekker E. A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation? *BMC Cancer.* 2016; 16: 862.
 13. Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. *Familial Cancer.* 2003; 2: 43–55.
 14. Fearnhead NS, Wilding JL, Winney B, et al. Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. *Proc Natl Acad Sci USA.* 2004; 101: 15992–7.
 15. Lefevre JH, Bonilla C, Colas C, et al. Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer. *J Hum Genet.* 2012; 57: 709–16.
 16. Dallosso AR, Dolwani S, Jones N, et al. Inherited predisposition to colorectal adenomas caused by multiple rare alleles of MUTYH but not OGG1, NUDT1, NTH1 or NEIL 1, 2 or 3. *Gut.* 2008; 57: 1252–5.
 17. Will O, Carvajal-Carmona LG, Gorman P, Howarth KM, Jones AM, Polanco-Echeverry GM, Chinaleong JA, Gunther T, Silver A, Clark SK, Tomlinson I. Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. *Gastroenterology.* 2007; 132: 527–30.
 18. Rio Frio T, Lavoie J, Hamel N, et al. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. *N Engl J Med.* 2010; 363: 2628–37.
 19. de Voer RM, Geurts van Kessel A, Weren RD, Ligtenberg MJ, Smeets D, Fu L, Vreede L, Kamping EJ, Verwiel ET, Hahn MM, Ariaans M, Spruijt L, van Essen T, Houge G, Schackert HK, Sheng JQ, Venselaar H, van Ravenswaaij-Arts CM, van Krieken JH, Hoogerbrugge N, Kuiper RP. Germline mutations in the spindle assembly checkpoint genes BUB1 and BUB3 are risk factors for colorectal cancer. *Gastroenterology.* 2013; 145: 544–7.
 20. Horpaopan S, Spier I, Zink AM, Altmüller J, Holzapfel S, Laner A, Vogt S, Uhlhaas S, Heilmann S, Stienen D, Pasternack SM, Keppler K, Adam R, Kayser K, Moebus S, Draaken M, Degenhardt F, Engels H, Hofmann A, Nöthen MM, Steinke V, Perez-Bouza A, Herms S, Holinski-Feder E, Fröhlich H, Thiele H, Hoffmann P, Aretz S. Genomewide CNV analysis in 221 unrelated patients and targeted high-throughput sequencing reveal novel causative candidate genes for colorectal adenomatous polyposis. *Int J Cancer.* 2015; 136: E578–89.
 21. Gilissen C, Hoischen A, Brunner HG, Veltman JA. Disease gene identification strategies for exome sequencing. *Eur J Hum Genet.* 2012; 20: 490–7.
 22. Palles C, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet.* 2013; 45(2): 136–44.
 23. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, van Zelst-Stams WA, Jongmans MC, Gilissen C, Hehir-Kwa JY, Hoischen A, Shendure J, Boyle EA, Kamping EJ, Nagtegaal ID, Tops BB, Nagengast FM, Geurts van Kessel A, van Krieken JH, Kuiper RP, Hoogerbrugge N. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. *Nat Genet.* 2015; 47(6): 668–71.

第 13 章

1. Schreibman IR, Baker M, Amos C, McGarrity TJ. The Hamartomatous polyposis syndromes—a clinical and molecular review. *Am J Gastroenterol.* 2005; 100: 476–90.
2. Ngeow J, Heald B, Rybicki LA, et al. Prevalence of germline PTEN, BMPR1A, SMAD4, STK11, and ENG mutations in patients with moderate-load colorectal polyps. *Gastroenterology.* 2013; 144: 1402–9. <https://doi.org/10.1053/j.gastro.2013.02.001>.
3. Jelsig AM. Hamartomatous polyps—a clinical and molecular genetic study. *Dan Med J.* 2016. <https://doi.org/10.1111/cge.12693>.
4. Aretz S. The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. *Dtsch Arztebl Int.* 2010; 107: 163–73. <https://doi.org/10.3238/arztebl.2010.0163>.
5. van Lier M, Wagner A, Mathus-Vliegen E, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review

- and surveillance recommendations. *Am J Gastroenterol.* 2010; 105: 1258–64. <https://doi.org/10.1038/ajg.2009.725>.
6. Latchford A, Phillips R. Gastrointestinal polyps and cancer in Peutz-Jeghers syndrome: clinical aspects. *Familial Cancer.* 2011; 10: 455–61. <https://doi.org/10.1007/s10689-011-9442-1>.
 7. Giardiello F, Trimbath J. Peutz-Jeghers syndrome and management recommendations. *Clin Gastroenterol Hepatol.* 2006; 4: 408–15. <https://doi.org/10.1016/j.cgh.2005.11.005>.
 8. Entius MM, Westerman AM, Giardiello FM, et al. Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations. *Gut.* 1997; 41: 320–2.
 9. Yaguchi T, Wen-Ying L, Hasegawa K, et al. Peutz-Jeghers polyp with several foci of glandular dysplasia: report of a case. *Dis Colon Rectum.* 1982; 25: 592–6.
 10. Beggs A, Latchford A, Vasen H, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. *Gut.* 2010; 59: 975–86. <https://doi.org/10.1136/gut.2009.198499>.
 11. Vogel T, Schumacher V, Saleh A, et al. Extraintestinal polyps in Peutz-Jeghers syndrome: presentation of four cases and review of the literature. *Deutsche Peutz-Jeghers-Studiengruppe. Int J Color Dis.* 2000; 15: 118–23.
 12. Amos CI, Keitheri-Cheteri MB, Sabripour M, et al. Genotype-phenotype correlations in Peutz-Jeghers syndrome. *J Med Genet.* 2004; 41: 327–33. <https://doi.org/10.1136/jmg.2003.010900>.
 13. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology.* 2000; 119: 1447–53. <https://doi.org/10.1053/gast.2000.20228>.
 14. Hearle N, Schumacher V, Menko FH, et al. Frequency and Spectrum of cancers in the Peutz-Jeghers syndrome. *Clin Cancer Res.* 2006; 12: 3209–15. <https://doi.org/10.1158/1078-0432.CCR-06-0083>.
 15. Korsse SE, Harinck F, van Lier MGF, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. *J Med Genet.* 2013; 50: 59–64. <https://doi.org/10.1136/jmedgenet-2012-101277>.
 16. Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. *Gastroenterology.* 2004; 126: 1788–94. <https://doi.org/10.1053/j.gastro.2004.03.014>.
 17. Resta N, Pierannunzio D, Lenato GM, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. *Dig Liver Dis.* 2013; 45: 606–11. <https://doi.org/10.1016/j.dld.2012.12.018>.
 18. Mehenni H, Resta N, Park J-G, et al. Cancer risks in LKB1 germline mutation carriers. *Gut.* 2006; 55: 984–90. <https://doi.org/10.1136/gut.2005.082990>.
 19. Korsse SE, Dewint P, Kuipers EJ, van Leerdam ME. Small bowel endoscopy and Peutz-Jeghers syndrome. *Best Pract Res Clin Gastroenterol.* 2012; 26: 263–78. <https://doi.org/10.1016/j.bpg.2012.03.009>.
 20. Jelsig AM, Qvist N, Brusgaard K, et al. Hamartomatous polyposis syndromes: a review. *Orphanet J Rare Dis.* 2014; 9: 101. <https://doi.org/10.1186/1750-1172-9-101>.
 21. van Lier M, Mathus-Vliegen E, Wagner A, et al. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? *Am J Gastroenterol.* 2011; 106: 940–5. <https://doi.org/10.1038/ajg.2010.473>.
 22. Goldstein SA, Hoffenberg EJ. Peutz-Jegher syndrome in childhood. *J Pediatr Gastroenterol Nutr.* 2013; 56: 191–5. <https://doi.org/10.1097/MPG.0b013e318271643c>.
 23. Brown G, Fraser C, Schofield G, et al. Video capsule endoscopy in Peutz-Jeghers syndrome: a blinded comparison with barium follow-through for detection of small-bowel polyps. *Endoscopy.* 2006; 38: 385–90. <https://doi.org/10.1055/s-2006-925028>.
 24. Gupta A, Postgate AJ, Burling D, et al. A prospective study of MR Enterography versus capsule endoscopy for the surveillance of adult patients with Peutz-Jeghers syndrome. *Am J Roentgenol.* 2010; 195: 108–16. <https://doi.org/10.2214/AJR.09.3174>.
 25. Aretz S, Stienen D, Uhlhaas S, et al. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. *Hum Mutat.* 2005; 26: 513–9. <https://doi.org/10.1002/humu.20253>.
 26. Papp J, Kovacs ME, Solyom S, et al. High prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers syndrome patients. *BMC Med Genet.* 2010; 11: 169. <https://doi.org/10.1186/1471-2350-11-169>.
 27. Mehenni H, Resta N, Guanti G, et al. Molecular and clinical characteristics in 46 families affected with Peutz-Jeghers syndrome. *Dig Dis Sci.* 2007; 52: 1924–33. <https://doi.org/10.1007/s10620-006-9435-3>.
 28. Plawski A, Cichy W, Klinecicz B. Juvenile polyposis syndrome. *Arch Med Sci.* 2014; 10: 570–7. <https://doi.org/10.5114/aoms.2014.43750>.
 29. Chen H-M, Fang J-Y. Genetics of the hamartomatous polyposis syndromes: a molecular review. *Int J Color Dis.* 2009; 24: 865–74. <https://doi.org/10.1007/s00384-009-0714-2>.
 30. Latchford A, Neale K, Phillips R, Clark S. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-

- term outcome. *Dis Colon Rectum*. 2012; 55: 1038–43. <https://doi.org/10.1097/DCR.0b013e31826278b3>.
31. Brosens LA, Langeveld D, Arnout W, et al. Juvenile polyposis syndrome. *World J Gastroenterol*. 2011; 17: 4839–44. <https://doi.org/10.3748/wjg.v17.i44.4839>.
 32. Kapetanakis A, Vini D, Plitsis G. Solitary juvenile polyps in children and colon cancer. *Hepato-Gastroenterology*. 1996; 43: 1530–1.
 33. Nugent KP, Talbot IC, Hodgson SV, Phillips RK. Solitary juvenile polyps: not a marker for subsequent malignancy. *Gastroenterology*. 1993; 105: 698–700.
 34. Coburn M, Pricolo V, DeLuca F, Bland K. Malignant potential in intestinal juvenile polyposis syndromes. *Ann Surg Oncol*. 1995; 2: 386–91.
 35. Sachatello CR, Griffen WO. Hereditary polyposis diseases of the gastrointestinal tract: a working classification. *Am J Surg*. 1975; 129: 198–203.
 36. Sachatello CR, Hahn IS, Carrington CB. Juvenile gastrointestinal polyposis in a female infant: report of a case and review of the literature of a recently recognized syndrome. *Surgery*. 1974; 75: 107–14.
 37. Alimi A, Weeth-Feinstein LA, Stettner A, et al. Overlap of juvenile polyposis syndrome and Cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: implications for treatment and surveillance. *Am J Med Genet*. 2015; 167: 1305–8. <https://doi.org/10.1002/ajmg.a.36876>.
 38. Delnatte C, Sanlaville D, Mougnot J-F, et al. Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. *Am J Hum Genet*. 2006; 78: 1066–74. <https://doi.org/10.1086/504301>.
 39. Menko F, Kneepkens C, De Leeuw N, et al. Variable phenotypes associated with 10q23 micro-deletions involving the PTEN and BMPR1A genes. *Clin Genet*. 2008; 74: 145–54. <https://doi.org/10.1111/j.1399-0004.2008.01026.x>.
 40. Merg A, Howe JR. Genetic conditions associated with intestinal juvenile polyps. *Am J Med Genet*. 2004; 129: 44–55. <https://doi.org/10.1002/ajmg.c.30020>.
 41. Desai D, Murday V, Phillips R, et al. A survey of phenotypic features in juvenile polyposis. *J Med Genet*. 1998; 35: 476–81.
 42. Aytac E, Sulu B, Heald B, et al. Genotype-defined cancer risk in juvenile polyposis syndrome. *Br J Surg*. 2015; 102: 114–8. <https://doi.org/10.1002/bjs.9693>.
 43. Friedl W, Uhlhaas S, Schulmann K, et al. Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. *Hum Genet*. 2002; 111: 108–11. <https://doi.org/10.1007/s00439-002-0748-9>.
 44. Aretz S, Stienen D, Uhlhaas S, et al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. *J Med Genet*. 2007; 44: 702–9. <https://doi.org/10.1136/jmg.2007.052506>.
 45. O'Malley M, LaGuardia L, Kalady MF, et al. The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. *Dis Colon Rectum*. 2012; 55: 886–92. <https://doi.org/10.1097/DCR.0b013e31825aad32>.
 46. Jass J, Williams C, Bussey H, Morson B. Juvenile polyposis—a precancerous condition. *Histopathology*. 1988; 13: 619–30.
 47. Brosens LA, van Hattem A, Hyland LM, et al. Risk of colorectal cancer in juvenile polyposis. *Gut*. 2007; 56: 965–7. <https://doi.org/10.1136/gut.2006.116913>.
 48. Howe J, Mitros F, Summers R. The risk of gastrointestinal carcinoma in familial juvenile polyposis. *Ann Surg Oncol*. 1998; 5: 751–6.
 49. Ma C, Giardiello FM, Montgomery EA. Upper tract juvenile polyps in juvenile polyposis patients: dysplasia and malignancy are associated with foveolar, intestinal, and pyloric differentiation. *Am J Surg Pathol*. 2014; 38: 1618–26. <https://doi.org/10.1097/PAS.000000000000283>.
 50. Walpole IR, Cullity G, Opitz JM, Reynolds JF. Juvenile polyposis: a case with early presentation and death attributable to adenocarcinoma of the pancreas. *Am J Med Genet*. 1989; 32: 1–8. <https://doi.org/10.1002/ajmg.1320320102>.
 51. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut*. 2010; 59: 666–89. <https://doi.org/10.1136/gut.2009.179804>.
 52. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol*. 2015; 110: 223–62. <https://doi.org/10.1038/ajg.2014.435>.
 53. Faughnan M, Palda V, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. *J Med Genet*. 2011; 48: 73–87. <https://doi.org/10.1136/jmg.2009.069013>.
 54. Howe J, Sayed M, Ahmed A, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and

- absence of BMPR2, BMPR1B, and ACVR1 mutations. *J Med Genet.* 2004; 41: 484–91. <https://doi.org/10.1136/jmg.2004.018598>.
55. Daly MB, Pilarski R, Axilbund J, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 *J Natl Compr Canc Netw* 2017; 15: 9–20 doi: 10.6004/jccn.2017.0003.
 56. Bannayan G. Lipomatosis, angiomatosis, and macrencephalia. A previously undescribed congenital syndrome. *Arch Pathol.* 1971; 92: 1–5.
 57. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. *J Med Genet.* 2000; 37: 828–30. <https://doi.org/10.1136/jmg.37.11.828>.
 58. Ngeow J, Eng C. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol. *Methods.* 2015; 77–78: 11–9. <https://doi.org/10.1016/j.ymeth.2014.10.011>.
 59. Nelen MR, Padberg GW, Peeters EAJ, et al. Localization of the gene for Cowden disease to chromosome 10q22–23. *Nat Genet.* 1996; 13: 114–6. <https://doi.org/10.1038/ng0596-114>.
 60. Uppal S, Mistry D, Coatesworth A. Cowden disease: a review. *Int J Clin Pract.* 2007; 61: 645–52. <https://doi.org/10.1111/j.1742-1241.2006.00896.x>.
 61. Coriat R, Mozer M, Caux E, et al. Endoscopic findings in Cowden syndrome. *Endoscopy.* 2011; 43: 723–6. <https://doi.org/10.1055/s-0030-1256342>.
 62. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. *Gastroenterology.* 2010; 139: 1927–33. <https://doi.org/10.1053/j.gastro.2010.06.061>.
 63. Levi Z, Baris HN, Kedar I, et al. Upper and lower gastrointestinal findings in PTEN mutation-positive Cowden syndrome patients participating in an active surveillance program. *Clin Transl Gastroenterol.* 2011; 2: e5. <https://doi.org/10.1038/ctg.2011.4>.
 64. Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. *Mayo Clin Proc.* 2011; 86: 489–92. <https://doi.org/10.4065/mcp.2010.0816>.
 65. Tan M-H, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. *Am J Hum Genet.* 2011; 88: 42–56. <https://doi.org/10.1016/j.ajhg.2010.11.013>.
 66. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet.* 2013; 50: 255–63. <https://doi.org/10.1136/jmedgenet-2012-101339>.
 67. Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. *J Clin Endocrinol Metab.* 2011; 96: E2063–71. <https://doi.org/10.1210/jc.2011-1616>.
 68. Nieuwenhuis MH, Kets CM, Murphy-Ryan M, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. *Familial Cancer.* 2014; 13: 57–63. <https://doi.org/10.1007/s10689-013-9674-3>.
 69. Tan M, Mester J, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res.* 2012; 18: 400–7. <https://doi.org/10.1158/1078-0432.CCR-11-2283>.
 70. Sherman SK, Maxwell JE, Qian Q, et al. Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations. *Cancer Genet.* 2015; 208: 41–6. <https://doi.org/10.1016/j.cancergen.2014.11.002>.
 71. NCCN. Genetic/familial high-risk assessment: breast and ovarian. *Natl Compr Cancer Netw.* 2016.
 72. Ngeow J, Liu C, Zhou K, et al. Detecting germline PTEN mutations among at-risk patients with cancer: an age- and sex-specific cost-effectiveness analysis. *J Clin Oncol.* 2015; 33: 2537–44. <https://doi.org/10.1200/JCO.2014.60.3456>.
 73. Ngeow J, Stanuch K, Mester JL, et al. Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations. *J Clin Oncol.* 2014; 32: 1818–24. <https://doi.org/10.1200/JCO.2013.53.6656>.
 74. Gorlin RJ, Cohen MM, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. *Am J Med Genet.* 1992; 44: 307–14. <https://doi.org/10.1002/ajmg.1320440309>.
 75. Marsh D, Kum J, Lunetta K, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. *Hum Mol Genet.* 1999; 8: 1461–72.
 76. Mester J, Eng C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. *Genet Med.* 2012; 14: 819–22. <https://doi.org/10.1038/gim.2012.51>.
 77. Ni Y, He X, Chen J, et al. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. *Hum Mol Genet.* 2012; 21: 300–10. <https://doi.org/10.1093/hmg/ddr459>.

78. Ni Y, Zbuk KM, Sadler T, et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. *Am J Hum Genet.* 2008; 83: 261–8. <https://doi.org/10.1016/j.ajhg.2008.07.011>.
79. Nizialek EA, Mester JL, Dhiman VK, et al. KLLN epigenotype-phenotype associations in Cowden syndrome. *Eur J Hum Genet.* 2015; 23: 1538–43. <https://doi.org/10.1038/ejhg.2015.8>.
80. Colby S, Yehia L, Niazi F, et al. Exome sequencing reveals germline gain-of-function EGFR mutation in an adult with Lhermitte-Duclos disease. *Cold Spring Harb Mol Case Stud.* 2016; 2: a001230. <https://doi.org/10.1101/mcs.a001230>.
81. Yehia L, Niazi F, Ni Y, et al. Germline heterozygous variants in SEC23B are associated with Cowden syndrome and enriched in apparently sporadic thyroid cancer. *Am J Hum Genet.* 2015; 97: 661–76. <https://doi.org/10.1016/j.ajhg.2015.10.001>.
82. Ni Y, Seballos S, Fletcher B, et al. Germline compound heterozygous poly-glutamine deletion in USF3 may be involved in predisposition to heritable and sporadic epithelial thyroid carcinoma. *Hum Mol Genet.* dww382. 2016. <https://doi.org/10.1093/hmg/ddw382>.
83. Schwartz R. Basal-cell-nevus syndrome and gastrointestinal polyposis. *N Engl J Med.* 1978; 299: 49. <https://doi.org/10.1056/NEJM197807062990118>.
84. Plesec T, Brown K, Allen C, et al. Clinicopathological features of a kindred with SCG5–GREM1-associated hereditary mixed polyposis syndrome. *Hum Pathol.* 2017; 60: 75–81. <https://doi.org/10.1016/j.humpath.2016.10.002>.
85. Jaeger E, Leedham S, Lewis A, et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. *Nat Genet.* 2012; 44: 699–703. <https://doi.org/10.1038/ng.2263>.
86. Thomas HJ, Whitelaw SC, Cottrell SE, et al. Genetic mapping of hereditary mixed polyposis syndrome to chromosome 6q. *Am J Hum Genet.* 1996; 58: 770–6.
87. Cao X, Eu KW, Kumarasinghe MP, et al. Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genome-wide high-density single nucleotide polymorphism (SNP) scan and identification of BMPRIA loss of function. *J Med Genet.* 2006; 43: e13. <https://doi.org/10.1136/jmg.2005.034827>.
88. O’Riordan JM, O’Donoghue D, Green A, et al. Hereditary mixed polyposis syndrome due to a BMPRIA mutation. *Color Dis.* 2009; 12: 570–3. <https://doi.org/10.1111/j.1463-1318.2009.01931.x>.
89. Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen’s disease): clinicopathological spectrum with pathogenetic considerations. *Int J Clin Exp Pathol.* 2012; 5: 852–62.
90. Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. *Genet Med.* 2011; 13: 755–64. <https://doi.org/10.1097/GIM.0b013e318216cc6d>.
91. Uusitalo E, Rantanen M, Kallionpää RA, et al. Distinctive cancer associations in patients with Neurofibromatosis type 1. *J Clin Oncol.* 2016; 34: 1978–86. <https://doi.org/10.1200/JCO.2015.65.3576>.
92. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. *Br J Cancer.* 2006; 95: 233–8. <https://doi.org/10.1038/sj.bjc.6603227>.
93. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the Management of Medullary Thyroid Carcinoma. *Thyroid.* 2015; 25: 567–610. <https://doi.org/10.1089/thy.2014.0335>.

第 14 章

1. Whitelaw SC, Murday VA, Tomlinson IPM, Thomas HJW, Cottrell S, Ginsberg A, Bukofzer S, Hodgson SV, Skudowitz RB, Jass JR, Talbot IC, Northover JMA, Bodmer WF, Solomon E. Clinical and molecular features of hereditary mixed polyposis syndrome. *Gastroenterology.* 1997;112: 327–34.
2. Rosen P, Samuel Z, Brazowski E. A prospective study of the clinical, genetic screening and pathologic features of a family with hereditary mixed polyposis syndrome. *Am J Gastroenterol.* 2003;98: 2317–20.
3. Tomlinson I, Rahman N, Frayling I, Mangion J, Barfoot R, Hamoudi R, Seal S, Northover J, Thomas HJ, Neale K, Hodgson S, Talbot I, Houlston R, Stratton MR. Inherited susceptibility to colorectal adenomas and carcinomas: evidence for a new predisposition gene on 15q14–q22. *Gastroenterology.* 1999;116: 789–95.
4. Rohlin A, Eiengard F, Lundstam U, Zagoras T, Nilsson S, Edsjo A, Pedersen J, Svensson J, Skullman S, Goran Karlsson B, Bjork J, Nordling M. GREM1 and POLE variants in hereditary colorectal cancer syndromes. *Genes Chromosomes Cancer.* 2016;55: 95–106.
5. Venkatachalam R, Verwiel ETP, Kamping EJ, Hoenselaar E, Gorgens H, Schackert HK, van Krieken HJM, Ligtenberg MJL, Hoererbrugge N, van Kessel AG, Kuiper RP. Identification of candidate predisposing copy number

- variants in familial and early-onset colorectal cancer patients. *Int J Cancer*. 2011;129: 1635–42.
6. Tomlinson I, Jaeger E, Leedham S, Thomas H. The classification of intestinal polyposis. *Nat Genet*. 2013;45: 2–3.
 7. Thomas HJW, Whitelaw SC, Cottrell SC, Murday VA, Tomlinson IPA, Markie D, Jones T, Bishop DT, Hodgson SV, Sheer D, Northover JMA, Talbot IC, Solomon E, Bodmer WF. Genetic mapping of the hereditary mixed polyposis syndrome to chromosome 6q. *Am J Hum Genet*. 1996;58: 770–6.
 8. Jaegers EEM, Woodford-Richens KL, Lockett M, Rowan AJ, Sawyer EJ, Heinimann K, Rozen P, Murday VA, Whitelaw SC, Ginsberg A, Atkin WS, Lynch HT, Southey MC, Eng C, Bodmer WF, Talbot IC, Hodgson SV, Thomas HJW, Tomlinson IPM. An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus is associated with hereditary mixed polyposis syndrome. *Am J Hum Genet*. 2003;72: 1261–7.
 9. Jaeger E, Leedham S, Lewis A, Segditsas S, Becker M, Cuadrado PR, Davis H, Kaur K, Heinimann K, Howarth K, East J, Taylor J, Thomas H, Tomlinson I. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. *Nat Genet*. 2012;44: 699–703.
 10. Lewis A, Freeman-Mills L, de la Calle-Mustienes E, Giráldez-Pérez RM, Davis H, Jaeger E, Becker M, Hubner NC, Nguyen LN, Zeron-Medina J, Bond G, Stunnenberg HG, Carvajal JJ, Gomez-Skarmeta JL, Leedham S, Tomlinson I. A polymorphic enhancer near GREM1 influences bowel cancer risk through differential CDX2 and TCF7L2 binding. *Cell Rep*. 2014;8: 983–90.
 11. Davis H, Irshad S, Bansal M, Rafferty H, Boitsova T, Bardella C, Jaeger E, Lewis A, Freeman-Mills L, Castro Giner F, Rodenas-Cuadrado P, Mallappa S, Clark S, Thomas H, Jeffrey R, Poulos R, Rodriguez-Justo M, Novelli M, Chetty R, Silver A, Sansom O, Greten F, Wang LM, East J, Tomlinson I, Needham S. Subtypes of inherited and sporadic colorectal cancer result from GREM1 induced acquisition of progenitor-like features by differentiated intestinal epithelial cells. *Nat Med*. 2015;21: 62–70.
 12. Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts B, Pritcahd C, Tomlinson I, King M, Levy-Lahad E, Peretz T, Goldberg Y. Features of patients with hereditary mixed polyposis syndrome caused by duplication of GREM1 and implications for screening and surveillance. *Gastroenterology*. 2017;156: 1876–80.
 13. Brazowski E, Misonzhnick-Bedny F, Rosen P. Immunohistochemical expression of COX-2 in polyps of hereditary mixed polyposis syndrome suggests the possibility of chemoprevention. *Dig Dis Sci*. 2004;49: 1906–11.
 14. Burn J, Gerdes A-M, McCrea F, Mecklin J-P, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard M-L, Dunlop M, JWC H, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJW, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT on behalf of the CAPP2 Investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011;378: 2081–7.
 15. Ballester-Vargas V, Tomlinson I. Hereditary mixed polyposis syndrome. In: Boardman LA, editor. *Intestinal Polyposis Syndromes*: Springer. ISBN 987-3-319-28101-8.

第 15 章

1. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med*. 1993; 329(27): 1977–81. <https://doi.org/10.1056/NEJM199312303292701>.
2. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. *Cancer*. 1975; 36(6): 2251–70.
3. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. *Gastroenterology*. 2010; 138(6): 2088–100. S0016-5085(10)00172-1 [pii] . <https://doi.org/10.1053/j.gastro.2009.12.066>.
4. Snover DC. Update on the serrated pathway to colorectal carcinoma. *Hum Pathol*. 2011; 42(1): 1–10. S0046-8177(10)00206-6 [pii] . <https://doi.org/10.1016/j.humpath.2010.06.002>.
5. Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol*. 2012; 107(9): 1315–29; quiz 4, 30. doi: ajg2012161 [pii] . <https://doi.org/10.1038/ajg.2012.161>.
6. Oono Y, Fu K, Nakamura H, Iriguchi Y, Yamamura A, Tomino Y, et al. Progression of a sessile serrated adenoma to an early invasive cancer within 8 months. *Dig Dis Sci*. 2009; 54(4): 906–9. <https://doi.org/10.1007/s10620-008-0407-7>.
7. Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. *J Clin Pathol*. 2010; 63(8): 681–6. jcp.2010.075507 [pii] . <https://doi.org/10.1136/jcp.2010.075507>.

8. IJspeert J, Bevan R, Senore C, Kaminski MF, Kuipers EJ, Mroz A, et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: a European overview. *Gut*. 2016. gutjnl-2015-310784 [pii] . <https://doi.org/10.1136/gutjnl-2015-310784>.
9. Lockett MJ, Atkin WS. Hyperplastic polyposis: prevalence and cancer risk. *Gut*. 2001; 48(Supl 1): A4.
10. Hyman NH, Anderson P, Blasyk H. Hyperplastic polyposis and the risk of colorectal cancer. *Dis Colon Rectum*. 2004; 47(12): 2101-4. <https://doi.org/10.1007/s10350-004-0709-6>.
11. Boparai KS, Mathus-Vliegen EM, Koornstra JJ, Nagengast FM, van Leerdam M, van Noesel CJ, et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. *Gut*. 2010; 59(8): 1094-100. gut.2009.185884 [pii] . <https://doi.org/10.1136/gut.2009.185884>.
12. Hazewinkel Y, Tytgat KM, van Eeden S, Bastiaansen B, Tanis PJ, Boparai KS, et al. Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. *Gastroenterology*. 2014; 147(1): 88-95. S0016-5085(14)00364-3 [pii] . <https://doi.org/10.1053/j.gastro.2014.03.015>.
13. Orłowska J. Hyperplastic polyposis syndrome and the risk of colorectal cancer. *Gut*. 2012; 61(3): 470-1.; author reply 1-2. gutjnl-2011-300141 [pii] . <https://doi.org/10.1136/gutjnl-2011-300141>.
14. Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. *Endoscopy*. 2006; 38(3): 266-70. <https://doi.org/10.1055/s-2006-925026>.
15. Moreira L, Pellise M, Carballal S, Bessa X, Ocana T, Serradesanferm A, et al. High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes. *Gut*. 2013; 62(3): 476-7. gutjnl-2012-303496 [pii] . <https://doi.org/10.1136/gutjnl-2012-303496>.
16. Biswas S, Ellis AJ, Guy R, Savage H, Madronal K, East JE. High prevalence of hyperplastic polyposis syndrome (serrated polyposis) in the NHS bowel cancer screening programme. *Gut*. 2013; 62(3): 475. gutjnl-2012-303233 [pii] . <https://doi.org/10.1136/gutjnl-2012-303233>.
17. Ferrandez A, Samowitz W, DiSario JA, Burt RW. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. *Am J Gastroenterol*. 2004; 99(10): 2012-8. <https://doi.org/10.1111/j.1572-0241.2004.30021.x>. AJG30021 [pii] .
18. Lage P, Cravo M, Sousa R, Chaves P, Salazar M, Fonseca R, et al. Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: a contribution for future guidelines based on a clinical study. *Am J Gastroenterol*. 2004; 99(9): 1779-84. <https://doi.org/10.1111/j.1572-0241.2004.30178.x>. AJG30178 [pii] .
19. Chow E, Lipton L, Lynch E, D'Souza R, Aragona C, Hodgkin L, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. *Gastroenterology*. 2006; 131(1): 30-9. S0016-5085(06)00713-X [pii] . <https://doi.org/10.1053/j.gastro.2006.03.046>.
20. Kalady MF, Jarrar A, Leach B, LaGuardia L, O'Malley M, Eng C, et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. *Dis Colon Rectum*. 2011; 54(2): 164-70. <https://doi.org/10.1007/DCR.0b013e3181fd4c15>. 00003453-201102000-00007 [pii] .
21. Navarro M, Gonzalez S, Iglesias S, Capella G, Rodriguez-Moranta F, Blanco I. Hyperplastic polyposis syndrome: phenotypic diversity and association to colorectal cancer. *Med Clin (Barc)*. 2013; 141(2): 62-6. S0025-7753(12)00512-X [pii] . <https://doi.org/10.1016/j.medcli.2012.04.024>.
22. Carballal S, Rodriguez-Alcalde D, Moreira L, Hernandez L, Rodriguez L, Rodriguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. *Gut*. 2015. gutjnl-2015-309647 [pii] . <https://doi.org/10.1136/gutjnl-2015-309647>.
23. IJspeert J, Rana SA, Atkinson NS, van Herwaarden YJ, Bastiaansen BA, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. *Gut*. 2015. gutjnl-2015-310630 [pii] . <https://doi.org/10.1136/gutjnl-2015-310630>.
24. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, Gattas M, et al. Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. *Int J Color Dis*. 2010; 25(6): 703-12. <https://doi.org/10.1007/s00384-010-0907-8>.
25. IJspeert J, Bossuyt PM, Kuipers EJ, Stegeman I, de Wijkerslooth TR, Stoop EM, et al. Smoking status informs about the risk of advanced serrated polyps in a screening population. *Endosc Int Open*. 2016; 4(1): E73-8. <https://doi.org/10.1055/s-0034-1393361>.
26. Boparai KS, Reitsma JB, Lemmens V, van Os TA, Mathus-Vliegen EM, Koornstra JJ, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. *Gut*. 2010; 59(9): 1222-5. gut.2009.200741 [pii] . <https://doi.org/10.1136/gut.2009.200741>.
27. Oquinena S, Guerra A, Pueyo A, Eguaras J, Montes M, Razquin S, et al. Serrated polyposis: prospective

- study of first-degree relatives. *Eur J Gastroenterol Hepatol.* 2013; 25(1): 28–32. <https://doi.org/10.1097/MEG.0b013e3283598506>.
28. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology.* 2012; 143(3): 844–57. S0016–5085(12)00812–8 [pii] . <https://doi.org/10.1053/j.gastro.2012.06.001>.
 29. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015; 110(2): 223–62.; quiz 63. [ajg2014435 \[pii\] . https://doi.org/10.1038/ajg.2014.435](https://doi.org/10.1038/ajg.2014.435).
 30. Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirmio P, et al. Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. *Histopathology.* 2011; 58(5): 679–92. <https://doi.org/10.1111/j.1365-2559.2011.03821.x>.
 31. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. *Nat Rev Cancer.* 2004; 4(12): 937–47. nrc1503 [pii] . <https://doi.org/10.1038/nrc1503>.
 32. Kim KM, Lee EJ, Ha S, Kang SY, Jang KT, Park CK, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. *Am J Surg Pathol.* 2011; 35(9): 1274–86. <https://doi.org/10.1097/PAS.0b013e318224cd2e>.
 33. Moran A, Ortega P, de Juan C, Fernandez-Marcelo T, Frias C, Sanchez-Pernaute A, et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. *World J Gastrointest Oncol.* 2010; 2(3): 151–8. <https://doi.org/10.4251/wjgo.v2.i3.151>.
 34. Yamane L, Scapulatempo-Neto C, Reis RM, Guimaraes DP. Serrated pathway in colorectal carcinogenesis. *World J Gastroenterol.* 2014; 20(10): 2634–40. <https://doi.org/10.3748/wjg.v20.i10.2634>.
 35. Rosty C, Parry S, Young JP. Serrated polyposis: an enigmatic model of colorectal cancer pre-disposition. *Pathol Res Int.* 2011; 2011: 157073. <https://doi.org/10.4061/2011/157073>.
 36. Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. *Am J Gastroenterol.* 2012; 107(5): 770–8. [ajg201252 \[pii\] . https://doi.org/10.1038/ajg.2012.52](https://doi.org/10.1038/ajg.2012.52).
 37. Gala MK, Mizukami Y, Le LP, Moriichi K, Austin T, Yamamoto M, et al. Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. *Gastroenterology.* 2014; 146(2): 520–9. S0016–5085(13)01519–9 [pii] . <https://doi.org/10.1053/j.gastro.2013.10.045>.
 38. de Lau W, Peng WC, Gros P, Clevers H. The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength. *Genes Dev.* 2014; 28(4): 305–16. 28/4/305 [pii] . <https://doi.org/10.1101/gad.235473.113>.
 39. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. *Nature.* 2012; 488(7413): 665–9. nature11308 [pii] . <https://doi.org/10.1038/nature11308>.
 40. Taupin D, Lam W, Rangiah D, McCallum L, Whittle B, Zhang Y, et al. A deleterious RNF43 germline mutation in a severely affected serrated polyposis kindred. *Hum Genome Var.* 2015; 2: 15013. <https://doi.org/10.1038/hgv.2015.13>.
 41. Yan HH, Lai JC, Ho SL, Leung WK, Law WL, Lee JF, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. *Gut.* 2016. [gutjnl-2016-311849 \[pii\] . https://doi.org/10.1136/gutjnl-2016-311849](https://doi.org/10.1136/gutjnl-2016-311849).
 42. Sekine S, Yamashita S, Tanabe T, Hashimoto T, Yoshida H, Taniguchi H, et al. Frequent PTPRK–RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. *J Pathol.* 2016; 239(2): 133–8. <https://doi.org/10.1002/path.4709>.
 43. Buchanan DD, Clendenning M, Zhuoer L, Stewart JR, Joseland S, Woodall S, et al. Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study. *Gut.* 2016. [gutjnl-2016-312773 \[pii\] . https://doi.org/10.1136/gutjnl-2016-312773](https://doi.org/10.1136/gutjnl-2016-312773).
 44. IJspert J, van Doorn SC, van der Brug YM, Bastiaansen BA, Fockens P, Dekker E. The proximal serrated polyp detection rate is an easy-to-measure proxy for the detection rate of clinically relevant serrated polyps. *Gastrointest Endosc.* 2015; 82(5): 870–7. S0016–5107(15)00216–3 [pii] . <https://doi.org/10.1016/j.gie.2015.02.044>.

第 16 章

1. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated

- sequences reveal a new mechanism for colonic carcinogenesis. *Nature*. 1993; 363(6429): 558–61.
2. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. *Science (New York, NY)*. 1993; 260(5109): 812–6.
 3. Verstrepen KJ, Jansen A, Lewitter F, Fink GR. Intragenic tandem repeats generate functional variability. *Nat Genet*. 2005; 37(9): 986–90.
 4. Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the colon cancer family registry. *J Mol Diagn: JMD*. 2011; 13(3): 271–81.
 5. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res*. 1998; 58(22): 5248–57.
 6. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. *Gastroenterology*. 2002; 123(6): 1804–11.
 7. Yamamoto H, Imai K. Microsatellite instability: an update. *Arch Toxicol*. 2015; 89(6): 899–921.
 8. Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). *J Med Genet*. 2007; 44(6): 353–62.
 9. Pineda M, Gonzalez S, Lazaro C, Blanco I, Capella G. Detection of genetic alterations in hereditary colorectal cancer screening. *Mutat Res*. 2010; 693(1–2): 19–31.
 10. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. *Clin Cancer Res: Off J Am Assoc Cancer Res*. 2004; 10(1 Pt 1): 191–5.
 11. Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al. MLH1 promoter hyper-methylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. *Eur J Hum Genet: EJHG*. 2012; 20(7): 762–8.
 12. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. *J Med Genet*. 2012; 49(3): 151–7.
 13. Moreira L, Munoz J, Cuatrecasas M, Quintanilla I, Leoz ML, Carballed S, et al. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. *Cancer*. 2015; 121(9): 1395–404.
 14. Newton K, Jorgensen NM, Wallace AJ, Buchanan DD, Lalloo F, McMahon RF, et al. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch syndrome (HNPCC). *J Med Genet*. 2014; 51(12): 789–96.
 15. Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. *Genetics in medicine : Off J Am Coll Med Genet*. 2016; 18(4): 325–32.
 16. Shinbrot E, Henninger EE, Weinhold N, Covington KR, Goksenin AY, Schultz N, et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. *Genome research*. 2014; 24(11): 1740–50.
 17. Mertz TM, Baranovskiy AG, Wang J, Tahirov TH, Shcherbakova PV. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase delta mutation in human cells. *Oncogene*. 2017; 36(31): 4427–33.
 18. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. *Adv Anat Pathol*. 2009; 16(6): 405–17.
 19. Etzler J, Peyrl A, Zatkova A, Schildhaus HU, Ficek A, Merkelbach-Bruse S, et al. RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. *Hum Mutat*. 2008; 29(2): 299–305.
 20. van der Klift HM, Tops CM, Bik EC, Boogaard MW, Borgstein AM, Hansson KB, et al. Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. *Hum Mutat*. 2010; 31(5): 578–87.
 21. Vaughn CP, Robles J, Swensen JJ, Miller CE, Lyon E, Mao R, et al. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes. *Hum Mutat*. 2010; 31(5): 588–93.
 22. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to lynch syndrome. *Hum Mutat*. 2009; 30(2): 197–203.
 23. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation

- and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. *Nat Genet.* 2009; 41(1): 112–7.
24. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). *Crit Rev Oncol Hematol.* 2011; 79(1): 1–16.
 25. Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. *JAMA.* 2012; 308(5): 485–92.
 26. Castillejo A, Vargas G, Castillejo MI, Navarro M, Barbera VM, Gonzalez S, et al. Prevalence of germline MUTYH mutations among lynch-like syndrome patients. *Eur J Cancer.* 2014; 50(13): 2241–50.
 27. Morak M, Heidenreich B, Keller G, Hampel H, Laner A, de la Chapelle A, et al. Biallelic MUTYH mutations can mimic lynch syndrome. *Eur J Hum Genet : EJHG.* 2014; 22(11): 1334–7.
 28. Segui N, Navarro M, Pineda M, Koger N, Bellido F, Gonzalez S, et al. Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype. *Gut.* 2015; 64(2): 355–6.
 29. van Puijenbroek M, Nielsen M, Tops CM, Halfwerk H, Vasen HF, Weiss MM, et al. Identification of patients with (atypical) MUTYH-associated polyposis by KRAS2 c.34G>T prescreening followed by MUTYH hotspot analysis in formalin-fixed paraffin-embedded tissue. *Clin Cancer Res : Off J Am Assoc Cancer Res.* 2008; 14(1): 139–42.
 30. Knopperts AP, Nielsen M, Niessen RC, Tops CM, Jorritsma B, Varkevisser J, et al. Contribution of bi-allelic germline MUTYH mutations to early-onset and familial colorectal cancer and to low number of adenomatous polyps: case-series and literature review. *Familial Cancer.* 2013; 12(1): 43–50.
 31. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. *Nature.* 2008; 456(7218): 53–9.
 32. Rothberg JM, Hinz W, Rearick TM, Schultz J, Mileski W, Davey M, et al. An integrated semi-conductor device enabling non-optical genome sequencing. *Nature.* 2011; 475(7356): 348–52.
 33. Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, et al. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. *Arch Pathol Lab Med.* 2015; 139(4): 481–93.
 34. Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, et al. ACMG clinical laboratory standards for next-generation sequencing. *Genet Med : Off J Am Coll Med Genet.* 2013; 15(9): 733–47.
 35. Strom SP, Lee H, Das K, Vilain E, Nelson SF, Grody WW, et al. Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory. *Genet Med: Off J Am Coll Med Genet.* 2014; 16(7): 510–5.
 36. Baudhuin LM, Lagerstedt SA, Klee EW, Fadra N, Oglesbee D, Ferber MJ. Confirming variants in next-generation sequencing panel testing by Sanger sequencing. *J Mol Diagn : JMD.* 2015; 17(4): 456–61.
 37. Mu W, Lu HM, Chen J, Li S, Elliott AM. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. *J Mol Diagn : JMD.* 2016; 18(6): 923–32.
 38. Feliubadaló L, Tonda R, Gausachs M, Trotta JR, Castellanos E, Lopez-Doriga A, et al. Benchmarking of whole exome sequencing and ad hoc designed panels for genetic testing of hereditary cancer. *Sci Rep.* 2017; 7: 37984.
 39. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. *Nat Genet.* 2008; 40(6): 722–9.
 40. Yoon S, Xuan Z, Makarov V, Ye K, Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. *Genome Res.* 2009; 19(9): 1586–92.
 41. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics.* 2009; 25(21): 2865–71.
 42. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. *Nat Methods.* 2009; 6(9): 677–81.
 43. Bartenhagen C, Dugas M. Robust and exact structural variation detection with paired-end and soft-clipped alignments: SoftSV compared with eight algorithms. *Brief Bioinform.* 2016; 17(1): 51–62.
 44. Li J, Dai H, Feng Y, Tang J, Chen S, Tian X, et al. A comprehensive strategy for accurate mutation detection of the highly homologous PMS2. *J Mol Diagn : JMD.* 2015; 17(5): 545–53.
 45. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. *Cell.* 2013; 155(4): 858–68.
 46. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. *Clin Chem.* 2014; 60(9): 1192–9.
 47. Glen T. 2016 NGS field guide. 2016. *The Molecular Ecologist.* 2017, March. Available from: <http://www.molecularecologist.com/next-gen-fieldguide-2016/>.

48. Feliubadaló L, Lopez-Doriga A, Castellsague E, del Valle J, Menendez M, Tornero E, et al. Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes. *Eur J Hum Genet : EJHG*. 2013; 21(8): 864–70.
49. Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. *Genet Med : Off J Am Coll Med Genet*. 2016; 18(8): 823–32.
50. LaDuca H, Farwell KD, Vuong H, Lu HM, Mu W, Shahmirzadi L, et al. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels. *PLoS One*. 2017; 12(2): e0170843.
51. Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected lynch syndrome. *Gastroenterology*. 2015; 149(3): 604–13 e20.
52. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. *J Clin Oncol*. 2017; 35(10): 1086–95.
53. Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. *J Clin Oncol*. 2015; 33(5): 426–32.
54. Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. *Clin Genet*. 2014; 86(6): 510–20.
55. Ricker C, Culver JO, Lowstuter K, Sturgeon D, Sturgeon JD, Chanock CR, et al. Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. *Cancer Genet*. 2016; 209(4): 130–7.
56. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol*. 2017; 3(4): 464–471. doi: 10.1001/jamaoncol.2016.5194.
57. Slavin TP, Niell-Swiler M, Solomon I, Nehoray B, Rybak C, Blazer KR, et al. Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. *Front Oncol*. 2015; 5: 208.
58. Hermel DJ, McKinnon WC, Wood ME, Greenblatt MS. Multi-gene panel testing for hereditary cancer susceptibility in a rural Familial Cancer Program. *Familial Cancer*. 2017; 16(1): 159–66.
59. Howarth DR, Lum SS, Esquivel P, Garberoglio CA, Senthil M, Solomon NL. Initial results of multigene panel testing for hereditary breast and ovarian cancer and lynch syndrome. *Am Surg*. 2015; 81(10): 941–4.
60. Rohlin A, Rambech E, Kvist A, Torngren T, Eiengard F, Lundstam U, et al. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. *Familial Cancer*. 2017; 16(2): 195–203.
61. Illumina. TruSight Cancer Gene List (.xls). 2017. Available from: https://www.google.es/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0ahUKew_iJ24PerKTTAhUKthoKHSAdALsQFgg4MAI&url=https%3A%2F%2Fwww.illumina.com%2Fcontent%2Fdam%2Fillumina-marketing%2Fdocuments%2Fproducts%2Fgene_lists%2Fgene_list_trusight_cancer.xlsx&usq=AFQjCNEJE1drO3kJvcygtgOlazl2GfLlVgw&si_g2=QnYf4jA2e2g vW8YGrd2RTA&bvm=bv.152479541,d.d2s.
62. Illumina. TruSight Cancer. 2017. Available from: <https://www.illumina.com/products/by-type/clinical-research-products/trusight-cancer.html>.
63. Castellanos E, Gel B, Rosas I, Tornero E, Santin S, Pluvinet R, et al. A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape. *Sci Rep*. 2017; 7: 39348.
64. Eccles DM, Mitchell G, Monteiro AN, Schmutzler R, Couch FJ, Spurdle AB, et al. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance. *Ann oncol : Off J Eur Soc Med Oncol*. 2015; 26(10): 2057–65.
65. Balmana J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. *J Clin Oncol*. 2016; 34(34): 4071–8.
66. Whitworth J, Skytte AB, Sunde L, Lim DH, Arends MJ, Happerfield L, et al. Multilocus inherited Neoplasia alleles syndrome: a case series and review. *JAMA Oncol*. 2016; 2(3): 373–9.
67. Wimmer K, Kratz CP. Constitutional mismatch repair-deficiency syndrome. *Haematologica*. 2010; 95(5): 699–701.
68. Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, et al. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. *J Clin Oncol*. 2015; 33(18): 2084–91.

69. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. *Nature*. 2009; 461(7261): 272–6.
70. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proc Natl Acad Sci U S A*. 2009; 106(45): 19096–101.
71. Harding KE, Robertson NP. Applications of next-generation whole exome sequencing. *J Neurol*. 2014; 261(6): 1244–6.
72. Warr A, Robert C, Hume D, Archibald A, Deeb N, Watson M. Exome sequencing: current and future perspectives. *G3 (Bethesda)*. MD. 2015; 5(8): 1543–50.
73. Chilamakuri CS, Lorenz S, Madoui MA, Vodak D, Sun J, Hovig E, et al. Performance comparison of four exome capture systems for deep sequencing. *BMC Genomics*. 2014; 15: 449.
74. Meienberg J, Zerjavic K, Keller I, Okoniewski M, Patrignani A, Ludin K, et al. New insights into the performance of human whole-exome capture platforms. *Nucleic Acids Res*. 2015; 43(11): e76.
75. Wang JL, Yang X, Xia K, Hu ZM, Weng L, Jin X, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. *Brain*. 2010; 133(Pt 12): 3510–8.
76. Vissers LE, de Ligt J, Gilissen C, Janssen I, Stehouwer M, de Vries P, et al. A de novo paradigm for mental retardation. *Nat Genet*. 2010; 42(12): 1109–12.
77. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, et al. Exome sequencing identifies the cause of a mendelian disorder. *Nat Genet*. 2010; 42(1): 30–5.
78. Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. *JAMA*. 2014; 312(18): 1880–7.
79. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA*. 2014; 312(18): 1870–9.
80. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science (New York, NY)*. 2009; 324(5924): 217.
81. Nieminen TT, O'Donohue MF, Wu Y, Lohi H, Scherer SW, Paterson AD, et al. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary non-polyposis colorectal carcinoma without DNA mismatch repair deficiency. *Gastroenterology*. 2014; 147(3): 595–8 e5.
82. Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, et al. Whole-genome sequencing in a patient with Charcot-Marie-tooth neuropathy. *N Engl J Med*. 2010; 362(13): 1181–91.
83. Sobreira NL, Cirulli ET, Avramopoulos D, Wohler E, Oswald GL, Stevens EL, et al. Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. *PLoS Genet*. 2010; 6(6): e1000991.
84. Rios J, Stein E, Shendure J, Hobbs HH, Cohen JC. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. *Hum Mol Genet*. 2010; 19(22): 4313–8.
85. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. *Nature*. 2011; 480(7375): 99–103.
86. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov*. 2012; 2(1): 41–6.
87. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nat Genet*. 2011; 43(7): 663–7.
88. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. *Nat Genet*. 2011; 43(11): 1104–7.
89. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet*. 2013; 45(2): 136–44.
90. Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. *Proc Natl Acad Sci U S A*. 2015; 112(17): 5473–8.
91. Lelieveld SH, Spielmann M, Mundlos S, Veltman JA, Gilissen C. Comparison of exome and genome sequencing Technologies for the Complete Capture of protein-coding regions. *Hum Mutat*. 2015; 36(8): 815–22.
92. Meynert AM, Ansari M, FitzPatrick DR, Taylor MS. Variant detection sensitivity and biases in whole genome and exome sequencing. *BMC bioinformatics*. 2014; 15: 247.
93. Abdel-Rahman MH, Rai K, Pilarski R, Davidorf FH, Cebulla CM. Germline BAP1 mutations misreported as somatic based on tumor-only testing. *Familial Cancer*. 2016; 15(2): 327–30.

第17章

1. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomark Prev.* 2017; 26(3): 404–12. <https://doi.org/10.1158/1055-9965.EPI-16-0693>.
2. American Cancer Society. Key statistics for colorectal cancer. 2016. <http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics>. Accessed 2 May 2016.
3. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol.* 2008; 26(35): 5783–8. <https://doi.org/10.1200/JCO.2008.17.5950>.
4. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med.* 2005; 352(18): 1851–60. <https://doi.org/10.1056/NEJMoa043146>.
5. Cross D, Rahm A, Le A, Webster J, Potosky A, Feigelson H, et al. PS1–08: Lynch syndrome screening patterning in colorectal cancer patients in a large multi-institutional cohort. *Clin Med Res.* 2012; 10(3): 146.
6. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med.* 2009; 11(1): 42–65.
7. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. *J Clin Oncol.* 2005; 23(3): 609–18.
8. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. *Eur J Cancer.* 2009; 45(10): 1890–6.
9. Diaz LA Jr, Le DT. PD–1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015; 373(20): 1979. <https://doi.org/10.1056/NEJMc1510353>.
10. Recommendations from the EGAPP Working Group. Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. *Genet Med.* 2009; 11(1): 35–41.
11. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on Colorectal Cancer. *Am J Gastroenterol.* 2014; 109(8): 1159–79. <https://doi.org/10.1038/ajg.2014.186>.
12. Referenced with permission from the NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Colorectal V.1.2016© National Comprehensive Cancer Network IArrAJ, <https://www.nccn.org/store/login/login.aspx?>
13. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015; 110(2): 223–62; quiz 63. <https://doi.org/10.1038/ajg.2014.435>.
14. Bessa X, Balleste B, Andreu M, Castells A, Bellosillo B, Balaguer F, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. *Clin Gastroenterol Hepatol.* 2008; 6(2): 206–14. <https://doi.org/10.1016/j.cgh.2007.10.011>.
15. Gausachs M, Mur P, Corral J, Pineda M, Gonzalez S, Benito L, et al. MLH1 promoter hyper-methylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. *Eur J Hum Genet.* 2012; 20(7): 762–8. <https://doi.org/10.1038/ejhg.2011.277>.
16. Grosse SD. When is genomic testing cost-effective? Testing for Lynch syndrome in patients with newly-diagnosed colorectal cancer and their relatives. *Health.* 2015; 3(4): 860–78.
17. Grosse SD, Palomaki GE, Mvundura M, Hampel H. The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates. *Genet Med.* 2015; 17(6): 510–1. <https://doi.org/10.1038/gim.2015.53>.
18. Gudgeon JM, Williams JL, Burt RW, Samowitz WS, Snow GL, Williams MS. Lynch syndrome screening implementation: business analysis by a healthcare system. *Am J Manag Care.* 2011; 17(8): e288–300. doi: 50524 [pii] .
19. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. *Genet Med.* 2010; 12(2): 93–104.
20. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. *Health Technol Assess.* 2014; 18(58): 1–406. <https://doi.org/10.1186/s13017-014-0058-1>.

- org/10.3310/hta18580.
21. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Ann Intern Med.* 2011; 155(2): 69–79. <https://doi.org/10.1059/0003-4819-155-2-201107190-00002>. 155/2/69 [pii] .
 22. Severin F, Stollenwerk B, Holinski-Feder E, Meyer E, Heinemann V, Giessen-Jung C, et al. Economic evaluation of genetic screening for Lynch syndrome in Germany. *Genet Med.* 2015; 17(10): 765–73. <https://doi.org/10.1038/gim.2014.190>.
 23. Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome. *Am J Manag Care.* 2012; 18(5): e179–85.
 24. Gould-Suarez M, El-Serag HB, Musher B, Franco LM, Chen GJ. Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome. *Dig Dis Sci.* 2014; 59(12): 2913–26. <https://doi.org/10.1007/s10620-014-3248-6>.
 25. Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, et al. Identification of individuals at risk for lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. *J Genet Couns.* 2012; 21(4): 484–93. <https://doi.org/10.1007/s10897-011-9465-7>.
 26. Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. *J Clin Oncol.* 2015; 33(2): 209–17. <https://doi.org/10.1200/JCO.2014.58.1322>.
 27. Monahan KJ, Alsina D, Bach S, Buchanan J, Burn J, Clark S, et al. Urgent improvements needed to diagnose and manage Lynch syndrome. *BMJ.* 2017; 356: j1388. <https://doi.org/10.1136/bmj.j1388>.
 28. Balmana J, Balaguer F, Cervantes A, Arnold D. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. *Ann Oncol: Off J Eur Soc Med Oncol/ESMO.* 2013; 24(Suppl 6): vi73–80. <https://doi.org/10.1093/annonc/mdt209>.
 29. Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. *J Clin Oncol.* 2012; 30(10): 1058–63. *JCO.2011.38.4719* [pii] 31.1200/JCO.2011.38.4719.
 30. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015; 372(26): 2509–20. <https://doi.org/10.1056/NEJMoa1500596>.
 31. Cragun D, DeBate RD, Vadaparampil ST, Baldwin J, Hampel H, Pal T. Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through. *Genet Med.* 2014; 16(10): 773–82. <https://doi.org/10.1038/gim.2014.31>.
 32. Cragun D, Pal T, Vadaparampil ST, Baldwin J, Hampel H, DeBate RD. Qualitative comparative analysis: a hybrid method for identifying factors associated with program effectiveness. *J Mixed Methods Res.* 2016; 10(3): 251–72. <https://doi.org/10.1177/1558689815572023>.
 33. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci: IS.* 2009; 4: 50. <https://doi.org/10.1186/1748-5908-4-50>.
 34. Sharaf RN, Myer P, Stave CD, Diamond LC, Ladabaum U. Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. *Clin Gastroenterol Hepatol.* 2013; 11(9): 1093–100. <https://doi.org/10.1016/j.cgh.2013.04.044>.
 35. Stoffel EM, Ford B, Mercado RC, Punglia D, Kohlmann W, Conrad P, et al. Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. *Clin Gastroenterol Hepatol.* 2008; 6(3): 333–8. <https://doi.org/10.1016/j.cgh.2007.12.014>.
 36. Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. *Curr Opin Lipidol.* 2005; 16(4): 428–33.
 37. Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. *Am J Surg Pathol.* 2014; 38(11): 1501–9. <https://doi.org/10.1097/PAS.0000000000000321>.
 38. Morrison J, Bronner M, Leach BH, Downs-Kelly E, Goldblum JR, Liu X. Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach. *Scand J Gastroenterol.* 2011; 46(11): 1340–8. <https://doi.org/10.3109/00365521.2011.610003>.
 39. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, et al. Comparison of clinical schemas

- and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. *Cancer*. 2012; 118(3): 681–8. <https://doi.org/10.1002/cncr.26323>.
40. Trano G, Sjrursen W, Wasmuth HH, Hofslie E, Vatten LJ. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. *Br J Cancer*. 2010; 102(3): 482–8. <https://doi.org/10.1038/sj.bjc.6605509>.
 41. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol*. 2016; 3(4): 464–71. <https://doi.org/10.1001/jamaoncol.2016.5194>.
 42. Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. *J Clin Oncol*. 2013; 31(10): 1336–40. <https://doi.org/10.1200/JCO.2012.45.1674>.
 43. Hampel H, Lattimer I, Frankel W. Universal Lynch syndrome screening result notification: efficacy affected by method. *J Genet Couns*. 2012; 21(6): 888–9.

第 18 章

1. Gonzaga-Juaregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. *Annu Rev Med*. 2012; 63: 35–61. <https://doi.org/10.1146/annurev-med-051010-162644>.
2. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ, Breast Cancer Information Core (BIC) Steering Committee. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to *BRCA1* and *BRCA2*. *Am J Hum Genet*. 2004; 75: 535–44.
3. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective lynch syndrome database. *Gut*. 2017; 66: 464–72. <https://doi.org/10.1136/gutjnl-2015-309675>.
4. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective lynch syndrome database. *Gut*. 2017; 66: 1657–64. <https://doi.org/10.1136/gutjnl-2016-311403>.
5. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). *J Med Genet*. 2014; 51: 355–65. <https://doi.org/10.1136/jmedgenet-2014-102284>.
6. Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a five-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants lodged on the InSiGHT locus-specific database. *Nat Genet*. 2014; 46: 107–15. <https://doi.org/10.1038/ng.2854>.
7. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015; 17: 405–24.
8. Genome Aggregation Database (gnomAD). 2016. <http://gnomad.broadinstitute.org/>. Accessed 17 Mar 2018.
9. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. *Cancer Res*. 2013; 73: 2025–30. <https://doi.org/10.1158/0008-5472>.
10. Zugazagoitia J, Pérez-Segura P, Manzano A, Blanco I, Vega A, Custodio A, et al. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. *Breast Cancer Res Treat*. 2014; 148: 415–21. <https://doi.org/10.1007/s10549-014-3167-4>.
11. Lucci-Cordisco E, Risio M, Venesio T, Genuardi M. The growing complexity of the intestinal polyposis syndromes. *Am J Med Genet A*. 2013; 161A: 2777–87. <https://doi.org/10.1002/ajmg.a.36253>.
12. Lucci-Cordisco E, Boccuto L, Neri G, Genuardi M. The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in lynch syndrome. *Cancer Biomark*. 2006; 2: 11–27.
13. Van Puijenbroek M, Nielsen M, Tops CM, Halfwerk H, Vasen HF, Weiss MM, et al. Identification of patients with (atypical) *MUTYH*-associated polyposis by *KRAS2* c.34G>T prescreening followed by *MUTYH* hotspot analysis in formalin-fixed paraffin-embedded tissue. *Clin Cancer Res*. 2008; 14: 139–42. <https://doi.org/10.1158/1078-0432.CCR-07-1705>.

14. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene *NTHL1* causes adenomatous polyposis and colorectal cancer. *Nat Genet.* 2015; 47: 668–71. <https://doi.org/10.1038/ng.3287>.
15. Briggs S, Tomlinson I. Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancers. *J Pathol.* 2013; 230: 148–53. <https://doi.org/10.1002/path.4185>.
16. Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, et al. Combined mismatch repair and *POLE/POLD1* defects explain unresolved suspected lynch syndrome cancers. *Eur J Hum Genet.* 2016; 24: 1089–92. <https://doi.org/10.1038/ejhg.2015.252>.
17. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Association of polymerase ϵ -mutated and microsatellite-unstable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. *JAMA Oncol.* 2015; 1: 1319–23. <https://doi.org/10.1001/jamaoncol.2015.2151>.
18. Tricarico R, Kasela M, Mareni C, Thompson BA, Drouet A, Staderini L, et al. Assessment of the InSiGHT interpretation criteria for the clinical classification of 24 *MLH1* and *MSH2* gene variants. *Hum Mutat.* 2017; 38: 64–77. <https://doi.org/10.1002/humu.23117>.
19. Baralle D, Lucassen A, Buratti E. Missed threads. The impact of pre-mRNA splicing defects on clinical practice. *EMBO Rep.* 2009; 10: 810–6. <https://doi.org/10.1038/embor.2009.170>.
20. Baralle D, Buratti E. RNA splicing in human disease and in the clinic. *Clin Sci (Lond).* 2017; 131: 355–68. <https://doi.org/10.1042/CS20160211>.
21. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. *Nat Rev Genet.* 2002; 3: 285–98.
22. Ward AJ, Cooper TA. The pathobiology of splicing. *J Pathol.* 2010; 220: 152–63. <https://doi.org/10.1002/path.2649>.
23. Klamt B, Koziell A, Poulat F, Wieacker P, Scambler P, Berta P, Gessler M. Frasier syndrome is caused by defective alternative splicing of *WT1* leading to an altered ratio of *WT1* +/-KTS splice isoforms. *Hum Mol Genet.* 1998; 7: 709–14.
24. Park SA, Ahn SI, Gallo J-M. Tau mis-splicing in the pathogenesis of neurodegenerative disorders. *BMB Rep.* 2016; 49: 405–13.
25. Spurdle AB, Couch FJ, Hogervorst FBL, Radice P, Sinilnikova OM, IARC Unclassified Genetic Variants Working Group. Prediction and assessment of splicing alterations: implications for clinical testing. *Hum Mutat.* 2008; 29: 1304–13. <https://doi.org/10.1002/humu.20901>.
26. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on *BRCA1* and *BRCA2* variants. *Hum Mutat.* 2012; 33: 1228–38. <https://doi.org/10.1002/humu.22101>.
27. Di Giacomo D, Gaildrat P, Abuli A, Abdat J, Frébourg T, Tosi M, Martins A. Functional analysis of a large set of *BRCA2* exon 7 variants highlights the predictive value of hexamer scores in detecting alterations of exonic splicing regulatory elements. *Hum Mutat.* 2013; 34: 1547–57. <https://doi.org/10.1002/humu.22428>.
28. Erkelenz S, Theiss S, Otte M, Widera M, Peter JO, Schaal H. Genomic HEXploring allows landscaping of novel potential splicing regulatory elements. *Nucleic Acids Res.* 2014; 42: 10681–97. <https://doi.org/10.1093/nar/gku736>.
29. Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RK, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. *Science.* 2015; 347: 1254806. <https://doi.org/10.1126/science.1254806>.
30. Soukariéh O, Gaildrat P, Hamieh M, Drouet A, Baert-Desurmont S, Frébourg T, et al. Exonic splicing mutations are more prevalent than currently estimated and can be predicted by using in Silico tools. *PLoS Genet.* 2016; 12: e1005756. <https://doi.org/10.1371/journal.pgen.1005756>.
31. Teraoka SN, Telatar M, Becker-Catania S, Liang T, Onengüt S, Tolun A, et al. Splicing defects in the ataxia-telangiectasia gene, *ATM*: underlying mutations and consequences. *Am J Hum Genet.* 1999; 64: 1617–31.
32. Ars E, Serra E, García J, Kruyer H, Gaona A, Lázaro C, Estivill X. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. *Hum Mol Genet.* 2000; 9: 237–47.
33. Lim KH, Ferraris L, Filloux ME, Raphael BJ, Fairbrother WG. Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes. *Proc Natl Acad Sci U S A.* 2011; 108: 11093–8. <https://doi.org/10.1073/pnas.1101135108>.
34. Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R, et al. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the *APC* gene. *Hum Mutat.* 2004; 24: 370–80.
35. Auclair J, Busine MP, Navarro C, Ruano E, Montmaigne G, Desseigne F, et al. Systematic mRNA analysis for the

- effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. *Hum Mutat.* 2006; 27: 145–54.
36. Adam R, Spier I, Zhao B, Kloth M, Marquez J, Hinrichsen I, et al. Exome sequencing identifies Biallelic *MSH3* Germline mutations as a recessive subtype of colorectal adenomatous polyposis. *Am J Hum Genet.* 2016; 99: 337–51. <https://doi.org/10.1016/j.ajhg.2016.06.015>.
 37. Plaschke J, Linnebacher M, Kloor M, Gebert J, Cremer FW, Tinschert S, et al. Compound heterozygosity for two *MSH6* mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. *Eur J Hum Genet.* 2006; 14: 561–6.
 38. Dallosso AR, Dolwani S, Jones N, Jones S, Colley J, Maynard J, et al. Inherited predisposition to colorectal adenomas caused by multiple rare alleles of *MUTYH* but not *OGG1*, *NUDT1*, *NTH1* or *NEIL 1, 2 or 3*. *Gut.* 2008; 57: 1252–5. <https://doi.org/10.1136/gut.2007.145748>.
 39. Pin E, Pastrello C, Tricarico R, Papi L, Quaiá M, Fornasari M, et al. *MUTYH* c.933+3A>C, associated with a severely impaired gene expression, is the first Italian founder mutation in *MUTYH*-associated polyposis. *Int J Cancer.* 2013; 132: 1060–9. <https://doi.org/10.1002/ijc.27761>.
 40. Borràs E, Pineda M, Cadiñanos J, Del Valle J, Brieger A, Hinrichsen I, et al. Refining the role of *PMS2* in lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. *J Med Genet.* 2013; 50: 552–63. <https://doi.org/10.1136/jmedgenet-2012-101511>.
 41. Pachlopnik Schmid J, Lemoine R, Nehme N, Cormier-Daire V, Revy P, Debeurme F, et al. Polymerase ϵ 1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature (‘FILS syndrome’). *J Exp Med.* 2013; 209: 2323–30. <https://doi.org/10.1084/jem.20121303>.
 42. Agrawal S, Pilarski R, Eng C. Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of *PTEN*. *Hum Mol Genet.* 2005; 14: 2459–68.
 43. Suphapeetiporn K, Kongkam P, Tantivatana J, Sinthuwit T, Tongkobpetch S, Shotelersuk V. *PTEN* c.511C>T nonsense mutation in a BRRS family disrupts a potential exonic splicing enhancer and causes exon skipping. *Jpn J Clin Oncol.* 2006; 36: 814–21.
 44. Papp J, Kovacs ME, Solyom S, Kasler M, Børresen-Dale A-L, Olah E. High prevalence of germline *STK11* mutations in Hungarian Peutz-Jeghers syndrome patients. *BMC Med Genet.* 2010; 11: 169. <https://doi.org/10.1186/1471-2350-11-169>.
 45. van der Klift HM, Jansen AML, van der Steenstraten N, Bik EC, Tops CMJ, Devilee P, Wijnen JT. Splicing analysis for exonic and intronic mismatch repair gene variants associated with lynch syndrome confirms high concordance between minigene assays and patient RNA analyses. *Mol Genet Genomic Med.* 2015; 3: 327–45. <https://doi.org/10.1002/mgg3.145>.
 46. Trojan J, Plotz G, Brieger A, Raedle J, Meltzer SJ, Wolter M, Zeuzem S. Activation of a cryptic splice site of *PTEN* and loss of heterozygosity in benign skin lesions in Cowden disease. *J Invest Dermatol.* 2001; 117: 1650–3.
 47. Reifemberger J, Rauch L, Beckmann MW, Megahed M, Ruzicka T, Reifemberger G. Cowden’s disease: clinical and molecular genetic findings in a patient with a novel *PTEN* germline mutation. *Br J Dermatol.* 2003; 148: 1040–6.
 48. Kaufmann A, Vogt S, Uhlhaas S, Stienen D, Kurth I, Hameister H, et al. Analysis of rare *APC* variants at the mRNA level: six pathogenic mutations and literature review. *J Mol Diagn.* 2009; 11: 131–9. <https://doi.org/10.2353/jmoldx.2009.080129>.
 49. Sharp A, Pichert G, Lucassen A, Eccles D. RNA analysis reveals splicing mutations and loss of expression defects in *MLH1* and *BRCA1*. *Hum Mutat.* 2004; 24: 272.
 50. Yan H, Papadopoulos N, Marra G, Ferrera C, Jiricny J, Boland CR, et al. Conversion of diploidy to haploidy. *Nature.* 2000; 403: 723–4.
 51. Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer family registry. *Hum Mutat.* 2013; 34: 200–9. <https://doi.org/10.1002/humu.22213>.
 52. Celebi JT, Wanner M, Ping XL, Zhang H, Peacocke M. Association of splicing defects in *PTEN* leading to exon skipping or partial intron retention in Cowden syndrome. *Hum Genet.* 2000; 107: 234–8.
 53. Tao H, Shinmura K, Hanaoka T, Natsukawa S, Shaura K, Koizumi Y, et al. A novel splicesite variant of the base excision repair gene *MYH* is associated with production of an aberrant mRNA transcript encoding a truncated *MYH* protein not localized in the nucleus. *Carcinogenesis.* 2004; 25: 1859–66.
 54. Abed AA, Günther K, Kraus C, Hohenberger W, Ballhausen WG. Mutation screening at the RNA level of the *STK11/LKB1* gene in Peutz-Jeghers syndrome reveals complex splicing abnormalities and a novel mRNA isoform (*STK11* c.597(insertion mark)598insIVS4). *Hum Mutat.* 2001; 18: 397–410.

55. Spier I, Horpaopan S, Vogt S, Ulhaas S, Morak M, Stienen D, et al. Deep intronic *APC* mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. *Hum Mutat.* 2012; 33: 1045–50. <https://doi.org/10.1002/humu.22082>.
56. Nieminen TT, Pavicic W, Porkka N, Kankainen M, Järvinen HJ, Lepistö A, Peltomäki P. Pseudoexons provide a mechanism for allele-specific expression of *APC* in familial adenomatous polyposis. *Oncotarget.* 2016; 7: 70685–98. <https://doi.org/10.18632/oncotarget.12206>.
57. Clendenning M, Buchanan DD, Walsh MD, Nagler B, Rosty C, Thompson B, et al. Mutation deep within an intron of *MSH2* causes lynch syndrome. *Familial Cancer.* 2011; 10: 297–301. <https://doi.org/10.1007/s10689-011-9427-0>.
58. Sjursen W, Bjørnevoll I, Engebretsen LF, Fjelland K, Halvorsen T, Myrvold HE. A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcripts. *Familial Cancer.* 2009; 8: 179–86. <https://doi.org/10.1007/s10689-008-9225-5>.
59. Liu Q, Thompson BA, Ward RL, Hesson LB, Sloane MA. Understanding the pathogenicity of noncoding mismatch repair gene promoter variants in lynch syndrome. *Hum Mutat.* 2016; 37: 417–26. <https://doi.org/10.1002/humu.22971>.
60. Yan H, Jin H, Xue G, Mei Q, Ding F, Hao L, Sun SH. Germline hMSH2 promoter mutation in a Chinese HNPCC kindred: evidence for dual role of LOH. *Clin Genet.* 2007; 72: 556–61.
61. Kadiyska TK, Todorov TP, Bichev SN, Vazharova RV, Nossikoff AV, Savov AS, et al. *APC* promoter 1B deletion in familial polyposis/DOUBLEHYPHEN implications for mutation-negative families. *Clin Genet.* 2014; 85: 452–7. <https://doi.org/10.1111/cge.12210>.
62. Lin Y, Lin S, Baxter MD, Lin L, Kennedy SM, Zhang Z, et al. Novel APC promoter and exon 1B deletion and allelic silencing in three mutation-negative classic familial adenomatous polyposis families. *Genome Med.* 2015; 7: 42. <https://doi.org/10.1186/s13073-015-0148>.
63. Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of lynch syndrome—literature review. *Hered Cancer Clin Pract.* 2013; 11: 9. <https://doi.org/10.1186/1897-4287-11-9>.
64. Diederichs S, Bartsch L, Berkman JC, Fröse K, Heitmann J, Hoppe C, et al. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. *EMBO Mol Med.* 2016; 8: 442–57. <https://doi.org/10.15252/emmm.201506055>.
65. ENIGMA Consortium. https://enigmaconsortium.org/wp-content/uploads/2017/12/ENIGMA_Rules_2017-06-29.pdf. Accessed 16 Mar 2018.
66. Thompson BA, Martins A, Spurdle AB. A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays. *Clin Genet.* 2015; 87: 100–8. <https://doi.org/10.1111/cge.12450>.
67. Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, et al. A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects. *Hum Mutat.* 2008; 29: 1412–24. <https://doi.org/10.1002/humu.20796>.
68. Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A survey of best practices for RNA-seq data analysis. *Genome Biol.* 2016; 17: 13. <https://doi.org/10.1186/s13059-016-0881-8>.
69. Saliba A-E, Westermann AJ, Gorski SA, Vogel J. Single-cell RNA-seq: advances and future challenges. *Nucleic Acids Res.* 2014; 42: 8845–60. <https://doi.org/10.1093/nar/gku555>.
70. Liu Q, Hesson LB, Nunez AC, Packham D, Williams R, Ward RL, Sloane MA. A cryptic paracentric inversion of MSH2 exons 2–6 causes lynch syndrome. *Carcinogenesis.* 2016; 37: 10–7. <https://doi.org/10.1093/carcin/bgv154>.
71. De Lellis L, Aceto GM, Curia MC, et al. Integrative analysis of hereditary nonpolyposis colorectal cancer: the contribution of allele-specific expression and other assays to diagnostic algorithms. *PLoS One.* 2013; 8: e81194. <https://doi.org/10.1371/journal.pone.0081194>.
72. Hesson LB, Packham D, Kwok C-T, Nunez AC, Ng B, Schmidt C, et al. Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression. *Hum Mutat.* 2015; 36: 622–30. <https://doi.org/10.1002/humu.22785>.
73. Lastella P, Surdo NC, Resta N, Guanti G, Stella A. In silico and in vivo splicing analysis of *MLH1* and *MSH2* missense mutations shows exon- and tissue-specific effects. *BMC Genomics.* 2006; 7: 243.
74. Kwok C-T, Ward RL, Hawkins NJ, Hitchins MP. Detection of allelic imbalance in MLH1 expression by pyrosequencing serves as a tool for the identification of germline defects in lynch syndrome. *Familial Cancer.* 2010; 9: 345–56. <https://doi.org/10.1007/s10689-009-9314-0>.
75. Santibanez Koref M, Wilson V, Cartwright N, Cunnington MS, Mathers JC, et al. MLH1 differential allelic expression in mutation carriers and controls. *Ann Hum Genet.* 2010; 74: 479–88. <https://doi.org/10.1111/j.1469-1809.2010.00603.x>.

76. Etzler J, Peyrl A, Zatkova A, Schildhaus H-U, Ficek A, Merkelbach-Bruse S, et al. RNA-based mutation analysis identifies an unusual MSH6 splicing defect and circumvents PMS2 pseudogene interference. *Hum Mutat.* 2008; 29: 299–305.
77. van der Klift HM, Mensenkamp AR, Drost M, Bik EC, Vos YJ, et al. Comprehensive mutation analysis of PMS2 in a large cohort of probands suspected of lynch syndrome or constitutional mismatch repair deficiency syndrome. *Hum Mutat.* 2016; 37: 1162–79. <https://doi.org/10.1002/humu.23052>.
78. Nasif S, Contu L, Mühlemann O. Beyond quality control: the role of nonsense-mediated mRNA decay (NMD) in regulating gene expression. *Semin Cell Dev Biol.* 2018; 75: 78–87. <https://doi.org/10.1016/j.semedb.2017.08.053>.
79. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, et al. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. *J Med Genet.* 2008; 45: 438–46. <https://doi.org/10.1136/jmg.2007.056895>.
80. Ward RL, Dobbins T, Lindor NM, Rapkins RW, Hitchins MP. Identification of constitutional *MLH1* epimutations and promoter variants in colorectal cancer patients from the Colon Cancer family registry. *Genet Med.* 2013; 15: 25–35. <https://doi.org/10.1038/gim.2012.91>.
81. Waidmann MS, Bleichrodt FS, Laslo T, Riedel CU. Bacterial luciferase reporters: the Swiss army knife of molecular biology. *Bioeng Bugs.* 2011; 2: 8–16. <https://doi.org/10.4161/bbug.2.1.13566>.
82. Gaildrat P, Krieger S, Théry JC, Killian A, Rousselin A, Berthet P, et al. The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements. *J Med Genet.* 2010; 47: 398–403. <https://doi.org/10.1136/jmg.2009.074047>.
83. Shimodaira H, Filosi N, Shibata H, Suzuki T, Radice P, Kanamaru R, et al. Functional analysis of human *MLH1* mutations in *Saccharomyces cerevisiae*. *Nat Genet.* 1998; 19: 384–9.
84. Nyström-Lahti M, Perrera C, Räschle M, Panyushkina-Seiler E, Marra G, Curci A, et al. Functional analysis of *MLH1* mutations linked to hereditary nonpolyposis colon cancer. *Genes Chromosomes Cancer.* 2002; 33: 160–7.
85. Trojan J, Zeuzem S, Randolph A, Hemmerle C, Brieger A, Raedle J, Plotz G, Jiricny J, Marra G. Functional analysis of h*MLH1* variants and HNPCC-related mutations using a human expression system. *Gastroenterology.* 2002; 122: 211–9.
86. Kondo E, Suzuki H, Horii A, Fukushige S. A yeast two-hybrid assay provides a simple way to evaluate the vast majority of h*MLH1* germ-line mutations. *Cancer Res.* 2003; 63: 3302–8.
87. Plotz G, Welsch C, Giron-Monzon L, Friedhoff P, Albrecht M, Piiper A, et al. Mutations in the MutSalpa interaction interface of *MLH1* can abolish DNA mismatch repair. *Nucleic Acids Res.* 2006; 34: 6574–86.
88. Ollila S, Dermadi Bebek D, Jiricny J, Nystrom M. Mechanisms of pathogenicity in human *MSH2* missense mutants. *Hum Mutat.* 2008; 29: 1355–63. <https://doi.org/10.1002/humu.20893>.
89. Drost M, Zonneveld JB, van Hees S, Rasmussen LJ, Hofstra RM, de Wind N. A rapid and cell-free assay to test the activity of lynch syndrome-associated *MSH2* and *MSH6* missense variants. *Hum Mutat.* 2012; 33: 488–94. <https://doi.org/10.1002/humu.22000>.
90. Wielders EA, Dekker RJ, Holt I, Morris GE, te Riele H. Characterization of *MSH2* variants by endogenous gene modification in mouse embryonic stem cells. *Hum Mutat.* 2011; 32: 389–96. <https://doi.org/10.1002/humu.21448>.
91. Marra G, D'Atri S, Yan H, Perrera C, Cannavo E, Vogelstein B, Jiricny J. Phenotypic analysis of h*MSH2* mutations in mouse cells carrying human chromosomes. *Cancer Res.* 2001; 61: 7719–21.
92. Blasi MF, Ventura I, Aquilina G, Degan P, Bertario L, Bassi C, et al. A human cell-based assay to evaluate the effects of alterations in the *MLH1* mismatch repair gene. *Cancer Res.* 2006; 66: 9036–44.
93. Mastrocola AS, Heinen CD. Lynch syndrome-associated mutations in *MSH2* alter DNA repair and checkpoint response functions in vivo. *Hum Mutat.* 2010; 31: E1699–708. <https://doi.org/10.1002/humu.21333>.
94. Takahashi M, Shimodaira H, Andreutti-Zaugg C, Iggo R, Kolodner RD, Ishioka C. Functional analysis of human *MLH1* variants using yeast and in vitro mismatch repair assays. *Cancer Res.* 2007; 67: 4595–604.
95. Belvederesi L, Bianchi F, Galizia E, Loretelli C, Bracci R, Catalani R, Amati M, Cellierino R. *MSH2* missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system. *Hum Mutat.* 2008; 29: E296–309. <https://doi.org/10.1002/humu.2087>.
96. Perera S, Bapat B. The *MLH1* variants p.Arg265Cys and p.Lys618Ala affect protein stability while p.Leu749Gln affects heterodimer formation. *Hum Mutat.* 2008; 29: 332. <https://doi.org/10.1002/humu.9523>.
97. Borràs E, Pineda M, Blanco I, Jewett EM, Wang F, Teulé A, et al. *MLH1* founder mutations with moderate penetrance in Spanish lynch syndrome families. *Cancer Res.* 2010; 70: 7379–91. <https://doi.org/10.1158/0008-5472>.
98. Hardt K, Heick SB, Betz B, Goecke T, Yazdanparast H, Küppers R, et al. Missense variants in h*MLH1* identified in patients from the German HNPCC consortium and functional studies. *Familial Cancer.* 2011; 10: 273–84. <https://doi.org/10.1007/s10689-011-9431-4>.

99. Hinrichsen I, Brieger A, Trojan J, Zeuzem S, Nilbert M, Plotz G. Expression defect size among unclassified MLH1 variants determines pathogenicity in lynch syndrome diagnosis. *Clin Cancer Res.* 2013; 19: 2432–41. <https://doi.org/10.1158/1078-0432.CCR-12-3299>.
100. Borràs E, Pineda M, Brieger A, Hinrichsen I, Gómez C, Navarro M, et al. Comprehensive functional assessment of *MLH1* variants of unknown significance. *Hum Mutat.* 2012; 33: 1576–88. <https://doi.org/10.1002/humu.22142>.
101. Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lönnqvist KE, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of *MLH1*. *Gastroenterology.* 2005; 129: 537–49.
102. Gassman NR, Clodfelter JE, McCauley AK, Bonin K, Salsbury FR Jr, Scarpinato KD. Cooperative nuclear localization sequences lend a novel role to the N-terminal region of MSH6. *PLoS One.* 2011; 6: e17907. <https://doi.org/10.1371/journal.pone.0017907>.
103. Belvederesi L, Bianchi F, Loretelli C, Bracci R, Cascinu S, Cellerino R. Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt *MSH6* nuclear transport impairment. *Familial Cancer.* 2012; 11: 675–80. <https://doi.org/10.1007/s10689-012-9558-y>.
104. Guerrette S, Wilson T, Gradia S, Fishel R. Interactions of human hMSH2 with hMSH3 and hMSH2 with hMSH6: examination of mutations found in hereditary nonpolyposis colorectal cancer. *Mol Cell Biol.* 1998; 18: 6616–23.
105. Guerrette S, Acharya S, Fishel R. The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. *J Biol Chem.* 1999; 274: 6336–41.
106. Yuan ZQ, Gottlieb B, Beitel LK, Wong N, Gordon PH, Wang Q, et al. Polymorphisms and HNPCC: PMS2–MLH1 protein interactions diminished by single nucleotide polymorphisms. *Hum Mutat.* 2002; 19: 108–13.
107. Clark AB, Cook ME, Tran HT, Gordenin DA, Resnick MA, Kunkel TA. Functional analysis of human MutS alpha and MutS beta complexes in yeast. *Nucleic Acids Res.* 1999; 27: 736–42.
108. Drotschmann K, Clark AB, Tran HT, Resnick MA, Gordenin DA, Kunkel TA. Mutator phenotypes of yeast strains heterozygous for mutations in the MSH2 gene. *Proc Natl Acad Sci U S A.* 1999; 96: 2970–5.
109. Iaccarino I, Marra G, Dufner P, Jiricny J. Mutation in the magnesium binding site of hMSH6 disables the hMutSalphal sliding clamp from translocating along DNA. *J Biol Chem.* 2000; 275: 2080–6.
110. Heinen CD, Wilson T, Mazurek A, Berardini M, Butz C, Fishel R. HNPCC mutations in hMSH2 result in reduced hMSH2–hMSH6 molecular switch functions. *Cancer Cell.* 2002; 1: 469–78.
111. Molatore S, Russo MT, D’Agostino VG, Barone F, Matsumoto Y, Albertini AM, et al. *MUTYH* mutations associated with familial adenomatous polyposis: functional characterization by a mammalian cell-based assay. *Hum Mutat.* 2010; 31: 159–66. <https://doi.org/10.1002/humu.21158>.
112. Komine K, Shimodaira H, Takao M, Soeda H, Zhang X, Takahashi M, Ishioka C. Functional complementation assay for 47 *MUTYH* variants in a MutY-disrupted *Escherichia coli* strain. *Hum Mutat.* 2015; 36: 704–11. <https://doi.org/10.1002/humu.22794>.
113. Shinmura K, Kato H, Goto M, Yamada H, Tao H, Nakamura S, Sugimura H. Functional evaluation of nine missense-type variants of the human DNA Glycosylase enzyme *MUTYH* in the Japanese population. *Hum Mutat.* 2016; 37: 350–3. <https://doi.org/10.1002/humu.22949104>.
114. Ali M, Kim H, Cleary S, Cupples C, Gallinger S, Bristow R. Characterization of mutant *MUTYH* proteins associated with familial colorectal cancer. *Gastroenterology.* 2008; 135: 499–507. <https://doi.org/10.1053/j.gastro.2008.04.035>.
115. D’Agostino VG, Minoprio A, Torreri P, Marioni I, Bossa C, Petrucci TC, et al. Functional analysis of *MUTYH* mutated proteins associated with familial adenomatous polyposis. *DNA Repair.* 2010; 9: 700–7. <https://doi.org/10.1016/j.dnarep.2010.03.008>.
116. Ou J, Niessen RC, Lützen A, Sijmons RH, Kleibeuker JH, de Wind N, et al. Functional analysis helps to clarify the clinical importance of unclassified variants in DNA mismatch repair genes. *Hum Mutat.* 2007; 28: 1047–54.
117. Rasmussen LJ, Heinen CD, Royer-Pokora B, Drost M, Tavtigian S, Hofstra RM, de Wind N. Pathological assessment of mismatch repair gene variants in lynch syndrome: past, present, and future. *Hum Mutat.* 2012; 33: 1617–25. <https://doi.org/10.1002/humu.22168>.
118. Thusberg J, Olatubosun A, Vihinen M. Performance of mutation pathogenicity prediction methods on missense variants. *Hum Mutat.* 2011; 32: 358–68. <https://doi.org/10.1002/humu.21445>.
119. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. *PLoS One.* 2012; 7: e46688. <https://doi.org/10.1371/journal.pone.0046688>.
120. Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, et al. Interpreting missense variants: comparing computational methods in human disease genes *CDKN2A*, *MLH1*, *MSH2*, *MECP2*, and tyrosinase (*TYR*). *Hum Mutat.* 2007; 28: 683–93.

121. Stone EA, Sidow A. Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. *Genome Res.* 2005; 15: 978–86.
122. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet.* 2013. <https://doi.org/10.1002/0471142905.hg0720s76>.
123. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat.* 2008; 29: 1282–91. <https://doi.org/10.1002/humu.20880>.

第19章

1. Win AK, Jenkins MA, Dowty JG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomarkers Prev.* 2017; 26: 404–412.
2. Giardiello FM, Allen JI, Axilbund JE, et al. US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. *Gastroenterology.* 2014; 147: 502–26.
3. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015; 110: 223–62.
4. Jasperson KW, Tuohy TT, Neklason DW, et al. Hereditary and familial colon cancer. *Gastroenterology.* 2010; 138: 2044–58.
5. Jenkins MA, Baglietto L, Dowty JG, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. *Clin Gastroenterol Hepatol.* 2006; 4: 489–98.
6. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology.* 2009; 137: 1621–7.
7. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. *J Clin Oncol.* 2012; 30: 4409–15.
8. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol.* 2012; 30: 958–64.
9. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology.* 2000; 118: 829–34.
10. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. *Gastroenterology.* 2006; 130: 665–71.
11. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology.* 2010; 138: 2300–6.
12. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. *JAMA.* 2006; 296: 1507–17.
13. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut.* 2013; 62: 812–23.
14. Ouakrim AD, Dashti SG, Buchanan DD, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. *J Natl Cancer Inst.* 2015; 107. <https://doi.org/10.1093/jnci/djv170>.
15. Park JG, Vasen HF, Park KJ, et al. Suspected hereditary non-polyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. *Dis Colon Rectum.* 1999; 42: 710–5.
16. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst.* 2004; 96: 261–8.
17. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst.* 1997; 89: 1758–62.
18. Kastrinos F, Uno H, Ukaegbu C, et al. Development and validation of the PREMM₅ model for comprehensive risk assessment of Lynch syndrome. *J Clin Oncol.* 2017; 35: 2165–72.
19. Kastrinos F, Steyerberg E, Mercado R, et al. The PREMM_{1,2,6} model predicts risk of germline *MLH1*, *MSH2*, and *MSH6* germline mutations based on cancer history. *Gastroenterology.* 2011; 140: 73–81.
20. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch repair genes in colon cancers. *N Engl J Med.* 2006; 354: 2751–63.
21. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA.*

- 2006; 296: 1479–87.
22. Hampel H. Genetic counseling and cascade genetic testing in Lynch syndrome. *Familial Cancer*. 2016; 15: 423–7.
 23. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary non-polyposis colorectal cancer). *N Engl J Med*. 2005; 352: 1851–60.
 24. Julié C, Trésallet C, Brouquet A, et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. *Am J Gastroenterol*. 2008; 103: 2825–35.
 25. Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. *Gut*. 2012; 61: 865–72.
 26. Grover S, Stoffel EM, Bussone L, et al. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. *Clin Gastroenterol Hepatol*. 2004; 2: 813–9.
 27. Flynn BS, Wood ME, Ashikaga T, et al. Primary care physicians' use of family history for cancer risk assessment. *BMC Fam Pract*. 2010; 11: 45.
 28. Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. *J Med Genet*. 2012; 49: 151–7.
 29. Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. *J Clin Oncol*. 2012; 30: 1058–63.
 30. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. *N Engl J Med*. 1998; 339: 511–8.
 31. Lipton LR, Johnson V, Cummings C, et al. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic. *J Clin Oncol*. 2004; 22: 4934–43.
 32. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of *MLH1* and *MSH2* mutations in Lynch syndrome. *JAMA*. 2006; 296: 1469–78.
 33. Kastrinos F, Ojha RP, Leenen C, et al. Comparison of prediction models for Lynch syndrome among individuals with colorectal cancer. *J Natl Cancer Inst*. 2015; 108(2). pii: djv308.
 34. Balaguer F, Balmaña J, Castellví-Bel S, et al. Validation and extension of the PREMM_{1,2} model in a population-based cohort of colorectal cancer patients. *Gastroenterology*. 2008; 134: 39–46.
 35. Balmaña J, Balaguer F, Castellví-Bel S, et al. Comparison of predictive models, clinical criteria and molecular tumor screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. *J Med Genet*. 2008; 45: 557–63.
 36. Monzon JG, Cremin C, Armstrong L, et al. Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. *Int J Cancer*. 2010; 126: 930–9.
 37. Green RC, Parfrey PS, Woods MO, et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. *J Natl Cancer Inst*. 2009; 101: 331–40.
 38. Trésallet C, Brouquet A, Julié C, et al. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. *Int J Cancer*. 2012; 130: 1367–77.
 39. Pouchet CJ, Wong N, Chong G, et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. *Ann Oncol*. 2009; 20: 681–8.
 40. Khan O, Blanco A, Conrad P, et al. Performance of Lynch syndrome predictive models in a multi-center US referral population. *Am J Gastroenterol*. 2011; 106: 1822–7.
 41. Kastrinos F, Steyerberg EW, Balmaña J, et al. Comparison of the clinical prediction model PREMM_{1,2,6} and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. *Gut*. 2013; 62: 272–9.
 42. National Comprehensive Cancer Network Guidelines Version 1.2017 Genetic/Familial High Risk Assessment: Colorectal. MS–15; Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed 3 Aug 2017.
 43. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Ann Intern Med*. 2011; 155: 69–79.
 44. Barzi A, Sadeghi S, Kattan MW, et al. Comparative effectiveness of screening strategies for Lynch syndrome. *J Natl Cancer Inst*. 2015; 107(4): djv005.
 45. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch

- syndrome in the general population. *Cancer Prev Res*. 2011; 4: 9–22.
46. Plichta JK, Griffin M, Thakuria J, et al. What's new in genetic testing for cancer susceptibility? *Oncology (Williston Park)*. 2016; 30: 787–99.
 47. ten Broeke SW, Nielsen M. A *PMS2*-specific colorectal surveillance guide. *Genet Med*. 2015; 17: 684.
 48. Braun D, Yang J, Griffin M, et al. A clinical decision support tool to predict cancer risk for commonly tested cancer-related germline mutations. Manuscript under review.
 49. Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. *Am J Hum Genet*. 2017; 100: 895–906.
 50. Cronin KA, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. *Cancer*. 2014; 120(Suppl 23): 3755–7.
 51. Drohan B, Ozanne EM, Hughes KS. Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. *Breast J*. 2009; 15(Suppl 1): S46–55.
 52. Doerr M, Teng K. Family history: still relevant in the genomics era. *Cleve Clin J Med*. 2012; 79: 331–6.
 53. Kastrinos F, Allen JI, Stockwell DH, et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. *Am J Gastroenterol*. 2009; 104: 1508–18.
 54. Gunaratnam NT, Akce M, Al Natour R, et al. Screening for cancer genetic syndromes with a simple risk-assessment tool in a community-based open-access colonoscopy practice. *Am J Gastroenterol*. 2016; 111: 589.
 55. Guivatchian T, Koeppel ES, Baker JR, et al. Family history in colonoscopy patients: feasibility and performance of electronic and paper-based surveys for colorectal cancer risk assessment in the outpatient setting. *Gastrointest Endosc*. 2017; 86: 684–691.
 56. Luba DG, DiSario JA, Rock C, et al. Community practice implementation of a self-administered version of PREMM_{1,2,6} to assess risk for Lynch syndrome. *Clin Gastroenterol Hepatol*. 2018; 16: 49–58.

第20章

1. Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut*. 2017; 66: 464–72.
2. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology*. 2000; 118: 829–34.
3. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology*. 1995; 108: 1405–11.
4. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol*. 2009; 27: 4793–7.
5. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. *Dis Colon Rectum*. 2002; 45: 1588–94.
6. Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol*. 2010; 8: 174–82.
7. Stuckless S, Green JS, Morgenstern M, et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an *MSH2* mutation. *Clin Genet*. 2012; 82: 439–45.
8. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology*. 2010; 138: 2300–6.
9. Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. *BMJ*. 2005; 331: 1047.
10. Edelstein DL, Axilbund J, Baxter M, et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. *Clin Gastroenterol Hepatol*. 2011; 9: 340–3.
11. De Jong AE, Morreau H, Van Puijtenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. *Gastroenterology*. 2004; 126: 42–8.
12. Vasen HF, Taal BG, Nagengast FM, et al. Hereditary nonpolyposis colorectal cancer: results of long-term surveillance in 50 families. *Eur J Cancer*. 1995; 31A: 1145–8.
13. Renkonen-Sinisalo L, Aarnio M, Mecklin JP, et al. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. *Cancer Detect Prev*. 2000; 24: 137–42.
14. Lindberg LJ, Ladelund S, Frederiksen BL, et al. Outcome of 24 years national surveillance in different hereditary

- colorectal cancer subgroups leading to more individualised surveillance. *J Med Genet.* 2016.
15. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA.* 2011; 305: 2304–10.
 16. Jenkins MA, Dowty JG, Ait Ouakrim D, et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. *J Clin Oncol.* 2015; 33: 326–31.
 17. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology.* 2008; 135: 419–28.
 18. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst.* 2010; 102: 193–201.
 19. Hurlstone DP, Karajeh M, Cross SS, et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective “back-to-back” endoscopic study. *Am J Gastroenterol.* 2005; 100: 2167–73.
 20. Rahmi G, Lecomte T, Malka D, et al. Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. *Am J Gastroenterol.* 2015; 110: 288–98.
 21. Capelle LG, Van Grieken NC, Lingsma HF, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. *Gastroenterology.* 2010; 138: 487–92.
 22. Win AK, Lindor NM, Young JP, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. *J Natl Cancer Inst.* 2012; 104: 1363–72.
 23. Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. *Clin Cancer Res.* 2000; 6: 2994–8.
 24. Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. *Scand J Gastroenterol.* 2002; 37: 574–7.
 25. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut.* 2013; 62: 812–23.
 26. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015; 110: 223–62; quiz 263.
 27. Koornstra JJ. Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. *Best Pract Res Clin Gastroenterol.* 2012; 26: 359–68.
 28. Schulmann K, Brasch FE, Kunstmann E, et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. *Gastroenterology.* 2005; 128: 590–9.
 29. ten Kate GL, Kleibeuker JH, Nagengast FM, et al. Is surveillance of the small bowel indicated for Lynch syndrome families? *Gut.* 2007; 56: 1198–201.
 30. Saurin JC, Pilleul F, Soussan EB, et al. Small-bowel capsule endoscopy diagnoses early and advanced neoplasms in asymptomatic patients with Lynch syndrome. *Endoscopy.* 2010; 42: 1057–62.
 31. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer.* 2008; 123: 444–9.
 32. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clin Genet.* 2009; 75: 141–9.
 33. Kastrinos F, Stoffel EM, Balmana J, et al. Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. *Cancer Epidemiol Biomark Prev.* 2008; 17: 2044–51.
 34. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol.* 2012; 30: 958–64.
 35. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. *Gut.* 2013; 62: 339–47.
 36. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology.* 2009; 137: 1621–7.
 37. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer.* 2002; 94: 1708–12.
 38. Gerritzen LH, Hoogerbrugge N, Oei AL, et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. *Familial Cancer.* 2009; 8: 391–7.
 39. Lecuru F, Le Frere Belda MA, Bats AS, et al. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. *Int J*

- Gynecol Cancer. 2008; 18: 1326–31.
40. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. *Int J Cancer*. 2007; 120: 821–4.
 41. Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol*. 2003; 91: 74–80.
 42. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med*. 2006; 354: 261–9.
 43. Stuckless S, Green J, Dawson L, et al. Impact of gynecological screening in Lynch syndrome carriers with an MSH2 mutation. *Clin Genet*. 2013; 83: 359–64.
 44. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. *Acta Obstet Gynecol Scand*. 2011; 90: 437–44.
 45. Chen LM, Yang KY, Little SE, et al. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families. *Obstet Gynecol*. 2007; 110: 18–25.
 46. Joost P, Therkildsen C, Dominguez-Valentin M, et al. Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations. *Urology*. 2015; 86: 1212–7.
 47. Myrhoj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. *Familial Cancer*. 2008; 7: 303–7.
 48. Mork M, Hubosky SG, Roupert M, et al. Lynch syndrome: a primer for urologists and panel recommendations. *J Urol*. 2015; 194: 21–9.
 49. Mallinson EK, Newton KF, Bowen J, et al. The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. *Gut*. 2010; 59: 1378–82.
 50. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). *Gut*. 2008; 57: 704–13.
 51. Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. *Ann Surg Oncol*. 2008; 15: 2439–50.
 52. Balmana J, Balaguer F, Cervantes A, et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2013; 24(Suppl 6 vi): 73–80.
 53. Gibbons DC, Sinha A, Phillips RK, et al. Colorectal cancer: no longer the issue in familial adenomatous polyposis? *Familial Cancer*. 2011; 10: 11–20.
 54. Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. *Gut*. 1992; 33: 357–60.
 55. Friederich P, de Jong AE, Mathus-Vliegen LM, et al. Risk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2008; 6: 1237–42.
 56. Tajika M, Nakamura T, Nakahara O, et al. Prevalence of adenomas and carcinomas in the ileal pouch after proctocolectomy in patients with familial adenomatous polyposis. *J Gastrointest Surg*. 2009; 13: 1266–73.
 57. Smith JC, Schaffer MW, Ballard BR, et al. Adenocarcinomas after prophylactic surgery for familial adenomatous polyposis. *J Cancer Ther*. 2013; 4: 260–70.
 58. Matsumoto T, Esaki M, Fujisawa R, et al. Chromoendoscopy, narrow-band imaging colonoscopy, and autofluorescence colonoscopy for detection of diminutive colorectal neoplasia in familial adenomatous polyposis. *Dis Colon Rectum*. 2009; 52: 1160–5.
 59. Biasco G, Pantaleo MA, Di Febo G, et al. Risk of duodenal cancer in patients with familial adenomatous polyposis. *Gut*. 2004; 53: 1547; author reply 1547.
 60. Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. *Lancet*. 1989; 2: 783–5.
 61. Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. *Gut*. 2004; 53: 381–6.
 62. Brosens LA, Keller JJ, Offerhaus GJ, et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. *Gut*. 2005; 54: 1034–43.
 63. Yamada A, Watabe H, Iwama T, et al. The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. *Familial Cancer*. 2014; 13: 23–8.
 64. Sarre RG, Frost AG, Jagelman DG, et al. Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps. *Gut*. 1987; 28: 306–14.
 65. Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous

- polyposis. *Clin Gastroenterol Hepatol*. 2008; 6: 180–5.
66. Aretz S, Stienen D, Friedrichs N, et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). *Hum Mutat*. 2007; 28: 985–92.
 67. Balaguer F, Castellvi-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. *Clin Gastroenterol Hepatol*. 2007; 5: 379–87.
 68. Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. *JAMA*. 2012; 308: 485–92.
 69. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. *Gastroenterology*. 2009; 137: 1976–85 e1–10.
 70. Nielsen M, Morreau H, Vasen HF, et al. MUTYH-associated polyposis (MAP). *Crit Rev Oncol Hematol*. 2011; 79: 1–16.
 71. Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. *Genet Med*. 2016; 18: 325–32.
 72. Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. *J Med Genet*. 2004; 41: 484–91.
 73. Latchford AR, Neale K, Phillips RK, et al. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. *Dis Colon Rectum*. 2012; 55: 1038–43.
 74. Schreiberman IR, Baker M, Amos C, et al. The hamartomatous polyposis syndromes: a clinical and molecular review. *Am J Gastroenterol*. 2005; 100: 476–90.
 75. Dunlop MG, British Society for G, Association of Coloproctology for Great B, et al. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, juvenile polyposis, and Peutz-Jeghers syndrome. *Gut*. 2002; 51(Suppl 5): V21–7.
 76. Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. *Gut*. 2010; 59: 975–86.
 77. Tomlinson IP, Houlston RS. Peutz-Jeghers syndrome. *J Med Genet*. 1997; 34: 1007–11.
 78. van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. *Gut*. 2011; 60: 141–7.
 79. Kastrinos F, Syngal S. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? *J Clin Oncol*. 2012; 30: 1024–7.
 80. Carballal S, Rodriguez-Alcalde D, Moreira L, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. *Gut*. 2015; 65(11): 1829–37.
 81. Boparai KS, van den Broek FJ, van Eeden S, et al. Increased polyp detection using narrow band imaging compared with high resolution endoscopy in patients with hyperplastic polyposis syndrome. *Endoscopy*. 2011; 43: 676–82.
 82. Pellise M, Diaz Tasende J, Balaguer F, et al. Technical review of advanced diagnostic endoscopy in patients at high risk of colorectal cancer. *Gastroenterol Hepatol*. 2012; 35: 278–92.
 83. Vasen HF, Ghorbanoghli Z, Bourdeaut F, et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). *J Med Genet*. 2014; 51: 283–93.
 84. Durno C, Boland CR, Cohen S, et al. Recommendations on surveillance and management of Biallelic Mismatch Repair Deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology*. 2017; 30175–0(17): S0016–5085.
 85. Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. *J Clin Oncol*. 2012; 30: 4409–15.
 86. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. *Clin Gastroenterol Hepatol*. 2014; 12: 715–27.
 87. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. *J Clin Oncol*. 2015; 33: 209–17.
 88. Guillen-Ponce C, Serrano R, Sanchez-Heras AB, et al. Clinical guideline seom: hereditary colorectal cancer. *Clin Transl Oncol*. 2015; 17: 962–71.
 89. Boparai KS, Reitsma JB, Lemmens V, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. *Gut*. 2010; 59: 1222–5.
 90. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal (Version 2.2016).

http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Accessed April 6, 2017.

第21章

1. Kobayashi H, Ishida H, Ueno H, et al. Association between the age and the development of colorectal cancer in patients with familial adenomatous polyposis: a multi-institutional study. *Surg Today*. 2017; 47: 690–6.
2. Rajaratnam SG, Eglinton TW, Hider P, et al. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. *Int J Color Dis*. 2011; 26: 1365.
3. Warriar SK, Kalady MF. Familial adenomatous polyposis: challenges and pitfalls of surgical treatment. *Clin Colon Rectal Surg*. 2012; 25: 083–9.
4. Gordon PH, Nivatvongs S. Principles and practice of surgery for the colon, rectum, and anus: CRC Press, Boca Raton, FL; 2007.
5. Debinski HS, Love S, Spigelman AD, et al. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. *Gastroenterology*. 1996; 110: 1028–30.
6. Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. *Lancet*. 1989; 2: 783–5.
7. Lynch PM, Morris JS, Wen S, et al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. *Gastrointest Endosc*. 2016; 84: 115–125.e114.
8. Ishikawa H, Mutoh M, Iwama T, et al. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. *Endoscopy*. 2016; 48: 51–5.
9. Nieuwenhuis MH, LM M-V, Slors FJ, et al. Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis. *Clin Gastroenterol Hepatol*. 2007; 5: 374–8.
10. Soravia C, Klein L, Berk T, et al. Comparison of ileal pouch-anal anastomosis and ileorectal anastomosis in patients with familial adenomatous polyposis. *Dis Colon Rectum*. 1999; 42: 1028–33.
11. Van Duijvendijk P, Slors J, Taat C, et al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch—anal anastomosis for familial adenomatous polyposis. *Br J Surg*. 2000; 87: 590–6.
12. Bülow C, Vasen H, Järvinen H, et al. Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. *Gastroenterology*. 2000; 119: 1454–60.
13. Stelzner F. Homingareale bei erblichen, synchronen und metachronen Rektokolonkrebsen. *Chirurg*. 2006; 77: 1056–60.
14. Koskenvuo L, Renkonen-Sinisalo L, Järvinen H, et al. Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. *Int J Color Dis*. 2014; 29: 225–30.
15. Bertario L, Russo A, Radice P, et al. Genotype and phenotype factors as determinants for rectal stump cancer in patients with familial adenomatous polyposis. *Ann Surg*. 2000; 231: 538–43.
16. Björk JA, Åkerbrant HI, Iselius LE, et al. Risk factors for rectal cancer morbidity and mortality in patients with familial adenomatous polyposis after colectomy and ileorectal anastomosis. *Dis Colon Rectum*. 2000; 43: 1719–25.
17. Bülow S, Bülow C, Vasen H, et al. Colectomy and ileorectal anastomosis is still an option for selected patients with familial adenomatous polyposis. *Dis Colon Rectum*. 2008; 51: 1318.
18. Durno C, Monga N, Bapat B, et al. Does early colectomy increase Desmoid risk in familial adenomatous polyposis? *Clin Gastroenterol Hepatol*. 2007; 5: 1190–4.
19. Sturt NJH, Clark SK. Current ideas in desmoid tumours. *Familial Cancer*. 2006; 5: 275–85.
20. Church JM, Xhaja X, Warriar SK, et al. Desmoid tumors do not prevent proctectomy following abdominal colectomy and ileorectal anastomosis in patients with familial adenomatous polyposis. *Dis Colon Rectum*. 2014; 57: 343–7.
21. Larson DW, Davies MM, Dozois EJ, et al. Sexual function, body image, and quality of life after laparoscopic and open ileal pouch-anal anastomosis. *Dis Colon Rectum*. 2008; 51: 392–6.
22. Kock NG. Intra-abdominal “reservoir” in patients with permanent ileostomy. Preliminary observations on a procedure resulting in fecal “continence” in five ileostomy patients. *Arch Surg (Chicago, Ill 1960)*. 1969; 99: 223–31.
23. Gerber A, Apt MK, Craig PH. The improved quality of life with the Kock continent ileostomy. *J Clin Gastroenterol*. 1984; 6: 513–7.
24. Bonjer HJ, Deijen CL, Abis GA, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. *N Engl J Med*. 2015; 372: 1324–32.
25. Indar AA, Efron JE, Young-Fadok TM. Laparoscopic ileal pouch-anal anastomosis reduces abdominal and pelvic

- adhesions. *Surg Endosc*. 2009; 23: 174.
26. Bartels SA, D'hoore A, Cuesta MA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. *Ann Surg*. 2012; 256: 1045–8.
 27. Fajardo AD, Dharmarajan S, George V, et al. Laparoscopic versus open 2-stage ileal pouch: laparoscopic approach allows for faster restoration of intestinal continuity. *J Am Coll Surg*. 2010; 211: 377–83.
 28. Schiessling S, Leowardi C, Kienle P, et al. Laparoscopic versus conventional ileoanal pouch procedure in patients undergoing elective restorative proctocolectomy (LapConPouch Trial)—a randomized controlled trial. *Langenbeck's Arch Surg*. 2013; 398: 807–16.
 29. Maartense S, Dunker MS, Slors JF, et al. Hand-assisted laparoscopic versus open restorative proctocolectomy with ileal pouch anal anastomosis: a randomized trial. *Ann Surg*. 2004; 240: 984–92.
 30. Ueno H, Kobayashi H, Konishi T, et al. Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. *Int J Clin Oncol*. 2016; 21: 713–22.
 31. Lindsey I, Guy R, Warren B, et al. Anatomy of Denonvilliers' fascia and pelvic nerves, impotence, and implications for the colorectal surgeon. *Br J Surg*. 2000; 87: 1288–99.
 32. De Zeeuw S, Ahmed Ali U, Van Der Kolk MB, et al. Ileal pouch anal anastomosis with close rectal dissection using automated vessel sealers for ulcerative colitis: a promising alternative. *Dig Surg*. 2011; 28: 345–51.
 33. Lindsey I, George BD, Kettlewell MGW, et al. Impotence after mesorectal and close rectal dissection for inflammatory bowel disease. *Dis Colon Rectum*. 2001; 44: 831–5.
 34. Bartels S, Gardenbroek T, Aarts M, et al. Short-term morbidity and quality of life from a randomized clinical trial of close rectal dissection and total mesorectal excision in ileal pouch-anal anastomosis. *Br J Surg*. 2015; 102: 281–7.
 35. Sylla P, Rattner DW, Delgado S, et al. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. *Surg Endosc*. 2010; 24: 1205–10.
 36. Leo CA, Samaranyake S, Perry-Woodford ZL, et al. Initial experience of restorative proctocolectomy for ulcerative colitis by transanal total mesorectal rectal excision and singleincision abdominal laparoscopic surgery. *Color Dis*. 2016; 18: 1162–6.
 37. Koedam T, Van Ramshorst G, Deijen C, et al. Transanal total mesorectal excision (TaTME) for rectal cancer: effects on patient-reported quality of life and functional outcome. *Tech Coloproctol*. 2017; 21: 25–33.
 38. Kirat HT, Remzi FH. Technical aspects of ileoanal pouch surgery in patients with ulcerative colitis. *Clin Colon Rectal Surg*. 2010; 23: 239–47.
 39. Möslein G. Surgical considerations in FAP-related pouch surgery: could we do better? *Fam Cancer*. 2016; 15: 457–66.
 40. Parks A, Nicholls R. Proctocolectomy without ileostomy for ulcerative colitis. *Br Med J*. 1978; 2: 85–8.
 41. Heald R, Allen D. Stapled ileo-anal anastomosis: a technique to avoid mucosal proctectomy in the ileal pouch operation. *Br J Surg*. 1986; 73: 571–2.
 42. Slors J, Ponson A, Taat C, et al. Risk of residual rectal mucosa after proctocolectomy and ileal pouch-anal reconstruction with the double-stapling technique. *Dis Colon Rectum*. 1995; 38: 207–10.
 43. Von Roon AC, Will OC, Man RF, et al. Mucosectomy with handsewn anastomosis reduces the risk of adenoma formation in the anorectal segment after restorative proctocolectomy for familial adenomatous polyposis. *Ann Surg*. 2011; 253: 314–7.
 44. Ganschow P, Treiber I, Hinz U, et al. Residual rectal mucosa after stapled vs. handsewn ileal J-pouch-anal anastomosis in patients with familial adenomatous polyposis coli (FAP)—a critical issue. *Langenbeck's Arch Surg*. 2015; 400: 213–9.
 45. Silva-Velazco J, Stocchi L, Wu X-R, et al. Twenty-year-old stapled pouches for ulcerative colitis without evidence of rectal cancer: implications for surveillance strategy? *Dis Colon Rectum*. 2014; 57: 1275–81.
 46. Utsunomiya J, Iwama T, Imajo M, et al. Total colectomy, mucosal proctectomy, and ileoanal anastomosis. *Dis Colon Rectum*. 1980; 23: 459–66.
 47. Hughes JP, Bauer AR, Bauer CM. Stapling techniques for easy construction of an ileal J-pouch. *Am J Surg*. 1988; 155: 783–5.
 48. Schneider R, Schneider C, Dalchow A, et al. Prophylactic surgery in familial adenomatous polyposis (FAP)—a single surgeon's short-and long-term experience with hand-assisted proctocolectomy and smaller J-pouches. *Int J Color Dis*. 2015; 30: 1109–15.
 49. Block M, Börjesson L, Lindholm E, et al. Pouch design and long-term functional outcome after ileal pouch-anal anastomosis. *Br J Surg*. 2009; 96: 527–32.
 50. Campos FG. Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. *World Journal of Gastroenterology: WJG*. 2014; 20: 16620–9.

51. Carne PWG, Pemberton JH. Technical aspects of ileoanal pouch surgery. *Clin Colon Rectal Surg.* 2004; 17: 35–41.
52. Sagar PM, Lewis W, Holdsworth PJ, et al. One-stage restorative proctocolectomy without temporary defunctioning ileostomy. *Dis Colon Rectum.* 1992; 35: 582–8.
53. Heuschen UA, Hinz U, Allemeyer EH, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. *Ann Surg.* 2002; 235: 207–16.
54. Miccini M, Bonapasta SA, Gregori M, et al. Ghost ileostomy: real and potential advantages. *Am J Surg.* 2010; 200: e55–7.
55. Mari FS, Di Cesare T, Novi L, et al. Does ghost ileostomy have a role in the laparoscopic rectal surgery era? A randomized controlled trial. *Surg Endosc.* 2015; 29: 2590–7.
56. Hartley J, Church J, Gupta S, et al. Significance of incidental desmoids identified during surgery for familial adenomatous polyposis. *Dis Colon Rectum.* 2004; 47: 334–40.
57. Quast DR, Schneider R, Burdzik E, et al. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. *Familial Cancer.* 2016; 15: 31–40.
58. Brosens LA, Keller JJ, Offerhaus GJA, et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. *Gut.* 2005; 54: 1034–43.
59. Galle TS, Juel K, Bülow S. Causes of death in familial adenomatous polyposis. *Scand J Gastroenterol.* 1999; 34: 808–12.
60. Groves C, Saunders B, Spigelman A, et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. *Gut.* 2002; 50: 636–41.
61. Kalady MF, Clary BM, Tyler DS, et al. Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. *J Gastrointest Surg.* 2002; 6: 82–7.
62. Watanabe Y, Ishida H, Baba H, et al. Pancreas-sparing total duodenectomy for Spigelman stage IV duodenal polyposis associated with familial adenomatous polyposis: experience of 10 cases at a single institution. *Fam Cancer.* 2017; 16: 91–8.
63. Samadder NJ, Neklason DW, Boucher KM, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. *JAMA.* 2016; 315: 1266–75.
64. Møller P, Seppälä T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective lynch syndrome database. *Gut.* 2016.
65. (Nice) TNOICE. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27): NICE guidance; 2017.
66. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary non-polyposis colorectal cancer). *N Engl J Med.* 2005; 66: 1657–64.
67. Kastrinos F, Syngal S. Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? *J Clin Oncol.* 2012; 30: 1024–7.
68. Pearlman R, Frankel WL, Swanson B, et al. Prevalence and Spectrum of Germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol.* 2016.
69. Yurgelun MB, Kulke MH, Fuchs CS et al. (2017) Cancer susceptibility gene mutations in individuals with colorectal cancer. *J Clin Oncol* 0: JCO.2016.2071.0012.
70. Kumarasinghe AP, De Boer B, Bateman AC, et al. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. *Pathology.* 2010; 42: 414–20.
71. Vilkin A, Leibovici-Weissman YA, Halpern M, et al. Immunohistochemistry staining for mismatch repair proteins: the endoscopic biopsy material provides useful and coherent results. *Hum Pathol.* 2015; 46: 1705–11.
72. Kim TJ, Kim ER, Hong SN, et al. Survival outcome and risk of metachronous colorectal cancer after surgery in Lynch syndrome. *Ann Surg Oncol.* 2017; 66: 1657–64.
73. Fitzgibbons R Jr, Lynch HT, Stanislav GV, et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). *Ann Surg.* 1987; 206: 289.
74. Stupart DA, Goldberg PA, Baigrie RJ, et al. Surgery for colonic cancer in HNPCC: total vs segmental colectomy. *Color Dis.* 2011; 13: 1395–9.
75. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut.* 2010; 2010: 228056.
76. De Vos Tot Nederveen Cappel WH, Buskens E, Van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. *Gut.* 2003; 52: 1752–5.
77. Syngal S, Weeks JC, Schrag D, et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. *Ann Intern Med.* 1998; 129: 787–96.

78. Maeda T, Cannom RR, Beart RW Jr, et al. Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. *J Clin Oncol.* 2010; 28: 1175–80.
79. Elton C, Makin G, Hitos K, et al. Mortality, morbidity and functional outcome after ileorectal anastomosis. *Br J Surg.* 2003; 90: 59–65.
80. Haanstra JF, Tot Nederveen WHDV, Gopie JP, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy. *Dis Colon Rectum.* 2012; 55: 653–9.
81. Cirillo L, Urso ED, Parrinello G, et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. *Ann Surg.* 2013; 257: 900–4.
82. Kalady MF, McGannon E, Vogel JD, et al. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. *Ann Surg.* 2010; 252: 507–13.
83. Rodríguez-Bigas MA, Vasen H, Pekka-Mecklin J, et al. Rectal cancer risk in hereditary non-polyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. *Ann Surg.* 1997; 225: 202.
84. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg.* 2004; 240: 711–8.
85. Lee JS, Petrelli NJ, Rodríguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. *Am J Surg.* 2001; 181: 207–10.
86. Kalady MF, Lipman J, McGannon E, et al. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. *Ann Surg.* 2012; 255: 1121–5.
87. Meagher A, Farouk R, Dozois R, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. *Br J Surg.* 1998; 85: 800–3.
88. HFA V, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut.* 2013; 62: 812–23.
89. Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet.* 2012; 378: 2081–7.
90. Burn J, Sheth H. The role of aspirin in preventing colorectal cancer. *Br Med Bull.* 2016; 119: 17–24.
91. Jass J, Smyrk TC, Stewart S, et al. Pathology of hereditary non-polyposis colorectal cancer. *Anticancer Res.* 1993; 14: 1631–4.
92. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology.* 2010; 138: 2300–6.
93. Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut: gutjnl-2015-309675;* 2015.
94. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (hnpcc) syndrome. *Int J Cancer.* 1995; 64: 430–3.
95. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. *Hum Mol Genet.* 1997; 6: 105–10.
96. Quehenberger F, Vasen H, Van Houwelingen H. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet.* 2005; 42: 491–6.
97. Obermair A, Youlden DR, Young JP, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. *Int J Cancer.* 2010; 127: 2678–84.
98. Faubion S, Kuhle CL, Shuster LT, et al. Long-term health consequences of premature or early menopause and considerations for management. *Climacteric.* 2015; 18: 483–91.
99. Schmeler KM, Lynch HT, Chen L-M, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med.* 2006; 354: 261–9.
100. Boks DE, Trujillo AP, Voogd AC, et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. *Int J Cancer.* 2002; 102: 198–200.

第22章

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin.* 2014; 64(1): 9–29.
2. Hawk ET, Levin B. Colorectal cancer prevention. *J Clin Oncol.* 2005; 23(2): 378–91.
3. Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-based family history-specific risks for colorectal cancer: a constellation approach. *Gastroenterology.* 2010; 138(3): 877–85.

4. Fearon ER. Molecular genetics of colorectal cancer. *Annu Rev Pathol.* 2011; 6: 479–507.
5. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). *Fed Proc.* 1976; 35(6): 1332–8.
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell.* 1990; 61(5): 759–67.
7. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature.* 2009; 457(7229): 608–11.
8. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. *Science.* 2010; 330(6004): 612–6.
9. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. *Pathol Res Int.* 2012; 2012: 509348.
10. Issa J-P. Colon cancer: it's CIN or CIMP. *Clin Cancer Res off J am Assoc Cancer Res.* 2008; 14(19): 5939–40.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; 144(5): 646–74.
12. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. *Gastroenterology.* 2008; 135(4): 1079–99.
13. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. *Science.* 1993; 260(5109): 812–6.
14. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature.* 1993; 363(6429): 558–61.
15. González-García I, Moreno V, Navarro M, Martí-Ragué J, Marcuello E, Benasco C, et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. *J Natl Cancer Inst.* 2000; 92(7): 544–9.
16. Pedroni M, Tamassia MG, Percesepe A, Roncucci L, Benatti P, Lanza G, et al. Microsatellite instability in multiple colorectal tumors. *Int J Cancer.* 1999; 81(1): 1–5.
17. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence. *Nat Rev Clin Oncol.* 2010; 7(3): 153–62.
18. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. *Cancer Res.* 1999; 59(21): 5438–42.
19. Ballestar E, Esteller M. SnapShot: the human DNA methylome in health and disease. *Cell.* 2008; 135(6): 1144. e1.
20. Liu Y, Siegmund KD, Laird PW, Berman BP. Bis-SNP: combined DNA methylation and SNP calling for Bisulfite-seq data. *Genome Biol.* 2012; 13(7): R61.
21. Hinoue T, Weisenberger DJ, Lange CPE, Shen H, Byun H-M, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. *Genome Res.* 2012; 22(2): 271–82.
22. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell.* 1995; 83(3): 493–501.
23. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. *J Clin Gastroenterol.* 1998; 27(Suppl 1): S47–52.
24. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. *Gastroenterology.* 1994; 107(4): 1183–8.
25. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat Rev Cancer.* 2001; 1(1): 11–21.
26. Fritsche E, Baek SJ, King LM, Zeldin DC, Eling TE, Bell DA. Functional characterization of cyclooxygenase-2 polymorphisms. *J Pharmacol Exp Ther.* 2001; 299(2): 468–76.
27. Smith CE, Soti S, Jones TA, Nakagawa A, Xue D, Yin H. Non-steroidal anti-inflammatory drugs are caspase inhibitors. *Cell Chem Biol.* 2017; 24(3): 281–92.
28. Jana NR. NSAIDs and apoptosis. *Cell Mol Life Sci CMLS.* 2008; 65(9): 1295–301.
29. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. *Nature.* 1998; 396(6706): 77–80.
30. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. *J Surg Oncol.* 1983; 24(1): 83–7.
31. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N Engl J Med.* 1993; 328(18): 1313–6.
32. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. *N Engl J Med.* 2002; 346(14): 1054–9.
33. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. *Gastroenterology.* 1991; 101(3): 635–9.
34. Barry ELR, Baron JA, Grau MV, Wallace K, Haile RW. K-ras mutations in incident sporadic colorectal adenomas.

- Cancer. 2006; 106(5): 1036–40.
35. Brosens LAA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, et al. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the-765G->C COX-2 polymorphism. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2005; 11(11): 4090–6.
 36. Bertoni G, Sassatelli R, Bedogni G, Nigrisoli E. Sulindac-associated ulcerative pouchitis in familial adenomatous polyposis. *Am J Gastroenterol*. 1996; 91(11): 2431–2.
 37. Lanza LL, Walker AM, Bortnichak EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. *Arch Intern Med*. 1995; 155(13): 1371–7.
 38. Patrono C. Cardiovascular effects of nonsteroidal anti-inflammatory drugs. *Curr Cardiol Rep*. 2016; 18(3): 25.
 39. Anwar A, Anwar IJ, Delafontaine P. Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. *Trends Cardiovasc Med*. 2015; 25(8): 726–35.
 40. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med*. 2000; 342(26): 1946–52.
 41. Phillips RKS, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. *Gut*. 2002; 50(6): 857–60.
 42. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2003; 9(13): 4756–60.
 43. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, et al. Rofecoxib reduces polyp recurrence in familial polyposis. *Dig Dis Sci*. 2003; 48(10): 1998–2002.
 44. Arber N, Eagle CJ, Spicak J, Rác I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. *N Engl J Med*. 2006; 355(9): 885–95.
 45. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. *Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer*. 2013; 191: 67–93.
 46. Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. *Am J Gastroenterol*. 2010; 105(6): 1437–43.
 47. Burn J, Mathers J, Bishop DT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). *Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer*. 2013; 191: 157–83.
 48. Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome. *Familial Cancer*. 2013; 12(4): 707–18.
 49. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. *Cancer Res*. 1997; 57(2): 199–201.
 50. Celano P, Baylin SB, Casero RA. Polyamines differentially modulate the transcription of growth-associated genes in human colon carcinoma cells. *J Biol Chem*. 1989; 264(15): 8922–7.
 51. Celano P, Berchtold CM, Giardiello FM, Casero RA. Modulation of growth gene expression by selective alteration of polyamines in human colon carcinoma cells. *Biochem Biophys Res Commun*. 1989; 165(1): 384–90.
 52. Casero RA. Say what? The activity of the polyamine biosynthesis inhibitor difluoromethylornithine in chemoprevention is a result of reduced thymidine pools? *Cancer Discov*. 2013; 3(9): 975–7.
 53. Witherspoon M, Chen Q, Kopelovich L, Gross SS, Lipkin SM. Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine. *Cancer Discov*. 2013; 3(9): 1072–81.
 54. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. *Cancer Prev Res Phila Pa*. 2008; 1(1): 32–8.
 55. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. *Cancer Res*. 2000; 60(18): 5040–4.
 56. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alphafluoro-5-androsten-17-one, and ellagic acid individually and in combination. *Cancer Res*. 1991; 51(17): 4528–34.

57. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodríguez JM, et al. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. *Carcinogenesis*. 1999; 20(9): 1709–13.
58. Meyskens FL, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. *Clin Cancer Res Off J Am Assoc Cancer Res*. 1999; 5(5): 945–51.
59. Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, et al. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 1998; 7(11): 989–92.
60. Meyskens FL, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, et al. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. *J Natl Cancer Inst*. 1994; 86(15): 1122–30.
61. Meyskens FL, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, et al. Effect of alphasdifluoromethylornithine on rectal mucosal levels of polyamines in a randomized, doubleblinded trial for colon cancer prevention. *J Natl Cancer Inst*. 1998; 90(16): 1212–8.
62. Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. *JAMA*. 2016; 315(12): 1266–75.
63. Vrhovac B. Placebo and its importance in medicine. *Int J Clin Pharmacol Biopharm*. 1977; 15(4): 161–5.
64. Ricciardiello L, Ahnen DJ, Lynch PM. Chemoprevention of hereditary colon cancers: time for new strategies. *Nat Rev Gastroenterol Hepatol*. 2016; 13(6): 352–61.
65. Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet Lond Engl*. 2011; 378(9809): 2081–7.
66. Mathers JC, Movahedi M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet Oncol*. 2012; 13(12): 1242–9.
67. Burn J, Bishop DT, Mecklin J-P, Macrae F, Möslein G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. *N Engl J Med*. 2008; 359(24): 2567–78.
68. Liljegren A, Barker G, Elliott F, Bertario L, Bisgaard ML, Eccles D, et al. Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. *J Clin Oncol Off J Am Soc Clin Oncol*. 2008; 26(20): 3434–9.
69. Movahedi M, Bishop DT, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: a prospective investigation in the CAPP2 Study. *J Clin Oncol Off J Am Soc Clin Oncol*. 2015; 33(31): 3591–7.
70. Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2006; 15(7): 1382–91.
71. Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. *N Engl J Med*. 2016; 375(26): 2519–29.
72. You YN, Vilar E. Classifying MMR variants: time for revised nomenclature in Lynch syndrome. *Clin Cancer Res Off J Assoc Cancer Res*. 2013; 19(9): 2280–2.
73. Boland CR. Recent discoveries in the molecular genetics of Lynch syndrome. *Familial Cancer*. 2016; 15(3): 395–403.
74. Chen Y, Peate M, Kaur R, Meiser B, Wong T, Kirk J, et al. Exploring clinicians' attitudes about using aspirin for risk reduction in people with Lynch syndrome with no personal diagnosis of colorectal cancer. *Familial Cancer*. 2017; 16(1): 99–109.
75. Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, et al. Leveraging premalignant biology for immune-based cancer prevention. *Proc Natl Acad Sci U SA*. 2016; 113(39): 10750–8.
76. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, et al. Precancer atlas to drive precision prevention trials. *Cancer Res*. 2017; 77(7): 1510–41.

第23章

1. Greaves M, Maley CC. Clonal evolution in cancer. *Nature*. 2012; 481(7381): 306–13. <https://doi.org/10.1038/>

- nature10762.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144(5): 646–74. <https://doi.org/10.1016/j.cell.2011.02.013>.
 - Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. *Nature*. 1997; 386(6625): 623–7. <https://doi.org/10.1038/386623a0>.
 - Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA. Can chromosomal instability initiate tumorigenesis? *Semin Cancer Biol*. 2005; 15(1): 43–9. <https://doi.org/10.1016/j.semcancer.2004.09.007>.
 - Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. *Proc Natl Acad Sci USA*. 1999; 96(15): 8681–6.
 - Lao VV, Grady WM. Epigenetics and colorectal cancer. *Nat Rev Gastroenterol Hepatol*. 2011; 8(12): 686–700. <https://doi.org/10.1038/nrgastro.2011.173>.
 - Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG, Wong WD, Gerald WL, Klimstra DS. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. *Am J Surg Pathol*. 2003; 27(11): 1407–17.
 - Shia J, Holck S, Depetris G, Greenson JK, Klimstra DS. Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry. *Familial Cancer*. 2013; 12(2): 241–60. <https://doi.org/10.1007/s10689-013-9612-4>.
 - Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel DM, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. *Br J Cancer*. 2005; 92(9): 1746–53. <https://doi.org/10.1038/sj.bjc.6602534>.
 - Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindouh F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science*. 2006; 313(5795): 1960–4. <https://doi.org/10.1126/science.1129139>.
 - Jung SB, Lee HI, Oh HK, Shin IH, Jeon CH. Clinico-pathologic parameters for prediction of microsatellite instability in colorectal cancer. *Cancer Res Treat Off J Kor Cancer Assoc*. 2012; 44(3): 179–86. <https://doi.org/10.4143/crt.2012.44.3.179>.
 - Boland CR, Goel A. Microsatellite instability in colorectal cancer. *Gastroenterology*. 2010; 138(6): 2073–87. e2073. <https://doi.org/10.1053/j.gastro.2009.12.064>.
 - Kloor M, Huth C, Voigt AY, Benner A, Schirmacher P, von Knebel Doeberitz M, Blaker H. Prevalence of mismatch repair-deficient crypt foci in lynch syndrome: a pathological study. *Lancet Oncol*. 2012; 13(6): 598–606. [https://doi.org/10.1016/S1470-2045\(12\)70109-2](https://doi.org/10.1016/S1470-2045(12)70109-2).
 - Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rodland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Sampson JR, Capella G, Mecklin JP, Moslein G. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut*. 2017; 66(3): 464–72. <https://doi.org/10.1136/gutjnl-2015-309675>.
 - Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhajee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Comish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015. <https://doi.org/10.1056/NEJMoa1500596>.
 - Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjord JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Illicic T, Imbeaud S, Imielinski M, Jager N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, Lopez-Otin C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdes-Mas R, van Buuren MM, van't Veer L, Vincent-Salomon A, Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. *Nature*. 2013; 500(7463): 415–21. <https://doi.org/10.1038/nature12477>.
 - Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P,

- Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. *PLoS One*. 2010; 5(12): e15661. <https://doi.org/10.1371/journal.pone.0015661>.
18. Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, Jegou G, Wanherdrick K, Joly AL, Buhard O, Gobbo J, Penard-Lacronique V, Zouali H, Tubacher E, Kirzin S, Selves J, Milano G, Etienne-Grimaldi MC, Bengrine-Lefevre L, Louvet C, Tournigand C, Lefevre JH, Parc Y, Turet E, Flejou JF, Gaub MP, Garrido C, Duval A. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. *Nat Med*. 2011; 17(10): 1283–9. <https://doi.org/10.1038/nm.2457>.
 19. Sarmakorpi H, Alhopuro P, Lehtonen R, Tuimala J, Mecklin JP, Jarvinen HJ, Jiricny J, Karhu A, Aaltonen LA. Background mutation frequency in microsatellite-unstable colorectal cancer. *Cancer Res*. 2007; 67(12): 5691–8. <https://doi.org/10.1158/0008-5472.CAN-06-4314>.
 20. Woerner SM, Kloor M, von Knebel DM, Gebert JF. Microsatellite instability in the development of DNA mismatch repair deficient tumors. *Cancer Biomark Sect A Dis Markers*. 2006; 2(1–2): 69–86.
 21. Alhopuro P, Sarmakorpi H, Niittymaki I, Bistrom M, Raitila A, Saharinen J, Nousiainen K, Lehtonen HJ, Heliovaara E, Puhakka J, Tuupainen S, Sousa S, Seruca R, Ferreira AM, Hofstra RM, Mecklin JP, Jarvinen H, Ristimaki A, Orntoft TF, Hautaniemi S, Arango D, Karhu A, Aaltonen LA. Candidate driver genes in microsatellite-unstable colorectal cancer. *Int J Cancer*. 2012; 130(7): 1558–66. <https://doi.org/10.1002/ijc.26167>.
 22. Duval A, Rolland S, Compoint A, Tubacher E, Iacopetta B, Thomas G, Hamelin R. Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. *Hum Mol Genet*. 2001; 10(5): 513–8.
 23. Woerner SM, Gebert J, Yuan YP, Sutter C, Ridder R, Bork P, von Knebel Doeberitz M. Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. *Int J Cancer*. 2001; 93(1): 12–9.
 24. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B, Hamelin R. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. *Gastroenterology*. 2002; 123(6): 1804–11. <https://doi.org/10.1053/gast.2002.37070>.
 25. Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W, Wagner R, Gebert J, von Knebel Doeberitz M. T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. *Cancer Res*. 2005; 65(18): 8072–8. <https://doi.org/10.1158/0008-5472.CAN-04-4146>.
 26. Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, Bork P, Doeberitz M, Gebert JF. Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes. *Oncogene*. 2003; 22(15): 2226–35. <https://doi.org/10.1038/sj.onc.1206421>.
 27. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. *Cell*. 2013; 155(4): 858–68. <https://doi.org/10.1016/j.cell.2013.10.015>.
 28. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. *Nat Med*. 2016; 22(11): 1342–50. <https://doi.org/10.1038/nm.4191>.
 29. Warth A, Korner S, Penzel R, Muley T, Dienemann H, Schirmacher P, von Knebel-Doeberitz M, Weichert W, Kloor M. Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases. *Virchows Archiv Int J Pathol*. 2016; 468(3): 313–9. <https://doi.org/10.1007/s00428-015-1892-7>.
 30. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. *Science*. 1995; 268(5215): 1336–8.
 31. Kloor M, von Knebel Doeberitz M. The immune biology of microsatellite-unstable cancer. *Trends in Cancer*. 2016; 2(3): 121–31.
 32. Townsend A, Ohlen C, Rogers M, Edwards J, Mukherjee S, Bastin J. Source of unique tumour antigens. *Nature*. 1994; 371(6499): 662. <https://doi.org/10.1038/371662a0>.
 33. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science*. 2015; 348(6230): 69–74. <https://doi.org/10.1126/science.aaa4971>.
 34. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. *Cancer Discov*. 2017; 7(3): 264–76. <https://doi.org/10.1158/2159-8290.CD-16-0828>.

35. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. *Cell Rep*. 2016; 17(4): 1206. <https://doi.org/10.1016/j.celrep.2016.10.009>.
36. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. *EMBO J*. 2013; 32(2): 194–203. <https://doi.org/10.1038/emboj.2012.333>.
37. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. *Int J Cancer*. 2001; 93(1): 6–11.
38. Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G. A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2–restricted CD8+ T cells. *Cancer Immunol Immunother CII*. 2001; 50(9): 469–76.
39. Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel DM. Identification of an HLA-A0201–restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. *J Clin Immunol*. 2003; 23(5): 415–23.
40. Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. *Cancer Immun*. 2004; 4: 14.
41. Maletzki C, Schmidt F, Dirks WG, Schmitt M, Linnebacher M. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-unstable haematological malignancies: frameshift peptides for treating MSI+ blood cancers. *Eur J Cancer*. 2013; 49(11): 2587–95. <https://doi.org/10.1016/j.ejca.2013.02.035>.
42. Saeterdal I, Bjorheim J, Lislud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Moller M, Lindblom A, Gaudernack G. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. *Proc Natl Acad Sci U S A*. 2001; 98(23): 13255–60. <https://doi.org/10.1073/pnas.231326898>.
43. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel DM. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. *Gastroenterology*. 2008; 134(4): 988–97. <https://doi.org/10.1053/j.gastro.2008.01.015>.
44. Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, Angell HK, Fredriksen T, Elie N, Fauquembergue E, Drouet A, Leprince J, Benichou J, Mauillon J, Le Pessot F, Sesboue R, Tuech JJ, Sabourin JC, Michel P, Frebourg T, Galon J, Latouche JB. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. *Cancer Res*. 2015; 75(17): 3446–55. <https://doi.org/10.1158/0008-5472.CAN-14-3051>.
45. Staffa L, Echterdiek F, Nelius N, Benner A, Werft W, Lahrman B, Grabe N, Schneider M, Tariverdian M, von Knebel DM, Blaker H, Kloor M. Mismatch repair-deficient crypt foci in lynch syndrome-molecular alterations and association with clinical parameters. *PLoS One*. 2015; 10(3): e0121980. <https://doi.org/10.1371/journal.pone.0121980>.
46. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. *Nat Immunol*. 2002; 3(11): 991–8. <https://doi.org/10.1038/ni1102-991>.
47. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. *Curr Opin Immunol*. 2014; 27: 16–25. <https://doi.org/10.1016/j.coi.2014.01.004>.
48. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet*. 2005; 42(6): 491–6. <https://doi.org/10.1136/jmg.2004.024299>.
49. Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. *Int J Cancer*. 2010; 127(5): 1001–10. <https://doi.org/10.1002/ijc.25283>.
50. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. *Cell*. 2015; 160(1–2): 48–61. <https://doi.org/10.1016/j.cell.2014.12.033>.
51. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. *Cancer Immunol Immunother CII*. 2007; 56(2): 227–36. <https://doi.org/10.1007/s00262-006-0183-1>.
52. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2–microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. *Tissue Antigens*. 2003; 61(3): 211–9.
53. Kloor M, Michel S, Buckowitz B, Ruschoff J, Buttner R, Holinski-Feder E, Dippold W, Wagner R, Tariverdian M, Benner A, Schwitalle Y, Kuchenbuch B, von Knebel DM. Beta2–microglobulin mutations in microsatellite unstable

- colorectal tumors. *Int J Cancer*. 2007; 121(2): 454–8. <https://doi.org/10.1002/ijc.22691>.
54. Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. *BMC Cancer*. 2007; 7: 33. <https://doi.org/10.1186/1471-2407-7-33>.
55. Echterdiek F, Janikovits J, Staffa L, Muller M, Lahrmann B, Fruhschutz M, Hartog B, Nelius N, Benner A, Tariverdian M, von Knebel DM, Grabe N, Kloor M. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. *Oncoimmunology*. 2016; 5(2): e1075692. <https://doi.org/10.1080/2162402X.2015.1075692>.
56. Tikidzhieva A, Benner A, Michel S, Formentini A, Link KH, Dippold W, von Knebel DM, Kornmann M, Kloor M. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. *Br J Cancer*. 2012; 106(6): 1239–45. <https://doi.org/10.1038/bjc.2012.53>.
57. Koelzer VH, Baker K, Kassahn D, Baumhoer D, Zlobec I. Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. *J Clin Pathol*. 2012; 65(11): 996–1002. <https://doi.org/10.1136/jclinpath-2012-200742>.
58. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel DM. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. *Cancer Res*. 2005; 65(14): 6418–24. <https://doi.org/10.1158/0008-5472.CAN-05-0044>.
59. Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel DM, Ferrone S, Kloor M. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. *Int J Cancer*. 2010; 127(4): 889–98. <https://doi.org/10.1002/ijc.25106>.
60. Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel DM, Kloor M. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. *Cancer Immunol Immunother*. 2014. <https://doi.org/10.1007/s00262-014-1638-4>.
61. Stelloo E, Versluis MA, Nijman HW, de Bruyn M, Plat A, Osse EM, van Dijk RH, Nout RA, Creutzberg CL, de Bock GH, Smit VT, Bosse T, Hollema H. Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. *Oncotarget*. 2016; 7(26): 39885–93. <https://doi.org/10.18632/oncotarget.9414>.
62. Llosa NJ, Cruise M, Tam A, Wick EC, Hechenbleikner EM, Taube JM, Blosser L, Fan H, Wang H, Lubner B, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov*. 2014. <https://doi.org/10.1158/2159-8290.CD-14-0863>.
63. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. *Science*. 2013; 339(6127): 1546–58. <https://doi.org/10.1126/science.1235122>.
64. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012; 487(7407): 330–7. <https://doi.org/10.1038/nature11252>.
65. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*. 2012; 12(4): 252–64. <https://doi.org/10.1038/nrc3239>.
66. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomicic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature*. 2014; 515(7528): 568–71. <https://doi.org/10.1038/nature13954>.
67. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011; 378(9809): 2081–7. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0).
68. Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis e Sousa C. Cyclooxygenase-dependent tumor growth through evasion of immunity. *Cell*. 2015; 162(6): 1257–70. <https://doi.org/10.1016/j.cell.2015.08.015>.

第24章

1. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. *Iowa Orthop J*.

- 2006; 26: 154–8.
2. Sell S. Cancer immunotherapy: breakthrough or ‘deja vu, all over again’? *Tumour Biol.* 2017; 39: 1010428317707764.
 3. Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. *Cancer Biol Med.* 2015; 12: 74–8.
 4. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? *BMC Med.* 2016; 14: 73.
 5. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. *Discov Med.* 2013; 15: 301–8.
 6. Bourdais R, Rousseau B, Pujals A, et al. Polymerase proofreading domain mutations: new opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. *Crit Rev Oncol Hematol.* 2017; 113: 242–8.
 7. Nystal E, Fernandez-Fernandez N, Vivas S, Olcoz JL. Factors determining colorectal cancer: the role of the intestinal microbiota. *Front Oncol.* 2015; 5: 220.
 8. Triantafyllidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. *Anticancer Res.* 2009; 29: 2727–37.
 9. Hong S, Lee HJ, Kim SJ, Hahn KB. Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. *World J Gastroenterol.* 2010; 16: 2080–93.
 10. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. *Am J Gastroenterol.* 2011; 106: 1340–50.
 11. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. *N Engl J Med.* 2005; 353: 2654–66.
 12. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science.* 2006; 313: 1960–4.
 13. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. *J Clin Oncol.* 2009; 27: 5944–51.
 14. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. *J Pathol.* 2014; 232: 199–209.
 15. Galon J, Mlecnik B, Marliot F, et al. Validation of the immunoscore (IM) as a prognostic marker in stage I / II / III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. *J Clin Oncol.* 2016; 34. (suppl; abstr 3500).
 16. Kwak Y, Koh J, Kim DW, Kang SB, Kim WH, Lee HS. Immunoscore encompassing CD3+and CD8+T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer. *Oncotarget.* 2016; 7: 81778–90.
 17. Sandel MH, Dadabayev AR, Menon AG, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. *Clin Cancer Res.* 2005; 11: 2576–82.
 18. Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. Intratumoral FoxP3+Helios+Regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer. *Front Immunol.* 2017; 8: 619.
 19. Rozek LS, Schmit SL, Greenson JK, et al. Tumor-infiltrating lymphocytes, Crohn’s-like lymphoid reaction, and survival from colorectal cancer. *J Natl Cancer Inst.* 2016; 108.
 20. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. *J Clin Oncol.* 2000; 18: 148–57.
 21. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. *Lancet.* 1999; 353: 345–50.
 22. Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. *Vaccine.* 2005; 23: 2379–87.
 23. de Weger VA, Turksma AW, Voorham QJ, et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-unstable colon cancer. *Clin Cancer Res.* 2012; 18: 882–9.
 24. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. *Cancer Immunol Immunother.* 2009; 58: 61–9.
 25. Zheng L, Edil BH, Soares KC, et al. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factorproducing bystander cell line in patients with

- metastatic colorectal cancer. *Ann Surg Oncol*. 2014; 21: 3931–7.
26. Senzer N, Barve M, Kuhn J, et al. Phase I trial of ‘bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell’ vaccine (FANG) in advanced cancer. *Mol Ther*. 2012; 20: 679–86.
 27. Miyagi Y, Imai N, Sasatomi T, et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. *Clin Cancer Res*. 2001; 7: 3950–62.
 28. Speetjens FM, Kuppen PJ, Welters MJ, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. *Clin Cancer Res*. 2009; 15: 1086–95.
 29. Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. *Cancer Prev Res (Phila)*. 2013; 6: 18–26.
 30. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heatshock protein gp96 after liver resection for metastatic colorectal cancer. *Clin Cancer Res*. 2003; 9: 3235–45.
 31. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. *Clin Cancer Res*. 2002; 8: 2044–51.
 32. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. *Clin Cancer Res*. 2004; 10: 3273–81.
 33. Kameshima H, Tsuruma T, Torigoe T, et al. Immunogenic enhancement and clinical effect by type- I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. *Cancer Sci*. 2011; 102: 1181–7.
 34. Okuno K, Sugiura F, Hida JI, et al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. *Exp Ther Med*. 2011; 2: 73–9.
 35. Hazama S, Nakamura Y, Tanaka H, et al. A phase I trial study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). *J Transl Med*. 2014; 12: 108.
 36. Kibe S, Yutani S, Motoyama S, et al. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. *Cancer Immunol Res*. 2014; 2: 1154–62.
 37. Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. *Clin Cancer Res*. 1999; 5: 1331–8.
 38. Kavanagh B, Ko A, Venook A, et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. *J Immunother*. 2007; 30: 762–72.
 39. Toh HC, Wang WW, Chia WK, et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. *Clin Cancer Res*. 2009; 15: 7726–36.
 40. Gao D, Li C, Xie X, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. *PLoS One*. 2014; 9: e93886.
 41. Caballero-Banos M, Benitez-Ribas D, Tabera J, et al. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. *Eur J Cancer*. 2016; 64: 167–74.
 42. Chaurasiya S, Warner S. Viroimmunotherapy for colorectal cancer: clinical studies. *Biomedicine*. 2017; 5: 11.
 43. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. *J Clin Oncol*. 2005; 23: 720–31.
 44. Elkord E, Dangoor A, Drury NL, et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. *J Immunother*. 2008; 31: 820–9.
 45. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. *Clin Cancer Res*. 2007; 13: 4487–94.
 46. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. *Cancer Immunol Immunother*. 2008; 57: 977–86.
 47. Kaufman HL, Lenz HJ, Marshall J, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. *Clin Cancer Res*. 2008; 14: 4843–9.
 48. Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected

- metastatic colorectal cancer. *Ann Surg.* 2013; 258: 879–86.
49. Balint JP, Gabitzsch ES, Rice A, et al. Extended evaluation of a phase I/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-] -CEA(6D) vaccine in late-stage colorectal cancer. *Cancer Immunol Immunother.* 2015; 64: 977–87.
 50. Gardini A, Ercolani G, Riccobon A, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. *J Surg Oncol.* 2004; 87: 46–52.
 51. Zhen YH, Liu XH, Yang Y, et al. Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. *Cancer Immunol Immunother.* 2015; 64: 1083–93.
 52. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Mol Ther.* 2011; 19: 620–6.
 53. Tran E, Robbins PF, Lu YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. *N Engl J Med.* 2016; 375: 2255–62.
 54. Maoz A, Rennert G, Gruber SB. T-cell transfer therapy targeting mutant KRAS. *N Engl J Med.* 2017; 376: e11.
 55. Yu S, Li A, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. *J Hematol Oncol.* 2017; 10: 78.
 56. Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T-cell therapy of solid tumors. *Immunol Cell Biol.* 2017; 95: 356–63.
 57. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther.* 2010; 18: 843–51.
 58. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011; 144: 646–74.
 59. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. *Cancer Metastasis Rev.* 2017; 36: 43–50.
 60. Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. *J Clin Oncol.* 2010; 28: 3485–90.
 61. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med.* 2012; 366: 2443–54.
 62. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med.* 2012; 366: 2455–65.
 63. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *J Clin Oncol.* 2010; 28: 3167–75.
 64. Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. *Clin Cancer Res.* 2013; 19: 462–8.
 65. Hermel D, Sigal D. ‘Check’ -ing the data: a review of immune checkpoint inhibitor biomarkers. *Personalized medicine in. Oncology.* 2016; 5: 234–40.
 66. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N Engl J Med.* 2014; 371: 2189–99.
 67. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science.* 2015; 350: 207–11.
 68. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science.* 2015; 348: 124–8.
 69. Boland CR, Goel A. Microsatellite instability in colorectal cancer. *Gastroenterology.* 2010; 138: 2073–87. e3.
 70. Timmermann B, Kerick M, Roehr C, et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. *PLoS One.* 2010; 5: e15661.
 71. Maby P, Tougeron D, Hamieh M, et al. Correlation between density of CD8+T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. *Cancer Res.* 2015; 75: 3446–55.
 72. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015; 372: 2509–20.
 73. Diaz LA, Marabelle A, Delord J, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. *J Clin Oncol.* 2017; 35. (suppl; abstr 3071).

74. Overman MJ, Lonardi S, Leone F, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. *J Clin Oncol.* 2017; 35. (suppl; abstr 591).
75. Bendell JC, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). *J Clin Oncol.* 2016; 34. (suppl; abstr 3502).

第25章

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017;67(1): 7–30.
2. Bailey CE, CY H, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. *JAMA Surg.* 2015;150(1): 17–22.
3. Jaspersion KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. *Gastroenterology.* 2010;138(6): 2044–58.
4. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. *JAMA Oncol.* 2017;3(4): 464–471.
5. Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. *J Clin Oncol.* 2015;33(31): 3544–9.
6. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med.* 2015;372(26): 2509–20.
7. Fearon ER. Molecular genetics of colorectal cancer. *Annu Rev Pathol.* 2011;6: 479–507.
8. Vilar E, Taberero J. Molecular dissection of microsatellite instable colorectal cancer. *Cancer Discov.* 2013;3(5): 502–11.
9. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. *J Natl Cancer Inst.* 2011;103(11): 863–75.
10. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. *J Clin Oncol.* 2005;23(3): 609–18.
11. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. *J Clin Oncol.* 2010;28(3): 466–74.
12. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence. *Nat Rev Clin Oncol.* 2010;7(3): 153–62.
13. Tejpar S, Bosman F, Delorenzi M, Fiocca R, Yan P, Klingbiel D, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3–EORTC 40993–SAKK 60/00 trial). *ASCO Meet Abstr.* 2009;27(15S): 4001.
14. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. *Cancer.* 2011;117(20): 4623–32.
15. Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. *N Engl J Med.* 2009;361(1): 98–9.
16. Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol.* 2011;29(15): 2011–9.
17. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. *J Clin Oncol.* 2011;29(19): 2675–82.
18. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. *Clin Cancer Res.* 2012;18(3): 890–900.
19. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. *Cancer Epidemiol Biomark Prev.* 2012;21(10): 1792–8.
20. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. *Eur J Cancer.* 2009;45(10): 1890–6.
21. Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, et al. Confirmation of deficient mismatch

- repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. *J Clin Oncol (Meet Abstr)*. 2008;26(15 Suppl): 4008.
22. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. *Int J Cancer*. 2002;101(1): 23-31.
 23. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. *Cancer Res*. 2001;61(17): 6555-62.
 24. Vilar E, Scaltriti M, Balmana J, Saura C, Guzman M, Arribas J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. *Br J Cancer*. 2008;99(10): 1607-12.
 25. Rodriguez R, Hansen LT, Phear G, Scorch J, Spang-Thomsen M, Cox A, et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+cells and tumors containing a mutation of MRE11. *Clin Cancer Res*. 2008;14(17): 5476-83.
 26. Fallik D, Borriani F, Boige V, Viguier J, Jacob S, Miquel C, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. *Cancer Res*. 2003;63(18): 5738-44.
 27. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. *J Clin Oncol*. 2009;27(11): 1814-21.
 28. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. *Br J Cancer*. 2009;100(2): 266-73.
 29. Des Guetz G, Uzzan B, Nicolas P, Schischmanoff O, Perret GY, Morere JF. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. *Anticancer Res*. 2009;29(5): 1615-20.
 30. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. *Cancer*. 2001;91(12): 2417-22.
 31. Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, et al. Pathologic predictors of microsatellite instability in colorectal cancer. *Am J Surg Pathol*. 2009;33(1): 126-33.
 32. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. *Cancer Discov*. 2015;5(1): 16-8.
 33. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012;487(7407): 330-7.
 34. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Cancer Discov*. 2015;5(1): 43-51.
 35. Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, et al. Leveraging premalignant biology for immune-based cancer prevention. *Proc Natl Acad Sci U S A*. 2016;113: 10750-8.
 36. Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz HJ, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. *J Clin Oncol*. 2016;34(suppl; abstr 3501).
 37. Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. *J Clin Oncol*. 2017;35(suppl 4S; abstract 519).
 38. National Comprehensive Cancer Network. Colon Cancer (Version 1.2017). 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
 39. Hackl H, Charoentong P, Finotello F, Trajanoski Z. Computational genomics tools for dissecting tumour-immune cell interactions. *Nat Rev Genet*. 2016;17(8): 441-58.
 40. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultrahypermutated cancers. *Nat Genet*. 2015;47(3): 257-62.
 41. Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. *Nat Rev Cancer*. 2016;16(2): 71-81.
 42. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. *J Clin Oncol*. 2016;34(19): 2206-11.

43. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, et al. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the-765G-> C COX-2 polymorphism. *Clin Cancer Res*. 2005;11(11): 4090-6.
44. Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. *Gut*. 2002;50(5): 636-41.
45. Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. *Best Pract Res Clin Gastroenterol*. 2011;25(4-5): 607-22.
46. Gallagher MC, Phillips RK, Bulow S. Surveillance and management of upper gastrointestinal disease in familial adenomatous polyposis. *Familial Cancer*. 2006;5(3): 263-73.
47. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. *Proc Natl Acad Sci*. 2002;99(3): 1521-6.
48. Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. *JAMA*. 2016;315(12): 1266-75.
49. Kuwada SK, Burt R. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome. *Familial Cancer*. 2011;10(3): 469-72.
50. Komiya T, Blumenthal GM, Ballas MS, Dechowdhury R, Manu M, Fioravanti S, et al. A pilot study of sirolimus (S) in subjects with Cowden syndrome (CS) with germ-line mutations in PTEN. *J Clin Oncol*. 2013;31(15_suppl): 2532.

第 26 章

All websites mentioned were downloaded February 2017.

第 27 章

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015; 136(5): E359-86. <https://doi.org/10.1002/ijc.29210>.
2. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. *Cancer Epidemiol Biomark Prev*. 2007; 16(11): 2331-43. <https://doi.org/10.1158/1055-9965.epi-07-0648>.
3. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol*. 2000; 151(4): 346-57.
4. Ireland P, Jolley D, Giles G, O'Dea K, Powles J, Rutishauser I, et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. *Asia Pac J Clin Nutr*. 1994; 3(1): 19-31.
5. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. *Cancer Epidemiol Biomark Prev*. 1998; 7(8): 719-24.
6. Miller G. immortalization of human lymphocytes by Epstein-Barr virus. *Yale J Biol Med*. 1982; 55(3-4): 305-10.
7. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. *J Clin Oncol*. 2002; 20(4): 1043-8. <https://doi.org/10.1200/jco.20.4.1043>.
8. Buchanan DD, Sweet K, Drini M, Jenkins MA, Win AK, English DR, et al. Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. *PLoS One*. 2010; 5(7): e11636. <https://doi.org/10.1371/journal.pone.0011636>
9. Buchanan DD, Win AK, Walsh MD, Walters RJ, Clendenning M, Nagler BN, et al. Family history of colorectal cancer in BRAF p.V600E mutated colorectal cancer cases. *Cancer Epidemiol Biomark Prev*. 2013; 22(5): 917-26. <https://doi.org/10.1158/1055-9965.epi-12-1211>.
10. Weisenberger DJ, Levine AJ, Long TI, Buchanan DD, Walters R, Clendenning M, et al. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. *Cancer Epidemiol Biomark Prev*. 2015; 24(3): 512-9. <https://doi.org/10.1158/1055-9965.EPI-14-1161>.
11. Levine AJ, Win AK, Buchanan DD, Jenkins MA, Baron JA, Young JP, et al. Cancer risks for the relatives of

- colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry. *Cancer Prev Res.* 2012; 5(2): 328–35. <https://doi.org/10.1158/1940-6207.CAPR-11-0419>.
12. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. *JAMA.* 2005; 293(16): 1979–85. <https://doi.org/10.1001/jama.293.16.1979>.
 13. The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012; 491(7422): 56–65. <https://doi.org/10.1038/nature11632>.
 14. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. *Hum Mutat.* 2013; 34(3): 490–7. <https://doi.org/10.1002/humu.22262>.
 15. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst.* 2010; 102(3): 193–201. <https://doi.org/10.1093/jnci/djp473>.
 16. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology.* 2008; 135(2): 419–28. <https://doi.org/10.1053/j.gastro.2008.04.026>.
 17. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol.* 2012; 30(9): 958–64. <https://doi.org/10.1200/jco.2011.39.5590>.
 18. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, et al. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. *Gastroenterology.* 2015; 149(6): 1446–53. <https://doi.org/10.1053/j.gastro.2015.07.052>.
 19. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut.* 2011; 60(7): 950–7. <https://doi.org/10.1136/gut.2010.228056>.
 20. Win AK, Parry S, Parry B, Kalady MF, Macrae FA, Ahnen DJ, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers. *Ann Surg Oncol.* 2013; 20(6): 1829–36. <https://doi.org/10.1245/s10434-012-2858-5>.
 21. Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. *J Natl Cancer Inst.* 2012; 104(18): 1363–72. <https://doi.org/10.1093/jnci/djs351>.
 22. Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. *Int J Cancer.* 2010; 127(11): 2678–84. <https://doi.org/10.1002/ijc.25501>.
 23. Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. *J Natl Cancer Inst.* 2013; 105(4): 274–9. <https://doi.org/10.1093/jnci/djs525>.
 24. Heath JA, Reece JC, Buchanan DD, Casey G, Durmo CA, Gallinger S, et al. Childhood cancers in families with and without Lynch syndrome. *Fam Cancer.* 2015; 14(4): 545–51. <https://doi.org/10.1007/s10689-015-9810-3>.
 25. Win AK, Dowty JG, Antill YC, English DR, Baron JA, Young JP, et al. Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers. *Obstet Gynecol.* 2011; 117(4): 899–905. <https://doi.org/10.1097/AOG.0b013e3182110ea3>.
 26. Win AK, Dowty JG, English DR, Campbell PT, Young JP, Winship I, et al. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. *Br J Cancer.* 2011; 105(1): 162–9. <https://doi.org/10.1038/bjc.2011.172>.
 27. Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, et al. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. *Clin Cancer Res.* 2010; 16(4): 1331–9. <https://doi.org/10.1158/1078-0432.ccr-09-1877>.
 28. Dashti SG, Buchanan DD, Jayasekara H, Ait Ouakrim D, Clendenning M, Rosty C, et al. Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers. *Cancer Epidemiol Biomark Prev.* 2017; 26(3): 366–75. <https://doi.org/10.1158/1055-9965.epi-16-0496>.
 29. Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. *J Natl Cancer Inst.* 2015; 107(9). <https://doi.org/10.1093/jnci/djv170>.
 30. Chau R, Dashti SG, Ait Ouakrim D, Buchanan DD, Clendenning M, Rosty C, et al. Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. *Int J Epidemiol.* 2016; 45(3): 940–53. <https://doi.org/10.1093/ije/dyw036>.

31. Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. *JAMA*. 2015; 314(1): 61–71. <https://doi.org/10.1001/jama.2015.6789>.
32. Win AK, Clendenning M, Crawford W, Rosty C, Preston SG, Southey MC, et al. Genetic variants within the hTERT gene and the risk of colorectal cancer in Lynch syndrome. *Genes Cancer*. 2015; 6(11–12): 445–51. <https://doi.org/10.18632/genesandcancer.85>.
33. Win AK, Reece JC, Buchanan DD, Clendenning M, Young JP, Cleary SP, et al. Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene. *Fam Cancer*. 2015; 14(4): 575–83. <https://doi.org/10.1007/s10689-015-9824-x>.
34. Win AK, Hopper JL, Buchanan DD, Young JP, Tenesa A, Dowty JG, et al. Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? *Eur J Cancer*. 2013; 49(7): 1578–87. <https://doi.org/10.1016/j.ejca.2013.01.029>.
35. Stupart D, Win AK, Jenkins M, Winship IM, Goldberg P, Ramesar R. Fertility and apparent genetic anticipation in Lynch syndrome. *Fam Cancer*. 2014; 13(3): 369–74. <https://doi.org/10.1007/s10689-014-9714-7>.
36. Stupart D, Win AK, Winship IM, Jenkins M. Fertility after young-onset colorectal cancer: a study of subjects with Lynch syndrome. *Colorectal Dis*. 2015; 17(9): 787–93. <https://doi.org/10.1111/codi.12940>.
37. Shiovitz S, Copeland WK, Passarelli MN, Burnett-Hartman AN, Grady WM, Potter JD, et al. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer. *Br J Cancer*. 2014; 111(3): 598–602. <https://doi.org/10.1038/bjc.2014.309>.
38. Walsh MD, Cummings MC, Pearson SA, Clendenning M, Walters RJ, Nagler B, et al. Lynch syndrome-associated breast cancers do not overexpress chromosome 11–encoded mucins. *Modern Pathol*. 2013; 26(7): 944–54. <https://doi.org/10.1038/modpathol.2012.232>.
39. Antill YC, Dowty JG, Win AK, Thompson T, Walsh MD, Cummings MC, et al. Lynch syndrome and cervical cancer. *Int J Cancer*. 2015; 137(11): 2757–61. <https://doi.org/10.1002/ijc.29641>.
40. Rosty C, Walsh MD, Lindor NM, Thibodeau SN, Mundt E, Gallinger S, et al. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the Colon Cancer Family Registry. *Fam Cancer*. 2014; 13(4): 573–82. <https://doi.org/10.1007/s10689-014-9744-1>.
41. Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, et al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. *Am J Surg Pathol*. 2013; 37(10): 1592–602. <https://doi.org/10.1097/PAS.0b013e31828f233d>.
42. Newton K, Jorgensen NM, Wallace AJ, Buchanan DD, Lalloo F, RF MM, et al. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). *J Med Genet*. 2014; 51(12): 789–96. <https://doi.org/10.1136/jmedgenet-2014-102552>.
43. Tomsic J, Senter L, Liyanarachchi S, Clendenning M, Vaughn CP, Jenkins MA, et al. Recurrent and founder mutations in the PMS2 gene. *Clin Genet*. 2013; 83(3): 238–43. <https://doi.org/10.1111/j.1399-0004.2012.01898.x>.
44. Win AK, Jenkins MA, Buchanan DD, Clendenning M, Young JP, Giles GG, et al. Determining the frequency of de novo germline mutations in DNA mismatch repair genes. *J Med Genet*. 2011; 48(8): 530–4. <https://doi.org/10.1136/jmedgenet-2011-100082>.
45. Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet*. 2014; 46(2): 107–15. <https://doi.org/10.1038/ng.2854>.
46. Thompson BA, Greenblatt MS, Vallee MP, Herkert JC, Tessereau C, Young EL, et al. Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. *Hum Mutat*. 2013; 34(1): 255–65. <https://doi.org/10.1002/humu.22214>.
47. Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. *Hum Mutat*. 2013; 34(1): 200–9. <https://doi.org/10.1002/humu.22213>.
48. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2017; 26(3): 404–12. <https://doi.org/10.1158/1055-9965.epi-16-0693>.
49. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. *Gastroenterology*. 2014; 146(5): 1208–11. <https://doi.org/10.1053/j.gastro.2014.01.022>.

50. Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. *Cancer Epidemiol Biomark Prev.* 2006; 15(2): 312–4. <https://doi.org/10.1158/1055-9965.epi-05-0793>.
51. Win AK, Reece JC, Dowty JG, Buchanan DD, Clendenning M, Rosty C, et al. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. *Int J Cancer.* 2016; 139(7): 1557–63. <https://doi.org/10.1002/ijc.30197>.
52. Win AK, Cleary SP, Dowty JG, Baron JA, Young JP, Buchanan DD, et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. *Int J Cancer.* 2011; 129(9): 2256–62. <https://doi.org/10.1002/ijc.25870>.
53. Phipps AI, Lindor NM, Jenkins MA, Baron JA, Win AK, Gallinger S, et al. Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry. *Dis Colon Rectum.* 2013; 56(8): 937–44. <https://doi.org/10.1097/DCR.0b013e31828f9a57>.
54. Lynch PM. Colorectal cancer survival by location and microsatellite status: data from the Colon Cancer Family Registries and their implications. *Dis Colon Rectum.* 2013; 56(8): 935–6. <https://doi.org/10.1097/DCR.0b013e31828f9954>.
55. Phipps AI, Buchanan DD, Makar KW, Burnett-Hartman AN, Coghill AE, Passarelli MN, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. *Cancer Epidemiol Biomark Prev.* 2012; 21(10): 1792–8. <https://doi.org/10.1158/1055-9965.epi-12-0674>.
56. Levine AJ, Phipps AI, Baron JA, Buchanan DD, Ahnen DJ, Cohen SA, et al. Clinicopathologic risk factor distributions for *MLH1* promoter region methylation in CIMP-positive tumors. *Cancer Epidemiol Biomark Prev.* 2016; 25(1): 68–75. <https://doi.org/10.1158/1055-9965.epi-15-0935>.
57. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, et al. Association between molecular subtypes of colorectal cancer and patient survival. *Gastroenterology.* 2015; 148(1): 77–87. e2. <https://doi.org/10.1053/j.gastro.2014.09.038>.
58. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. *Br J Cancer.* 2013; 108(8): 1757–64. <https://doi.org/10.1038/bjc.2013.118>.
59. Phipps AI, Ahnen DJ, Cheng I, Newcomb PA, Win AK, Burnett T. PIK3CA somatic mutation status in relation to patient and tumor factors in racial/ethnic minorities with colorectal cancer. *Cancer Epidemiol Biomark Prev.* 2015; 24(7): 1046–51. <https://doi.org/10.1158/1055-9965.epi-15-0204>.
60. Loo LW, Tiirikainen M, Cheng I, Lum-Jones A, Seifried A, Church JM, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer. *Genes Chromosomes Cancer.* 2013; 52(5): 450–66. <https://doi.org/10.1002/gcc.22043>.
61. Passarelli MN, Coghill AE, Hutter CM, Zheng Y, Makar KW, Potter JD, et al. Common colorectal cancer risk variants in *SMAD7* are associated with survival among prediagnostic nonsteroidal anti-inflammatory drug users: a population-based study of postmeno-pausal women. *Genes Chromosomes Cancer.* 2011; 50(11): 875–86. <https://doi.org/10.1002/gcc.20913>.
62. Slattery ML, Curtin K, Poole EM, Duggan DJ, Samowitz WS, Peters U, et al. Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. *Int J Cancer.* 2011; 128(11): 2726–34. <https://doi.org/10.1002/ijc.25721>.
63. Coghill AE, Newcomb PA, Poole EM, Hutter CM, Makar KW, Duggan D, et al. Genetic variation in inflammatory pathways is related to colorectal cancer survival. *Clin Cancer Res.* 2011; 17(22): 7139–47. <https://doi.org/10.1158/1078-0432.ccr-11-1134>.
64. Passarelli MN, Newcomb PA, Makar KW, Burnett-Hartman AN, Phipps AI, David SP, et al. No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women. *Menopause.* 2014; 21(4): 415–20. <https://doi.org/10.1097/GME.0b013e31829e498d>.
65. Passarelli MN, Phipps AI, Potter JD, Makar KW, Coghill AE, Wernli KJ, et al. Common single-nucleotide polymorphisms in the estrogen receptor beta promoter are associated with colorectal cancer survival in postmenopausal women. *Cancer Res.* 2013; 73(2): 767–75. <https://doi.org/10.1158/0008-5472.can-12-2484>.
66. Phipps AI, Ahnen DJ, Campbell PT, Win AK, Jenkins MA, Lindor NM, et al. Family history of colorectal cancer is not associated with colorectal cancer survival regardless of microsatellite instability status. *Cancer Epidemiol Biomark Prev.* 2014; 23(8): 1700–4. <https://doi.org/10.1158/1055-9965.epi-14-0533>.
67. Adams SV, Ahnen DJ, Baron JA, Campbell PT, Gallinger S, Grady WM, et al. Survival after inflammatory bowel

- disease-associated colorectal cancer in the Colon Cancer Family Registry. *World J Gastroenterol.* 2013; 19(21): 3241–8. <https://doi.org/10.3748/wjg.v19.i21.3241>.
68. Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. *Cancer Epidemiol Biomark Prev.* 2015; 24(8): 1229–38. <https://doi.org/10.1158/1055-9965.epi-15-0094>.
 69. Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. *Cancer.* 2011; 117(21): 4948–57. <https://doi.org/10.1002/cncr.26114>.
 70. Phipps AI, Robinson JR, Campbell PT, Win AK, Figueiredo JC, Lindor NM, et al. Prediagnostic alcohol consumption and colorectal cancer survival: the Colon Cancer Family Registry. *Cancer.* 2016. <https://doi.org/10.1002/cncr.30446>.
 71. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. *Gut.* 2011; 60(4): 491–8. <https://doi.org/10.1136/gut.2010.221143>.
 72. Coghill AE, Newcomb PA, Chia VM, Zheng Y, Wernli KJ, Passarelli MN, et al. Pre-diagnostic NSAID use but not hormone therapy is associated with improved colorectal cancer survival in women. *Br J Cancer.* 2011; 104(5): 763–8. <https://doi.org/10.1038/sj.bjc.6606041>.
 73. Hardikar S, Newcomb PA, Campbell PT, Win AK, Lindor NM, Buchanan DD, et al. Prediagnostic physical activity and colorectal cancer survival: overall and stratified by tumor characteristics. *Cancer Epidemiol Biomark Prev.* 2015; 24(7): 1130–7. <https://doi.org/10.1158/1055-9965.epi-15-0039>.
 74. Jayasekara H, Reece JC, Buchanan DD, Rosty C, Dashti SG, Ait Ouakrim D, et al. Risk factors for metachronous colorectal cancer following a primary colorectal cancer: a prospective cohort study. *Int J Cancer.* 2016; 139(5): 1081–90. <https://doi.org/10.1002/ijc.30153>.
 75. Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P. Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. *Am J Epidemiol.* 2010; 172(9): 1000–14. <https://doi.org/10.1093/aje/kwq245>.
 76. Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, JR ML, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. *J Natl Cancer Inst.* 2010; 102(6): 391–400. <https://doi.org/10.1093/jnci/djq011>.
 77. Wernli KJ, Wang Y, Zheng Y, Potter JD, Newcomb PA. The relationship between gravidity and parity and colorectal cancer risk. *J Women's Health.* 2009; 18(7): 995–1001. <https://doi.org/10.1089/jwh.2008.1068>.
 78. Boardman LA, Morlan BW, Rabe KG, Petersen GM, Lindor NM, Nigon SK, et al. Colorectal cancer risks in relatives of young-onset cases: is risk the same across all first-degree relatives? *Clin Gastroenterol Hepatol.* 2007; 5(10): 1195–8. <https://doi.org/10.1016/j.cgh.2007.06.001>.
 79. Lindor NM, Rabe KG, Petersen GM, Chen H, Bapat B, Hopper J, et al. Parent of origin effects on age at colorectal cancer diagnosis. *Int J Cancer.* 2010; 127(2): 361–6. <https://doi.org/10.1002/ijc.25037>.
 80. Gong J, Hutter CM, Newcomb PA, Ulrich CM, Bien SA, Campbell PT, et al. Genome-wide interaction analyses between genetic variants and alcohol consumption and smoking for risk of colorectal cancer. *PLoS Genet.* 2016; 12(10): e1006296. <https://doi.org/10.1371/journal.pgen.1006296>.
 81. Makar KW, Poole EM, Resler AJ, Seufert B, Curtin K, Kleinstein SE, et al. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. *Cancer Causes Control.* 2013; 24(12): 2059–75. <https://doi.org/10.1007/s10552-013-0282-1>.
 82. Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. *JAMA.* 2015; 313(11): 1133–42. <https://doi.org/10.1001/jama.2015.1815>.
 83. Resler AJ, Makar KW, Heath L, Whitton J, Potter JD, Poole EM, et al. Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry. *Carcinogenesis.* 2014; 35(9): 2121–6. <https://doi.org/10.1093/carcin/bgu119>.
 84. Scherer D, Koepf LM, Poole EM, Balavarca Y, Xiao L, Baron JA, et al. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon Cancer Family Registry. *Genes Chromosomes Cancer.* 2014; 53(7): 568–78. <https://doi.org/10.1002/gcc.22167>.
 85. Seufert BL, Poole EM, Whitton J, Xiao L, Makar KW, Campbell PT, et al. IkappaBkbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. *Carcinogenesis.* 2013; 34(1): 79–85. <https://doi.org/10.1093/carcin/bgs296>.

86. Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. *Cancer Causes Control*. 2007; 18(7): 723–33. <https://doi.org/10.1007/s10552-007-9015-7>.
87. Campbell PT, Cotterchio M, Klar N, JR ML, Gallinger S. Colorectal cancer risk among postmenopausal hormone users in a population-based familial case-control study. *Ann Epidemiol*. 2003; 13(8): 562. [https://doi.org/10.1016/S1047-2797\(03\)00144-3](https://doi.org/10.1016/S1047-2797(03)00144-3).
88. Garcia-Albeniz X, Rudolph A, Hutter C, White E, Lin Y, Rosse SA, et al. CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk. *Br J Cancer*. 2016; 114(2): 221–9. <https://doi.org/10.1038/bjc.2015.443>.
89. Figueiredo J, Levine A, Lee W, Conti D, Poynter J, Campbell P, et al. Genes involved with folate uptake and distribution and their association with colorectal cancer risk. *Cancer Causes Control*. 2010; 21(4): 597–608. <https://doi.org/10.1007/s10552-009-9489-6>.
90. Levine AJ, Figueiredo JC, Lee W, Poynter JN, Conti D, Duggan DJ, et al. Genetic variability in the MTHFR gene and Colorectal cancer risk using the Colorectal Cancer Family Registry. *Cancer Epidemiol Biomark Prev*. 2010; 19(1): 89–100. <https://doi.org/10.1158/1055-9965.epi-09-0727>.
91. Levine AJ, Figueiredo JC, Lee W, Conti DV, Kennedy K, Duggan DJ, et al. A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. *Cancer Epidemiol Biomark Prev*. 2010; 19(7): 1812–21. <https://doi.org/10.1158/1055-9965.EPI-10-0151>.
92. Kim HS, Newcomb PA, Ulrich CM, Keener CL, Bigler J, Farin FM, et al. Vitamin D receptor polymorphism and the risk of colorectal adenomas. *Cancer Epidemiol Biomark Prev*. 2001; 10(8): 869–74.
93. Poynter JN, Jacobs ET, Figueiredo JC, Lee WH, Conti DV, Campbell PT, et al. Genetic variation in the vitamin D receptor (VDR) and the vitamin D-binding protein (GC) and risk for colorectal cancer: results from the Colon Cancer Family Registry. *Cancer Epidemiol Biomark Prev*. 2010; 19(2): 525–36. <https://doi.org/10.1158/1055-9965.EPI-09-0662>.
94. Sun Z, Wang PP, Roebathan B, Cotterchio M, Green R, Buehler S et al. Calcium and vitamin D and risk of colorectal cancer: results from a large population-based case-control study in Newfoundland and Labrador and Ontario. *Can J Public Health*. 2011; 102(5): 382–9.
95. Hiraki LT, Qu C, Hutter CM, Baron JA, Berndt SI, Bezieau S, et al. Genetic predictors of circulating 25-hydroxyvitamin d and risk of colorectal cancer. *Cancer Epidemiol Biomark Prev*. 2013; 22(11): 2037–46. <https://doi.org/10.1158/1055-9965.epi-13-0209>.
96. Du M, Zhang X, Hoffmeister M, Schoen RE, Baron JA, Berndt SI, et al. No evidence of gene-calcium interactions from genome-wide analysis of colorectal cancer risk. *Cancer Epidemiol Biomark Prev*. 2014; 23(12): 2971–6. <https://doi.org/10.1158/1055-9965.epi-14-0893>.
97. Joshi AD, Corral R, Siegmund KD, Haile RW, Le Marchand L, Martinez ME, et al. Red meat and poultry intake, polymorphisms in the nucleotide excision repair and mismatch repair pathways and colorectal cancer risk. *Carcinogenesis*. 2009; 30(3): 472–9. <https://doi.org/10.1093/carcin/bgn260>.
98. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. *Cancer Epidemiol Biomark Prev*. 2008; 17(11): 3098–107. <https://doi.org/10.1158/1055-9965.epi-08-0341>.
99. Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. *Cancer Epidemiol Biomark Prev*. 2007; 16(12): 2697–703. <https://doi.org/10.1158/1055-9965.EPI-07-0467>.
100. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A, Harper P. Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. *J Nutr*. 2006; 136(12): 3046–53.
101. Sun Z, Zhu Y, Wang PP, Roebathan B, Zhao J, Dicks E, et al. Reported intake of selected micronutrients and risk of colorectal cancer: results from a large population-based case-control study in Newfoundland, Labrador and Ontario, Canada. *Anticancer Res*. 2012; 32(2): 687–96.
102. Thrift AP, Gong J, Peters U, Chang-Claude J, Rudolph A, Slattery ML, et al. Mendelian randomization study of height and risk of colorectal cancer. *Int J Epidemiol*. 2015; 44(2): 662–72. <https://doi.org/10.1093/ije/dyv082>.
103. Thrift AP, Gong J, Peters U, Chang-Claude J, Rudolph A, Slattery ML, et al. Mendelian randomization study of body mass index and colorectal cancer risk. *Cancer Epidemiol Biomark Prev*. 2015; 24(7): 1024–31. <https://doi.org/10.1158/1055-9965.epi-14-1309>.
104. Jarvis D, Mitchell JS, Law PJ, Palin K, Tuupainen S, Gylfe A, et al. Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer. *Br J Cancer*. 2016; 115(2): 266–72. <https://doi.org/10.1038/bjc.2015.443>.

- org/10.1038/bjc.2016.188.
105. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. *Nat Genet.* 2008; 40(12): 1426–35. <https://doi.org/10.1038/ng.262>.
 106. Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et al. Genomewide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat Genet.* 2008; 40(5): 631–7. <https://doi.org/10.1038/ng.133>.
 107. Poynter JN, Figueiredo JC, Conti DV, Kennedy K, Gallinger S, Siegmund KD, et al. Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. *Cancer Res.* 2007; 67(23): 11128–32. <https://doi.org/10.1158/0008-5472.can-07-3239>.
 108. Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, et al. Genome-wide association study of colorectal cancer identifies six new susceptibility loci. *Nat Commun.* 2015; 6: 7138. <https://doi.org/10.1038/ncomms8138>.
 109. Al-Tassan NA, Whiffin N, Hosking FJ, Palles C, Farrington SM, Dobbins SE, et al. A new GWAS and meta-analysis with 1000 Genomes imputation identifies novel risk variants for colorectal cancer. *Sci Rep.* 2015; 5: 10442. <https://doi.org/10.1038/srep10442>.
 110. Cheng I, Kocarnik JM, Dumitrescu L, Lindor NM, Chang-Claude J, Avery CL, et al. Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. *Gut.* 2014; 63(5): 800–7. <https://doi.org/10.1136/gutjnl-2013-305189>.
 111. Cheng TH, Thompson D, Painter J, O'Mara T, Gorman M, Martin L, et al. Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. *Sci Rep.* 2015; 5: 17369. <https://doi.org/10.1038/srep17369>.
 112. Lemire M, Qu C, Loo LW, Zaidi SH, Wang H, Berndt SI, et al. A genome-wide association study for colorectal cancer identifies a risk locus in 14q23.1. *Hum Genet.* 2015; 134(11–12): 1249–62. <https://doi.org/10.1007/s00439-015-1598-6>.
 113. Whiffin N, Hosking FJ, Farrington SM, Palles C, Dobbins SE, Zgaga L, et al. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis. *Hum Mol Genet.* 2014; 23(17): 4729–37. <https://doi.org/10.1093/hmg/ddu177>.
 114. Zeng C, Matsuda K, Jia WH, Chang J, Kweon SS, Xiang YB, et al. Identification of susceptibility loci and genes for colorectal cancer risk. *Gastroenterology.* 2016; 150(7): 1633–45. <https://doi.org/10.1053/j.gastro.2016.02.076>.
 115. Jia WH, Zhang B, Matsuo K, Shin A, Xiang YB, Jee SH, et al. Genome-wide association analyses in east Asians identify new susceptibility loci for colorectal cancer. *Nat Genet.* 2013; 45(2): 191–6. <https://doi.org/10.1038/ng.2505>.
 116. Wang H, Haiman CA, Burnett T, Fortini BK, Kolonel LN, Henderson BE, et al. Fine-mapping of genome-wide association study-identified risk loci for colorectal cancer in African Americans. *Hum Mol Genet.* 2013; 22(24): 5048–55. <https://doi.org/10.1093/hmg/ddt337>.
 117. Wang H, Burnett T, Kono S, Haiman CA, Iwasaki M, Wilkens LR, et al. Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A. *Nat Commun.* 2014; 5: 4613. <https://doi.org/10.1038/ncomms5613>.
 118. Dunlop MG, Tenesa A, Farrington SM, Ballereau S, Brewster DH, Koessler T, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. *Gut.* 2013; 62(6): 871–81. <https://doi.org/10.1136/gutjnl-2011-300537>.
 119. Roberts A, Nancarrow D, Clendenning M, Buchanan DD, Jenkins MA, Duggan D, et al. Linkage to chromosome 2q32.2–q33.3 in familial serrated neoplasia (Jass syndrome). *Fam Cancer.* 2011; 10(2): 245–54. <https://doi.org/10.1007/s10689-010-9408-8>.
 120. Zogopoulos G, Jorgensen C, Bacani J, Montpetit A, Lepage P, Ferretti V, et al. Germline EPHB2 receptor variants in familial colorectal cancer. *PLoS One.* 2008; 3(8): e2885. <https://doi.org/10.1371/journal.pone.0002885>.
 121. Young J, Jass JR. The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. *Cancer Epidemiol Biomark Prev.* 2006; 15(10): 1778–84. <https://doi.org/10.1158/1055-9965.epi-06-0164>.
 122. Young J, Jenkins M, Parry S, Young B, Nancarrow D, English D, et al. Serrated pathway colorectal cancer in the population: genetic consideration. *Gut.* 2007; 56(10): 1453–9. <https://doi.org/10.1136/gut.2007.126870>.
 123. Yeoman A, Young J, Arnold J, Jass J, Parry S. Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry. *N Z Med J.* 2007; 120(1266): U2827.

124. Jiang X, Castelao JE, Vandenberg D, Carracedo A, Redondo CM, Conti DV, et al. Genetic variations in *SMAD7* are associated with colorectal cancer risk in the Colon Cancer Family Registry. *PLoS One*. 2013; 8(4): e60464. <https://doi.org/10.1371/journal.pone.0060464>.
125. Chang CM, Chia VM, Gunter MJ, Zanetti KA, Ryan BM, Goodman JE, et al. Innate immunity gene polymorphisms and the risk of colorectal neoplasia. *Carcinogenesis*. 2013; 34(11): 2512–20. <https://doi.org/10.1093/carcin/bgt228>.
126. Wang H, Taverna D, Stram DO, Fortini BK, Cheng I, Wilkens LR, et al. Genetic variation in the inflammation and innate immunity pathways and colorectal cancer risk. *Cancer Epidemiol Biomark Prev*. 2013; 22(11): 2094–101. <https://doi.org/10.1158/1055-9965.epi-13-0694>.
127. Abbenhardt C, Poole EM, Kulmacz RJ, Xiao L, Curtin K, Galbraith RL, et al. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. *Int J Mol Epidemiol Genet*. 2013; 4(3): 140–9.
128. Akbari MR, Anderson LN, Buchanan DD, Clendenning M, Jenkins MA, Win AK, et al. Germline HOXB13 p.Gly84Glu mutation and risk of colorectal cancer. *Cancer Epidemiol*. 2013; 37(4): 424–7. <https://doi.org/10.1016/j.canep.2013.03.003>.
129. Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, et al. Germline *TP53* mutations in patients with early-onset colorectal cancer in the Colon Cancer Family Registry. *JAMA Oncol*. 2015; 1(2): 214–21. <https://doi.org/10.1001/jamaoncol.2015.0197>.
130. Bapat B, Lindor NM, Baron J, Siegmund K, Li L, Zheng Y, et al. The association of tumor microsatellite instability phenotype with family history of colorectal cancer. *Cancer Epidemiol Biomark Prev*. 2009; 18(3): 967–75. <https://doi.org/10.1158/1055-9965.EPI-08-0878>.
131. English DR, Young JP, Simpson JA, Jenkins MA, Southey MC, Walsh MD, et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. *Cancer Epidemiol Biomark Prev*. 2008; 17(7): 1774–80. <https://doi.org/10.1158/1055-9965.EPI-08-0091>.
132. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. *Nat Genet*. 2006; 38(7): 787–93. <https://doi.org/10.1038/ng1834>.
133. Kambara T, Simms LA, VLJ W, Spring KJ, CVA W, Walsh MD, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. *Gut*. 2004; 53(8): 1137–44. <https://doi.org/10.1136/gut.2003.037671>.
134. Hitchins M, Williams R, Cheong K, Halani N, Lin VAP, Packham D, et al. MLH1 Germline Epimutations as a factor in hereditary nonpolyposis colorectal cancer. *Gastroenterology*. 2005; 129(5): 1392–9. <https://doi.org/10.1053/j.gastro.2005.09.003>.
135. Coolbaugh-Murphy MI, Xu J, Ramagli LS, Brown BW, Siciliano MJ. Microsatellite instability (MSI) increases with age in normal somatic cells. *Mech Ageing Dev*. 2005; 126(10): 1051–9. <https://doi.org/10.1016/j.mad.2005.06.005>.
136. Kakar S, Burgart LJ, Thibodeau SN, Rabe KG, Petersen GM, Goldberg RM, et al. Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age. *Cancer*. 2003; 97(6): 1421–7. <https://doi.org/10.1002/cncr.11206>.
137. Savio AJ, Daftary D, Dicks E, Buchanan DD, Parfrey PS, Young JP, et al. Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. *BMC Cancer*. 2016; 16: 113. <https://doi.org/10.1186/s12885-016-2149-9>.
138. Walters RJ, Williamson EJ, English DR, Young JP, Rosty C, Clendenning M, et al. Association between hypermethylation of DNA repetitive elements in white blood cell DNA and earlyonset colorectal cancer. *Epigenetics*. 2013; 8(7): 748–55. <https://doi.org/10.4161/epi.25178>.
139. Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2016. <https://doi.org/10.1158/1055-9965.EPI-16-0693>.
140. Kastrinos F, Ojha RP, Leenen C, Alvero C, Mercado RC, Balmana J, et al. Comparison of prediction models for Lynch syndrome among individuals with colorectal cancer. *J Natl Cancer Inst*. 2016; 108(2). <https://doi.org/10.1093/jnci/djv308>.
141. Kastrinos F, Steyerberg EW, Balmana J, Mercado R, Gallinger S, Haile R, et al. Comparison of the clinical prediction model PREMM(1, 2, 6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. *Gut*. 2013; 62(2): 272–9. <https://doi.org/10.1136/gutjnl-2011-301265>.
142. Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, et al. The PREMM(1, 2, 6) model

- predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. *Gastroenterology*. 2011; 140(1): 73–81. <https://doi.org/10.1053/j.gastro.2010.08.021>.
143. Casey G, Lindor NM, Papadopoulos N, Thibodeau SN, Moskowitz J, Steelman S, et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. *JAMA*. 2005; 293(7): 799–809. <https://doi.org/10.1001/jama.293.7.799>.
 144. Cleary SP, Kim H, Croitoru ME, Redston M, Knight JA, Gallinger S, et al. Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk. *Dis Colon Rectum*. 2008; 51(10): 1467–73; discussion 1473–74. <https://doi.org/10.1007/s10350-008-9356-7>.
 145. Hahnloser D, Petersen GM, Rabe K, Snow K, Lindor NM, Boardman L, et al. The APC E1317Q variant in adenomatous polyps and colorectal cancers. *Cancer Epidemiol Biomark Prev*. 2003; 12(10): 1023–8.
 146. Jaskowski L, Young J, Jackson L, Arnold S, Barker MA, Walsh MD, et al. Stability of BAT26 in Lynch syndrome colorectal tumours. *Eur J Hum Genet*. 2007; 15(2): 139–41; author reply 41–2. <https://doi.org/10.1038/sj.ejhg.5201740>.
 147. Jenkins MA, Hayashi S, O’Shea AM, Burgart LJ, Smyrk TC, Shimizu D, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. *Gastroenterology*. 2007; 133(1): 48–56. <https://doi.org/10.1053/j.gastro.2007.04.044>.
 148. Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, et al. Germ-line DNA copy number variation frequencies in a large North American population. *Hum Genet*. 2007; 122(3–4): 345–53. <https://doi.org/10.1007/s00439-007-0404-5>.
 149. Clendenning M, Macrae FA, Walsh MD, Walters RJ, Thibodeau SN, Gunawardena SR, et al. Absence of *PMS2* mutations in Colon-CFR participants whose colorectal cancers demonstrate unexplained loss of MLH1 expression. *Clin Genet*. 2013; 83(6): 591–3. <https://doi.org/10.1111/cge.12011>.
 150. Clendenning M, Walsh MD, Gelpi JB, Thibodeau SN, Lindor N, Potter JD, et al. Detection of large scale 3’ deletions in the *PMS2* gene amongst Colon-CFR participants: have we been missing anything? *Fam Cancer*. 2013; 12(3): 563–6. <https://doi.org/10.1007/s10689-012-9597-4>.
 151. Cunningham JM, Johnson RA, Litzelman K, Skinner HG, Seo S, Engelman CD, et al. Telomere length varies by DNA extraction method: implications for epidemiologic research. *Cancer Epidemiol Biomark Prev*. 2013; 22(11): 2047–54. <https://doi.org/10.1158/1055-9965.epi-13-0409>.
 152. Boardman LA, Litzelman K, Seo S, Johnson RA, Vanderboom RJ, Kimmel GW, et al. The association of telomere length with colorectal cancer differs by the age of cancer onset. *Clinical and Translat Gastroenterol*. 2014; 5: e52. <https://doi.org/10.1038/ctg.2014.3>.
 153. Kuroiwa-Trzmielina J, Wang F, Rapkins RW, Ward RL, Buchanan DD, Win AK, et al. SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer. *Clin Cancer Res*. 2016; 22(24): 6266–77. <https://doi.org/10.1158/1078-0432.ccr-15-2765>.
 154. Uddin M, Thiruvahindrapuram B, Walker S, Wang Z, Hu P, Lamoureux S, et al. A high-resolution copy-number variation resource for clinical and population genetics. *Genet Med*. 2015; 17(9): 747–52. <https://doi.org/10.1038/gim.2014.178>.
 155. Win AK, Buchanan DD, Rosty C, RJ MI, Dowty JG, Dite GS, et al. Role of tumour molecular and pathology features to estimate colorectal cancer risk for first-degree relatives. *Gut*. 2015; 64(1): 101–10. <https://doi.org/10.1136/gutjnl-2013-306567>.
 156. Kim JS, Coyte PC, Cotterchio M, Keogh LA, Flander LB, Gaff C, et al. The impact of receiving predictive genetic information about Lynch syndrome on individual colonoscopy and smoking behaviors. *Cancer Epidemiol Biomark Prev*. 2016; 25(11): 1524–33. <https://doi.org/10.1158/1055-9965.epi-16-0346>.
 157. Esplen MJ, Wong J, Aronson M, Butler K, Rothenmund H, Semotiuk K, et al. Long-term psychosocial and behavioral adjustment in individuals receiving genetic test results in Lynch syndrome. *Clin Genet*. 2015; 87(6): 525–32. <https://doi.org/10.1111/cge.12509>.
 158. Graves KD, Sinicrope PS, Esplen MJ, Peterson SK, Patten CA, Lowery J, et al. Communication of genetic test results to family and health-care providers following disclosure of research results. *Genet Med*. 2014; 16(4): 294–301. <https://doi.org/10.1038/gim.2013.137>.
 159. Patel SG, Ahnen DJ, Kinney AY, Horick N, Finkelstein DM, Hill DA, et al. Knowledge and uptake of genetic counseling and colonoscopic screening among individuals at increased risk for Lynch syndrome and their endoscopists from the Family Health Promotion Project. *Am J Gastroenterol*. 2016; 111(2): 285–93. <https://doi.org/10.1038/ajg.2015.397>.
 160. Flander L, Speirs-Bridge A, Rutstein A, Niven H, Win AK, Ait Ouakrim D, et al. Perceived versus predicted risks

- of colorectal cancer and self-reported colonoscopies by members of mismatch repair gene mutation-carrying families who have declined genetic testing. *J Genet Couns.* 2014; 23(1): 79–88. <https://doi.org/10.1007/s10897-013-9614-2>.
161. Steel EJ, Trainer AH, Heriot AG, Lynch C, Parry S, Win AK, et al. The experience of extended bowel resection in individuals with a high metachronous colorectal cancer risk: a qualitative study. *Oncol Nurs Forum.* 2016; 43(4): 444–52. <https://doi.org/10.1188/16.onf.444-452>.
 162. Adams SV, Ceballos R, Newcomb PA. Quality of life and mortality of long-term colorectal cancer survivors in the Seattle Colorectal Cancer Family Registry. *PLoS One.* 2016; 11(6): e0156534. <https://doi.org/10.1371/journal.pone.0156534>.
 163. Howell LA, Brockman TA, Sinicrope PS, Patten CA, Decker PA, Ehlers SL, et al. Receptivity and preferences in cancer risk reduction lifestyle programs: a survey of colorectal cancer family members. *J Behav Health.* 2013; 2(4): 279–90. <https://doi.org/10.5455/jbh.20130921013627>.
 164. Lowery JT, Horick N, Kinney AY, Finkelstein DM, Garrett K, Haile RW, et al. A randomized trial to increase colonoscopy screening in members of high-risk families in the Colorectal Cancer Family Registry and Cancer Genetics Network. *Cancer Epidemiol Biomark Prev.* 2014; 23(4): 601–10. <https://doi.org/10.1158/1055-9965.epi-13-1085>.
 165. Bharati R, Jenkins MA, Lindor NM, Le Marchand L, Gallinger S, Haile RW, et al. Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? *Gynecol Oncol.* 2014; 133(2): 287–92. <https://doi.org/10.1016/j.ygyno.2014.03.011>.
 166. Ahsan H, Halpern J, Kibriya MG, Pierce BL, Tong L, Gamazon E, et al. A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. *Cancer Epidemiol Biomark Prev.* 2014; 23(4): 658–69. <https://doi.org/10.1158/1055-9965.epi-13-0340>.
 167. Anderson LN, Cotterchio M, Knight JA, Borgida A, Gallinger S, Cleary SP. Genetic variants in vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada. *PLoS One.* 2013; 8(6): e66768. <https://doi.org/10.1371/journal.pone.0066768>.
 168. Bosetti C, Lucenteforte E, Bracci PM, Negri E, Neale RE, Risch HA, et al. Ulcer, gastric surgery and pancreatic cancer risk: an analysis from the international pancreatic cancer casecontrol consortium (PanC4). *Ann Oncol.* 2013; 24(11): 2903–10. <https://doi.org/10.1093/annonc/mdt336>.
 169. Jang JH, Cotterchio M, Borgida A, Liu G, Gallinger S, Cleary SP. Interaction of polymorphisms in mitotic regulator genes with cigarette smoking and pancreatic cancer risk. *Mol Carcinog.* 2013; 52(Suppl 1): E103–9. <https://doi.org/10.1002/mc.22037>.
 170. Olson SH, Hsu M, Satagopan JM, Maisonneuve P, Silverman DT, Lucenteforte E, et al. Allergies and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer casecontrol consortium. *Am J Epidemiol.* 2013; 178(5): 691–700. <https://doi.org/10.1093/aje/kwt052>.
 171. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the international pancreatic cancer case-control consortium. *Ann Oncol.* 2014; 25(10): 2065–72. <https://doi.org/10.1093/annonc/mdu276>.
 172. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). *Dis Colon Rectum.* 1991; 34(5): 424–5.
 173. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. *Gastroenterology.* 1999; 116(6): 1453–6.
 174. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary non-polyposis colorectal cancer. *Gastroenterology* 2000; 118(5): 829–834.
 175. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet.* 2011; 378(9809): 2081–7. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0).
 176. Hopper JL. Disease-specific prospective family study cohorts enriched for familial risk. *Epidemiol Perspect Innov.* 2011; 8(1): 2. <https://doi.org/10.1186/1742-5573-8-2>.
 177. Cicek MS, Cunningham JM, Fridley BL, Serie DJ, Bamlet WR, Diergaarde B et al. Colorectal cancer linkage on chromosomes 4q21, 8q13, 12q24, and 15q22. *PLoS One.* 2012; 7(5): e38175. <https://doi.org/10.1371/journal.pone.0038175>.
 178. Neklason DW, Kerber RA, Nilson DB, Anton-Culver H, Schwartz AG, Griffin CA et al. Common familial

- colorectal cancer linked to chromosome 7q31: a genome-wide analysis. *Cancer Res.* 2008; 68(21): 8993–7. <https://doi.org/10.1158/0008-5472.can-08-1376>.
179. Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD et al. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. *Cancer Res.* 2010; 70(13): 5409–18. <https://doi.org/10.1158/0008-5472.can-10-0188>.
180. DeRycke MS, Gunawardena SR, Middha S, Asmann YW, Schaid DJ, McDonnell SK et al. Identification of novel variants in colorectal cancer families by high-throughput exome sequencing. *Cancer Epidemiol Biomarkers Prev.* 2013; 22(7): 1239–51. <https://doi.org/10.1158/1055-9965.epi-12-1226>.

第28章

1. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2017; 66(3): 464–472.
2. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. *Gut.* 2017; 66(9): 1657–1664.
3. Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut.* 2017 Jul 28. <https://doi.org/10.1136/gutjnl-2017-314057>.
4. Seppälä T, Pylvänäinen K, Evans DG, Järvinen H, Renkonen-Sinisalo L, Bernstein I, et al. Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. *Hered Cancer Clin Pract.* 2017; 10; 15: 18.
5. Sjursen W, Haukanes BI, Grindedal EM, Aarset H, Stormorken A, Engebretsen LF, et al. Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. *J Med Genet.* 2010; 47(9): 579–85. <https://doi.org/10.1136/jmg.2010.077677>. Epub 2010 Jun 28. PubMed PMID: 20587412; PubMed Central PMCID: PMC2976029.

第29章

1. Fokkema IF, Taschner PE, Schaafsma GC, et al. LOVD v. 2.0: the next generation in gene variant databases. *Hum Mutat.* 2011; 32(5): 557–63.
2. Announcement of LOVD statistics. <http://www.lovd.nl/3.0/home>. Accessed 22 Feb 2018.
3. Brookes AJ, Robinson PN. Human genotype-phenotype databases: aims, challenges and opportunities. *Nat Rev Genet.* 2015; 16(12): 702–15.
4. Bean L, Hegde MR. Gene variant databases and sharing: creating a global genomic variant database for personalized medicine. *Hum Mutat.* 2016; 37(6): 559–63.
5. Povey S, Al Aqeel AI, Cambon-Thomsen A, et al. Practical guidelines addressing ethical issues pertaining to the curation of human locus-specific variation databases (LSDBs). *Hum Mutat.* 2010; 31(11): 1179–84.
6. Rodriguez LL, Brooks LD, Greenberg JH, Green ED. The complexities of genomic identifiability. *Science.* 2013; 339(6117): 275–6.3.
7. Plazzer JP, Bernstein IT, Devereau A. Disclaimer statements for gene/disease specific databases. Human Variome Project. http://www.humanvariomeproject.org/assets/hvp-guidelines/HVP-GL-002-01-EN-Disclaimer_Statements_for_GDSDBs.pdf. Accessed 12 Apr 2017.
8. Rehm HL, Berg JS, Brooks LD, et al. ClinGen—the clinical genome resource. *N Engl J Med.* 2015; 372(23): 2235–42.
9. Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet.* 2014; 46(2): 107–15.
10. Velde KJ, Kuiper J, Thompson BA, et al. Evaluation of CADD scores in curated mismatch repair gene variants yields a model for clinical validation and prioritization. *Hum Mutat.* 2015; 36(7): 712–9.

第30章

1. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and

- MSH2 mutation carriers. *Hum Mutat.* 2013; 34(3): 490–7. <https://doi.org/10.1002/humu.22262>.
2. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. *J Med Genet.* 2005; 42(6): 491–6. <https://doi.org/10.1136/jmg.2004.024299>.
 3. Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA.* 2011; 305(22): 2304–10. <https://doi.org/10.1001/jama.2011.743>.
 4. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst.* 2010; 102(3): 193–201. <https://doi.org/10.1093/jnci/djp473>.
 5. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology.* 2008; 135(2): 419–28.e1. <https://doi.org/10.1053/j.gastro.2008.04.026>.
 6. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology.* 2009; 137(5): 1621–7. <https://doi.org/10.1053/j.gastro.2009.07.039>.
 7. Choi Y-H, Cotterchio M, McKeown-Eyssen G, Neerav M, Bapat B, Boyd K, et al. Penetrance of colorectal cancer among *MLH1/MSH2* carriers participating in the colorectal cancer familial registry in Ontario. *Hered Cancer Clin Pract.* 2009; 7: 14. <https://doi.org/10.1186/1897-4287-7-14>.
 8. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. *Hum Mol Genet.* 1997; 6(1): 105–10.
 9. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. *Gastroenterology.* 2005; 129(2): 415–21. <https://doi.org/10.1016/j.gastro.2005.05.011>.
 10. ten Broeke SW, Brohet RM, Tops CM, van der Klift HM, Velthuisen ME, Bernstein I, et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. *J Clin Oncol.* 2015; 33(4): 319–25. <https://doi.org/10.1200/jco.2014.57.8088>.
 11. Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2017; 66(3): 464–72. <https://doi.org/10.1136/gutjnl-2015-309675>.
 12. Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, et al. Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. *Hum Mutat.* 2009; 30(5): 757–70. <https://doi.org/10.1002/humu.20936>.
 13. Thompson BA, Goldgar DE, Paterson C, Clendenning M, Walters R, Arnold S, et al. A multifactorial likelihood model for MMR gene variant classification incorporating probabilities based on sequence bioinformatics and tumor characteristics: a report from the Colon Cancer Family Registry. *Hum Mutat.* 2013; 34(1): 200–9. <https://doi.org/10.1002/humu.22213>.
 14. Spurdle AB. Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. *Curr Opin Genet Dev.* 2010; 20(3): 315–23. <https://doi.org/10.1016/j.gde.2010.03.009>.
 15. Lindor N, Peterson G, Spurdle A, Thompson B, Goldgar D, Thibodeau S. Pancreatic cancer and a novel *MSH2* germline alteration. *Pancreas.* 2011; 40(7): 1138–40. <https://doi.org/10.1097/MPA.0b013e318220c217>.
 16. Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, et al. The phenotypic expression of three *MSH2* mutations in large Newfoundland families with Lynch syndrome. *Fam Cancer.* 2007; 6(1): 1–12. <https://doi.org/10.1007/s10689-006-0014-8>.
 17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer.* 2010; 127(12): 2893–917. <https://doi.org/10.1002/ijc.25516>.
 18. Le Marchand L. Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans. *J Natl Cancer Inst Monogr.* 1999; 26: 101–5.
 19. Park JG, Park YJ, Wijnen JT, Vasen HF. Gene-environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. *Int J Cancer.* 1999; 82(4): 516–9.
 20. van Vliet CM, Dowty JG, van Vliet JL, Smith L, Mead LJ, Macrae FA, et al. Dependence of colorectal cancer risk on the parent-of-origin of mutations in DNA mismatch repair genes. *Hum Mutat.* 2011; 32(2): 207–12. <https://doi.org/10.1002/humu.21408>.
 21. Green J, O'Driscoll M, Barnes A, Maher ER, Bridge P, Shields K, et al. Impact of gender and parent of origin on the phenotypic expression of hereditary nonpolyposis colorectal cancer in a large Newfoundland kindred

- with a common MSH2 mutation. *Dis Colon Rectum*. 2002; 45(9): 1223–32. <https://doi.org/10.1097/01.DCR.0000027034.98952.85>.
22. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. *Gastroenterology*. 2000; 118(5): 829–34.
 23. Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut*. 2011; 60(7): 950–7. <https://doi.org/10.1136/gut.2010.228056>.
 24. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet*. 2011; 378(9809): 2081–7. [https://doi.org/10.1016/S0140-6736\(11\)61049-0](https://doi.org/10.1016/S0140-6736(11)61049-0).
 25. Win AK, Dowty JG, English DR, Campbell PT, Young JP, Winship I, et al. Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. *Br J Cancer*. 2011; 105(1): 162–9. <https://doi.org/10.1038/bjc.2011.172>.
 26. Botma A, Nagengast FM, Braem MGM, Hendriks JCM, Kleibeuker JH, Vasen HFA, et al. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. *J Clin Oncol*. 2010; 28(28): 4346–53. <https://doi.org/10.1200/jco.2010.28.0453>.
 27. Watson P, Ashwathnarayan R, Lynch HT, Roy HK. Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). *Arch Intern Med*. 2004; 164(22): 2429–31. <https://doi.org/10.1001/archinte.164.22.2429>.
 28. Pande M, Lynch PM, Hopper JL, Jenkins MA, Gallinger S, Haile RW, et al. Smoking and colorectal cancer in Lynch syndrome: results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center. *Clin Cancer Res*. 2010; 16(4): 1331–9. <https://doi.org/10.1158/1078-0432.ccr-09-1877>.
 29. Chau R, Dashti SG, Ait Ouakrim D, Buchanan DD, Clendenning M, Rosty C, et al. Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. *Int J Epidemiol*. 2016; 45(3): 940–53. <https://doi.org/10.1093/ije/dyw036>.
 30. Dashti SG, Buchanan DD, Jayasekara H, Ait Ouakrim D, Clendenning M, Rosty C, et al. Alcohol consumption and the risk of colorectal cancer for mismatch repair gene mutation carriers. *Cancer Epidemiol Biomark Prev*. 2017; 26(3): 366–75. <https://doi.org/10.1158/1055-9965.epi-16-0496>.
 31. Ferlitsch M, Reinhart K, Pramhas S, Wiener C, Gal O, Bannert C, et al. Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. *JAMA*. 2011; 306(12): 1352–8. <https://doi.org/10.1001/jama.2011.1362>.
 32. Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB, et al. Hereditary prostate cancer as a feature of Lynch syndrome. *Fam Cancer*. 2011; 10(1): 37–42. <https://doi.org/10.1007/s10689-010-9388-8>.
 33. Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM, et al. Germline mutations in mismatch repair genes associated with prostate cancer. *Cancer Epidemiol Biomark Prev*. 2009; 18(9): 2460–7. <https://doi.org/10.1158/1055-9965.EPI-09-0058>.
 34. Barrow PJ, Ingham S, O'Hara C, Green K, McIntyre I, Lalloo F, et al. The spectrum of urological malignancy in Lynch syndrome. *Fam Cancer*. 2013; 12(1): 57–63. <https://doi.org/10.1007/s10689-012-9573-z>.
 35. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. *Cancer Epidemiol Biomark Prev*. 2014; 23(3): 437–49. <https://doi.org/10.1158/1055-9965.epi-13-1165>.
 36. Win AK, Lindor NM, Jenkins MA. Risk of breast cancer in Lynch syndrome: a systematic review. *Breast Cancer Res*. 2013; 15(2): R27. <https://doi.org/10.1186/bcr3405>.
 37. Win AK, Lindor NM, Winship I, Tucker KM, Buchanan DD, Young JP, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. *J Natl Cancer Inst*. 2013; 105(4): 274–9. <https://doi.org/10.1093/jnci/djs525>.
 38. Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, et al. Risks of primary extracolonic cancers following colorectal cancer in Lynch syndrome. *J Natl Cancer Inst*. 2012; 104(18): 1363–72. <https://doi.org/10.1093/jnci/djs351>.
 39. Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol*. 2012; 30(9): 958–64. <https://doi.org/10.1200/JCO.2011.39.5590>.
 40. Elston RC, Stewart J. A general model for the genetic analysis of pedigree data. *Hum Hered*. 1971; 21(6): 523–42.

41. Lange K, Weeks D, Boehnke M. Programs for pedigree analysis: MENDEL, FISHER, and dGENE. *Genet Epidemiol.* 1988; 5(6): 471–2. <https://doi.org/10.1002/gepi.1370050611>.
42. Bonaiti B, Bonadona V, Perdry H, Andrieu N, Bonaiti-Pellie C. Estimating penetrance from multiple case families with predisposing mutations: extension of the ‘genotype-restricted likelihood’ (GRL) method. *Eur J Hum Genet.* 2011; 19(2): 173–9. <https://doi.org/10.1038/ejhg.2010.158>.
43. Carayol J, Bonaiti-Pellie C. Estimating penetrance from family data using a retrospective likelihood when ascertainment depends on genotype and age of onset. *Genet Epidemiol.* 2004; 27(2): 109–17. <https://doi.org/10.1002/gepi.20007>.
44. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. *Genet Epidemiol.* 2001; 21(1): 1–18. <https://doi.org/10.1002/gepi.1014>.
45. Gong G, Hannon N, Whittemore AS. Estimating gene penetrance from family data. *Genet Epidemiol.* 2010; 34(4): 373–81. <https://doi.org/10.1002/gepi.20493>.
46. Cannings C, Thompson EA, Skolnick MH. Probability functions on complex pedigrees. *Adv Appl Probab.* 1978; 10(1): 26–61. <https://doi.org/10.2307/1426718>.